ANTIVIRAL COMPOUNDS

COMPOSES ANTIVIRAUX

English Abstract

The present invention relates to novel compounds of general formula (I) wherein R1 to R4 and n have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

French Abstract

La présente invention concerne de nouveaux composés de formule générale (I) dans laquelle R1 à R4 et n ont les significations données dans la description et les revendications. L'invention concerne également un procédé de préparation de ces composés et leur utilisation pour traiter, prévenir ou atténuer des infections virales et leur utilisation pour traiter, prévenir ou atténuer des maladies associées à PLA2G16.

Claims

131
Claims
1. A compound of general formula I,
<IMG>
wherein
R1 denotes H, -OR a, -C(O)R a, -(CH2)n C(O)OR a or a group, optionally
substituted
by one or more, identical or different R a and/or R b, selected independently
from
one another among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl,
C4-16cycloalkylalkyl, C6-10aryl, 3-8 membered heterocycloalkyl, and 5-12
membered
heteroaryl, and
R1' denotes H or C1-4alkyl,
or R1 and R1' together with the adjacent nitrogen atom form a 4- to 10-
membered
heterocyclic group, which optionally may be substituted by one or more,
identical
or different R a and/or R b;
R2 denotes H or a group, optionally substituted by one or more, identical or
different R a and/or R b, selected independently from one another among C1-
6alkyl,
C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl, C4-16cycloalkylalkyl, C6-10aryl, C7-
16arylalkyl,
3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12
membered heteroaryl and 6-18 membered heteroarylalkyl;
R3 denotes H or a group, optionally substituted by one or more, identical or
different R a and/or R b, selected independently from one another among C1-
6alkyl,
C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl, C4-16cycloalkylalkyl, C6-10aryl,
C7-16arylalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl
and 6-18 membered heteroarylalkyl,
R4 denotes =O, halogen, or a group, optionally substituted by one or more,
identical or different R a and/or R b, selected independently from one another
among
C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl

132
or two R4 form an optionally substituted 3 to 6 membered cycloalkyl or
heterocycloalkyl ring,
n denotes 0, 1, 2, 3, or 4, and
each R a independently of one another denotes hydrogen or a group, optionally
substituted by one or more, identical or different R b and/or R c, selected
from
among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl, C4-
16cycloalkylalkyl,
C6-10aryl, C7-16arylalkyl, 3-8 membered heterocycloalkyl, 4-14 membered
heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered
heteroarylalkyl;
each R b is a suitable substituent and is selected in each case independently
of one
another from among =O, -OR c, C1-3haloalkyloxy, -OCF3, =S, -SR c, =NR c, =NOR
c,
=NNR c R c, =NN(R g)C(O)NR c R c, -NR c R c, -ONR c R c, -N(OR c)R c, -N(R
g)NR c R c,
halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)R c,
-S(O)OR c, -S(O)2R c, -S(O)2OR c, -S(O)NR c R c, -S(O)2NR c R c, -OS(O)R c,
-OS(O)2R c, -OS(O)2OR c, -OS(O)NR c R c, -OS(O)2NR c R c, -C(O)R c, -C(O)OR c,
-C(O)SR c, -C(O)NR c R c, -C(O)N(R g)NR c R c, -C(O)N(R g)OR c, -C(NR g)NR c R
c,
-C(NOH)R c, -C(NOH)NR c R c, -OC(O)R c, -OC(O)OR c, -OC(O)SR c, -OC(O)NR c R
c,
-OC(NR g)NR c R c, -SC(O)R c, -SC(O)OR c, -SC(O)NR c R c, -SC(NR g)NR c R c,
-N(R g)C(O)R c, -N[C(O)R c]2, -N(OR g)C(O)R c, -N(R g)C(NR g)R c,
-N(R g)N(R g)C(O)R c, -N[C(O)R c]NR c R c, -N(R g)C(S)R c, -N(R g)S(O)R c,
-N(R g)S(O)OR c, -N(R g)S(O)2R c, -N[S(O)2R c]2, -N(R g)S(O)2OR c,
-N(R g)S(O)2NR c R c, -N(R g)[S(O)2]2R c, -N(R g)C(O)OR c, -N(R g)C(O)SR c,
-N(R g)C(O)NR c R c, -N(R g)C(O)NR g NR c R c, -N(R g)N(R g)C(O)NR c R c,
-N(R g)C(S)NR c R c, -[N(R g)C(O)]2R c, -N(R g)[C(O)]2R c, -N{[C(O)]2R c}2,
-N(R g)[C(O)]2OR c, -N(R g)[C(O)]2NR c R c, -N{[C(O)]2OR c}2, -N{[C(O)]2NR c R
c}2,
-[N(R g)C(O)]2OR c, -N(R g)C(NR g)OR c, -N(R g)C(NOH)R c, -N(R g)C(NR g)SR c
and
-N(R g)C(NR g)NR c R c;
each R d independently of one another denotes hydrogen or a group, optionally
substituted by one or more, identical or different R d and/or R e, selected
from
among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl, C4-
16cycloalkylalkyl,
C6-10aryl, C7-16arylalkyl, 3-8 membered heterocycloalkyl, 4-14 membered
heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered
heteroarylalkyl;

133
each Rd denotes a suitable substitutent and is selected in each case
independently
of one another from among =O, -ORe, C1-3haloalkyloxy,-OCF3, =S, -SRe, =NRe,
=NORe, =NNRe Re, =NN(Rg)C(O)NRe Re, -NRe Re, -ONRe Re, -N(ORe)Re,
-N(Rg)NRe Re, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2,
-N3, -S(O)Re, -S(O)ORe, -S(O)2 Re, -S(O)2 ORe, -S(O)NRe Re, -S(O)2 NRe Re,
-OS(O)Re, -OS(O)2 Re, -OS(O)2 ORe, -OS(O)NRe Re, -OS(O)2 NRe Re, -C(O)Re,
-C(O)ORe, -C(O)SRe, -C(O)NRe Re, -C(O)N(Rg)NRe Re, -C(O)N(Rg)ORe,
-C(NRg)NRe Re, -C(NOH)Re, -C(NOH)NRe Re, -OC(O)Re, -OC(O)ORe,
-OC(O)SRe, -OC(O)NRe Re, -OC(NRg)NRe Re, -SC(O)Re, -SC(O)ORe,
-SC(O)NRe Re, -SC(NRg)NRe Re, -N(Rg)C(O)Re, -N[C(O)Re]2, -N(ORg)C(O)Re,
-N(Rg)C(NRg)Re, -N(Rg)N(Rg)C(O)Re, -N[C(O)Re]NRe Re, -N(Rg)C(S)Re,
-N(Rg)S(O)Re, -N(Rg)S(O)ORe, -N(Rg)S(O)2 Re, -N[S(O)2 R12, -N(Rg)S(O)2 ORe,
-N(Rg)S(O)2 NRe Re, -N(Rg)[S(O)2]2 Re, -N(Rg)C(O)ORe, -N(Rg)C(O)SRe,
-N(Rg)C(O)NRe Re, -N(Rg)C(O)NRg NRe Re, -N(Rg)N(Rg)C(O)NRe Re,
-N(Rg)C(S)NRe Re, -[N(Rg)C(O)]2 Re, -N(Rg)[C(O)]2 Re, -N{[C(O)]2 Re}2,
-N(Rg)[C(O)]2 ORe, -N(Rg)[C(O)]2 NRe Re, -N{[C(O)]2 ORe}2, -N{[C(O)]2 NRe
Re}2,
-[N(Rg)C(O)]2 ORe, -N(Rg)C(NRg)ORe, -N(Rg)C(NOH)Re, -N(Rg)C(NRg)SRe and
-N(Rg)C(NRg)NRe Re, and
each Re independently of one another denotes hydrogen or a group selected from
among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C6-ioaryl, 3-8
membered
heterocycloalkyl, and 5-12 membered heteroaryl; and
each R9 independently of one another denotes hydrogen, C1-6alkyl, C2-6alkenyl,
C2-6alkynyl, C3-8cycloalkyl, C6-10aryl, 3-8 membered heterocycloalkyl, or 5-12
membered heteroaryl;
optionally in the form of the tautomers, the racemates, the enantiomers, the
diastereomers, hydrates, isotopes, and mixtures thereof, and optionally the
pharmacologically acceptable salts thereof.
2. The compound according to claim 1, wherein R1 is -Ra, or selected from C1-
6alkyl,
C3-6cycloalkyl, C4-16cycloalkylalkyl and 3-8 membered heterocycloalkyl,
optionally
substituted by one or more, identical or different Ra and/or Rb.
3. The compound according to claim 1 or 2, wherein R1' is H.
4. The compound according to any one of claims 1 to 3, wherein R2 is H, C1-
6alkyl,
C3-10cycloalkyl, C4-16cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 3-8 membered

134
heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered
heteroaryl
and 6-18 membered heteroarylalkyl, optionally substituted by one or more,
identical or different Ra and/or Rb.
5. The compound according to claim 4, wherein R2 is H, or C1-6alkyl,
C4-16cycloalkylalkyl, C7-16arylalkyl, 4-14 membered heterocycloalkylalkyl, 5-
12
membered heteroaryl and 6-18 membered heteroarylalkyl, optionally substituted
by one or more, identical or different Ra and/or Rb.
6. The compound according to claim 4, wherein R2 is C1-6alkyl substituted by
halogen, ¨ORa, ¨C(O)Ra, ¨C(O)NRc Rc, C3-10cycloalkyl, C6-10aryl, 3-8 membered
heterocycloalkyl, and 5-12 membered heteroaryl.
7. The compound according to claim 6, wherein R2 is C1-2alkyl substituted by
tetrahydropyranyl, phenyl, pyrimidinyl, triazolyl, oxazolyl, oxadiazolyl, or
pyrrolidinyl, each optionally substited by one or more, identical or different
Ra
and/or Rb.
8. The compound according to claim 4, wherein R2 is phenyl, pyrazolyl,
pyridyl,
pyrimidinyl, pyridazinyl, pyrazinyl, each optionally substituted by one or
more,
identical or different Ra and/or Rb.
9. The compound according to any one of claims 1 to 8, wherein R3 is
C3-10cycloalkyl, C6-10aryl or C7-16arylalkyl, optionally substituted by one or
more,
identical or different Ra and/or Rb.
10. The compound according to claim 9, wherein R3 is C6-10aryl or C7-
16arylalkyl,
optionally substituted by one or more, identical or different Ra and/or Rb.
11. The compound according to claim 10, wherein R3 is phenyl or benzyl,
optionally
substituted by one or more, identical or different Ra and/or Rb.
12. The compound according to any one of claims 1 to 11, wherein n denotes 0.
13. The compound according to claim 1 chosen from Table 2.
14. A compound of general formula I according to any one of claims 1 to 13,
optionally
in the form of the tautomers, the racemates, the enantiomers, the
diastereomers,
hydrates, isotopes, and mixtures thereof, or the pharmacologically acceptable
salt
thereof for use as medicament.
15. A compound of general formula I according to any one of claims 1 to 13,
optionally
in the form of the tautomers, the racemates, the enantiomers, the
diastereomers,
hydrates, isotopes, and mixtures thereof, or the pharmacologically acceptable
salt

135
thereof for use in the treatment or prevention of infectious diseases, cancer
or
obesity.
16. A compound of general formula I according claim 15 for the treatment or
prevention of picornavirus infections.
17. Pharmaceutical preparations containing as active substance one or more
compounds of general formula I according to any one of claims 1 to 13
optionally
in the form of the tautomers, the racemates, the enantiomers, the
diastereomers,
hydrates, isotopes, and mixtures thereof, or the pharmacologically acceptable
salts
thereof, optionally in combination with conventional excipients and/or
carriers.
18. Pharmaceutical preparation comprising a compound of general formula I
according
to any one of claims 1 to 13, wherein the compounds are optionally present in
the
form of the tautomers, racemates, enantiomers, diastereomers, hydrates,
isotopes,
and mixtures thereof, or also as the respective pharmacologically acceptable
salts
of all the above mentioned forms, and at least one further active substance
different from formula I.

Description

DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 A 116
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des
brevets
JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 116
NOTE: For additional volumes, please contact the Canadian Patent Office
NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:

CA 03075812 2020-03-13
0 20191068841 PCT/EP2018/077072
1
ANTIVIRAL COMPOUNDS
Description
Field of the Invention
[001] The present invention relates to novel compounds of general formula I
(R4)n
0
R
R3
0
wherein R1 to R4 and n have the meanings given in the description and claims,
process
for preparing these compounds and their use as medicaments.
Background Art
[002] Viruses are major causes of disease and death throughout the world.
Although
vaccines and public health measures have greatly reduced the incidence of
certain
viral infections, such approaches have been less successful in tackling many
viruses of
significant medical and/or veterinary importance.
[003] For example, chronic infection with hepatitis C virus (HCV) is a major
health
problem that affects more than 170 million people worldwide and is a causative
agent
of liver cirrhosis, hepatocellular carcinoma, and liver failure. Flaviviruses
such as West
Nile virus (WNV), Japanese Encephalitis virus (JEV), and the Dengue viruses
(DENV)
are significant human pathogens that cause millions of infections each year.
Rhinoviruses are the most common viral infectious agents in humans and are the
predominant cause of the common cold.
[004] Pathogenic viruses can be classified into two general types with respect
to the
viral structure: enveloped viruses and non-enveloped viruses. Some well-known
enveloped viruses include herpes virus, influenza virus, paramyxovirus,
respiratory
syncytial virus, corona virus, HIV, hepatitis B virus, hepatitis C virus and
SARS-CoV
virus. Non-enveloped viruses, sometimes referred to as "naked" viruses,
include the
families Picornaviridae, Reoviridae, Caliciviridae, Adenoviridae and
Parvoviridae.

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
2
Members of these families include rhinovirus, poliovirus, adenovirus,
hepatitis A virus,
norovirus, papillomavirus, and rotavirus.
[005] The phospholipase A2, group XVI (PLA2G16) was identified as a new
molecular
target for antiviral drugs (W02011160043).
[006] PLA2G16encodes an A2 group XVI phospholipase which is also reported to
play roles in tumor metastasis (Xiong S. et al., Proc Natl Acad Sci U S A.
2014 Jul
29;111(30), 11145-11150; Li L. et al., Oncotarget. 7(14), 18021-18035, 2016).
[007] PLA2G16 has also been reported to play a crucial role in the development
of
obesity in mouse models (Jaworski K. et al., Nat. Med. 15(2): 159-68, 2009).
[008] However, there are still relatively few viral diseases for which
effective drugs are
available. Thus, there is still a need for new antiviral compounds and for new
approaches to identifying such compounds. It is a further aim of the present
invention
to provide for new compounds which have an inhibitory effect on the enzyme
PLA2G16 in vitro and in vivo and have suitable pharmacological and/or
pharmacokinetic properties to enable them to be used as medicaments.
Summary of invention
[009] It has surprisingly been found, that compounds of general formula I,
wherein R1
to R4 and n have the meanings below, act as specific inhibitors against
PLA2G16. The
compounds according to the invention are specifically useful as antiviral
compounds.
Thus, the compounds according to the invention may be used for example for
treating,
preventing, and/or ameliorating viral infections.
[010] Various objects, features, aspects, and advantages of the present
invention will
become more apparent from the following detailed description of embodiments of
the
invention.
Description of embodiments
[011] The present invention relates to compounds of general formula I
(R4) R2
n I
0
R
R3
I 1.
0
(I)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
3
wherein
R1 denotes H, ORa, -C(0)Ra, -(CH2)nC(0)0Ra or a group, optionally substituted
by one
or more, identical or different Ra and/or Rb, selected independently from one
another
among C1-6a1ky1, C2-6alkenyl, C2_6a1kyny1, C3-iocycloalkyl, C4-
16cycloalkylalkyl, C6-ioaryl,
3-8 membered heterocycloalkyl, and 5-12 membered heteroaryl, and
Rv denotes H or Ci_4a1ky1,
or R1 and R1' together with the adjacent nitrogen atom form a 4- to 10-
membered
heterocyclic group, which optionally may be substituted by one or more,
identical or
different Ra and/or Rb;
R2 denotes H or a group, optionally substituted by one or more, identical or
different Ra
and/or Rb, selected independently from one another among C1-6a1ky1, C2-
6a1keny1, C2-
6alkynyl, C3-iocycloalkyl, C4-16cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 3-
8 membered
heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered
heteroaryl and
6-18 membered heteroarylalkyl;
R3 denotes H or a group, optionally substituted by one or more, identical or
different Ra
and/or Rb, selected independently from one another among C1-6alkyl, Cmalkenyl,
Cmalkynyl, C3-1ocycloalkyl, C4-16cycloalkylalkyl, C6-ioaryl,
C7_16arylalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl
and
6-18 membered heteroarylalkyl,
R4 denotes =0, halogen, or a group, optionally substituted by one or more,
identical or
different Ra and/or Rb, selected independently from one another among
C1_6a1ky1,
Cmalkenyl, C2-6alkynyl, C3_6cycloalkyl
or two R4 form an optionally substituted 3 to 6 membered cycloalkyl or
heterocycloalkyl
ring,
n denotes 0, 1, 2, 3, or 4, and
each Ra independently of one another denotes hydrogen or a group, optionally
substituted by one or more, identical or different Rb and/or Rc, selected from
among
C1_6alkyl, C2-6alkenyl, C2-6alkynyl, C3-locycloalkyl, C4-16cycloalkylalkyl,
C6-loaryl, C7-16arylalkyl, 3-8 membered heterocycloalkyl, 4-14 membered
heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered
heteroarylalkyl;
each Rb is a suitable substituent and is selected in each case independently
of one
another from among =0, -OW, C1_3haloalkyloxy, -0CF3, =S, -SRe, =NRc, =NOW,
=NNRcRc, =NN(Rg)C(0)NRcRc, -NRcRc, -0NRcRc, -N(ORc)Rc, -N(Rg)NRcRc, halogen,

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
4
-CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(0)Rc, -S(0)0Rc, -S(0)2Rc,
-S(0)20Rc, -S(0)NRcRc, -S(0)2NRcRc, -0S(0)Rc, -0S(0)2Rc, -0S(0)20Rc,
-0S(0)NRcRc, -0S(0)2NRcRc, -C(0)Rc, -C(0)0Rc, _C(0)SRC, -C(0)NRcRc,
-C(0)N(Rg)NRcRc, -C(0)N(Rg)ORc, -C(NRg)NRcRc, -C(NOH)Rc, -C(NOH)NRcRc,
-0C(0)Rc, -0C(0)0Rc, -0C(0)SRC, -0C(0)NRcRc, -0C(NRg)NRcRc, -SC(0)Rc,
-SC(0)0Re, -SC(0)NRcRc, -SC(NRg)NRcRc, -N(R9)C(0)Rc, -N[C(0)R92,
-N(0R9)C(0)Rc, -N(Rg)C(NRg)Rc, -N(Rg)N(Rg)C(0)Rc, -N[C(0)Rc]NRcRc,
-N(Rg)C(S)Rc, -N(Rg)S(0)Rc, -N(R9)S(0)0Rc, -N(Rg)S(0)2Rc, -N[S(0)2R92,
-N(Rg)S(0)20Rc, -N(Rg)S(0)2NRcRc, -N(Rg)[S(0)2]2Rc, -N(Rg)C(0)0Rc,
-N(Rg)C(0)SRc, -N(Rg)C(0)NRcRc, -N(Rg)C(0)NRgNRcRc, -N(Rg)N(Rg)C(0)NRcRc,
-N(Rg)C(S)NRcRc, -[N(Rg)C(0)j2Rc, -N(Rg)[C(0)]2Rc, -N{[C(0)]2Rc}2,
-N(R9)[C(0)J2ORc, -N(Rg)[C(0)]2NReRc, -N{[C(0)]20R12, -N{[C(0)]2NRcRc}2,
-[N(Rg)C(0)]2ORc, -N(Rg)C(NRg)ORc, -N(Rg)C(NOH)Rc, -N(Rg)C(NRg)SRc and
-N(Rg)C(NRg)NRcRc;
each Rc independently of one another denotes hydrogen or a group, optionally
substituted by one or more, identical or different Rd and/or Re, selected from
among
C1_6alkyl, C2-6alkenyl, C2-6alkynyl, C3-locycloalkyl, C4-16cycloalkylalkyl,
C6-1 oaryl, C7-16arylalkyl, 3-8 membered heterocycloalkyl, 4-14 membered
heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered
heteroarylalkyl;
each Rd denotes a suitable substitutent and is selected in each case
independently of
one another from among =0, -0Re, Ci_3haloalkyloxy,-0CF3, =S, -SR, =NRe, =NORe,
=NNReRe, =NN(Rg)C(0)NReRe, -NReRe, -0NReRe, -N(ORe)Re, -N(Rg)NReRe,
halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(0)Re, -S(0)0Re,
-S(0)2Re, -S(0)20Re, -S(0)NReRe, -S(0)2NReRe, -0S(0)Re, -0S(0)2Re,
-0S(0)20Re, -0S(0)NReRe, -0S(0)2NReRe, -C(0)Re, -C(0)0Re, -C(0)SRe,
-C(0)NReRe, -C(0)N(Rg)NReRe, -C(0)N(Rg)0Re, -C(NRg)NReRe, -C(NOH)Re,
-C(NOH)NReRe, -0C(0)Re, -0C(0)0Re, -0C(0)SRe, -0C(0)NReRe,
-0C(NRg)NReRe, -SC(0)Re, -SC(0)0Re, -SC(0)NReRe, -SC(NRg)NReRe,
-N(R9)C(0)Re, -N[C(0)R12, -N(ORg)C(0)Re, -N(Rg)C(NRg)Re, -N(Rg)N(Rg)C(0)Re,
-N[C(0)R1NReRe, -N(Rg)C(S)Re, -N(Rg)S(0)Re, -N(Rg)S(0)0Re, -N(Rg)S(0)2Re,
-N [S(0)2R12, -N(Rg)S(0)20Re, -N(Rg)S(0)2NReRe, -N(Rg)[S(0)2]2Re, -
N(Rg)C(0)0Re,
-N(Rg)C(0)SRe, -N(R9)C(0)NReRe, -N(Rg)C(0)NRgNReRe, -N(Rg)N(Rg)C(0)NReRe,
-N(Rg)C(S)NReRe, -[N(R9)C(0)j2Re, -N(Rg)[C(0)]2Re, -N{[C(0)]2Re}2,

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
-N(Rg)[C(0)]20Re, -N(R9)[C(0)]2NReRe, -N{[C(0)]20Re}2, -N{[C(0)]2NReRe}2,
-[N(Rg)C(0)]20Re, -N(Rg)C(NRg)0Re, -N(Rg)C(NOH)Re, -N(Rg)C(NRg)SRe and
-N(Rg)C(NRg)NReRe; and
each Re independently of one another denotes hydrogen or a group selected from
among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, Cmcycloalkyl, C6-ioaryl, 3-8
membered
heterocycloalkyl, and 5-12 membered heteroaryl; and
each Rg independently of one another denotes hydrogen, C1_6alkyl, C2-6alkenyl,
Cmalkynyl, C3-8cycloalkyl, C6-ioaryl, 3-8 membered heterocycloalkyl, or 5-12
membered heteroaryl;
optionally in the form of the tautomers, the racemates, the enantiomers, the
diastereomers, hydrates, isotopes, and mixtures thereof, and optionally the
pharmacologically acceptable salts thereof.
[012] One embodiment of the invention relates to compounds as described
herein,
wherein R1 is -Ra, or selected from C1.6alkyl, Cmcycloalkyl,
C4_16cycloalkylalkyl and
3-8 membered heterocycloalkyl, optionally substituted by one or more,
identical or
different Ra and/or Rb.
[013] One embodiment of the invention relates to compounds as described
herein,
wherein RI is H.
[014] One embodiment of the invention relates to compounds as described
herein,
wherein R2 is H, Ci_6alkyl, C3_iocycloalkyl, C4_16cycloalkylalkyl, C6_10aryl,
C7_16arylalkyl,
3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12
membered heteroaryl and 6-18 membered heteroarylalkyl, optionally substituted
by
one or more, identical or different Ra and/or Rb.
[015] One embodiment of the invention relates to compounds as described
herein,
wherein R2 is H, or Ci-6alkyl, C4-16cycloalkylalkyl, C7-16arylalkyl, 4-14
membered
heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered
heteroarylalkyl,
optionally substituted by one or more, identical or different Ra and/or Rb.
[016] One embodiment of the invention relates to compounds as described
herein,
wherein R2 is Ci_6alkyl substituted by halogen, -0Ra, -C(0)Ra, -C(0)NRcRb,
C3_iocycloalkyl, C6_ioaryl, 3-8 membered heterocycloalkyl, and 5-12 membered
heteroaryl.
[017] One embodiment of the invention relates to compounds as described
herein,
wherein R2 is Ci-2alkyl substituted by tetrahydropyranyl, phenyl, pyrimidinyl,
triazolyl,

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
6
oxazolyl, oxadiazolyl, or pyrrolidinyl, each optionally substited by one or
more, identical
or different Ra and/or Rb.
[018] One embodiment of the invention relates to compounds as described
herein,
wherein R2 is phenyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl,
each
optionally substited by one or more, identical or different Ra and/or Rb.
[019] One embodiment of the invention relates to compounds as described
herein,
wherein R2 is C1_2alkyl, substituted by tetrahydropyranyl, phenyl,
pyrimidinyl, triazolyl,
oxazolyl, oxadiazolyl, or pyrrolidinyl, each optionally substited by one or
more, identical
or different Ra and/or Rb, or R2 is phenyl, pyrazolyl, pyridyl, pyrimidinyl,
pyridazinyl,
pyrazinyl, each optionally substited by one or more, identical or different Ra
and/or Rb.
[020] One embodiment of the invention relates to compounds as described
herein,
wherein R2 is
[021] One embodiment of the invention relates to compounds as described
herein,
wherein R3 is C3_1ocycloalkyl, C6_10aryl or C7_16arylalkyl, optionally
substituted by one or
more, identical or different Ra and/or Rb.
[022] One embodiment of the invention relates to compounds as described
herein,
wherein R3 is 06_10aryl or C7_16arylalkyl, optionally substituted by one or
more, identical
or different Ra and/or Rb.
[023] One embodiment of the invention relates to compounds as described
herein,
wherein R3 is phenyl or benzyl, optionally substituted by one or more,
identical or
different Ra and/or Rb.
[024] One embodiment of the invention relates to compounds as described
herein,
wherein n denotes 0.
[025] One embodiment of the invention relates to compounds as described
herein,
wherein the compounds are selected from Table 2.
[026] One embodiment of the invention relates to compounds as described
herein,
optionally in the form of the tautomers, the racemates, the enantiomers, the
diastereomers, hydrates, isotopes, and mixtures thereof, or the
pharmacologically
acceptable salt thereof, for use as medicament.
[027] The invention contemplates treatment of a wide variety of viral
infections in
human and/or animal subjects, e.g., infection due to any virus. In some
embodiments,
the virus is a picornavirus, e.g., a cardiovirus, enterovirus (e.g. a
coxsackievirus, a
rhinovirus, a poliovirus or echovirus), or hepatovirus. In some embodiments,
the virus

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
7
clusters phylogenetically within the enterovirus genus. In some embodiments,
the
picornavirus is classified with a species selected from the group consisting
of: human
enterovirus A, human enterovirus B, human enterovirus C, human enterovirus D,
simian enterovirus A, bovine enterovirus, porcine enterovirus B, human
rhinovirus A,
human rhinovirus B and human rhinovirus C. In some embodiments, the
picornavirus
is classified with a species selected from the group consisting of: human
enterovirus A,
human enterovirus B, human enterovirus C, human enterovirus D, human
rhinovirus A,
human rhinovirus B and human rhinovirus C.
[028] The invention provides use of the compounds for treating diseases and
medical
conditions resulting from viral infection, e.g., by a picornavirus. Exemplary
diseases
and conditions include, e.g., asthma exacerbation, bronchiolitis, colitis,
common cold,
COPD exacerbation, encephalitis, encephalomyelitis, enterocolitis, foot-and-
mouth
disease, hand-foot-and-mouth disease, gastroenteritis, herpangina, hepatitis,
meningitis, meningoencephalitis, myocarditis, pancreatitis, poliomyelitis, and
pneumonia. In some aspects, the invention contemplates ex vivo uses of the
PLA2G16
inhibitors.
[029] Thus, one embodiment of the invention relates to compounds as described
herein, optionally in the form of the tautomers, the racemates, the
enantiomers, the
diastereomers, hydrates, isotopes, and mixtures thereof, or the
pharmacologically
acceptable salt thereof, for use as antiviral agents.
[030] A further embodiment of the invention relates to compounds as described
herein, optionally in the form of the tautomers, the racemates, the
enantiomers, the
diastereomers, hydrates, isotopes, and mixtures thereof, or the
pharmacologically
acceptable salt thereof, for use in the treatment or prevention of infectious
diseases,
cancer or obesity.
[031] One embodiment of the invention relates to compounds as described
herein,
optionally in the form of the tautomers, the racemates, the enantiomers, the
diastereomers, hydrates, isotopes, and mixtures thereof, or the
pharmacologically
acceptable salt thereof, for use in treating, preventing, and/or ameliorating
viral
infections.
[032] One embodiment of the invention relates to compounds as described
herein,
optionally in the form of the tautomers, the racemates, the enantiomers, the
diastereomers, hydrates, isotopes, and mixtures thereof, or the
pharmacologically

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
8
acceptable salt thereof, for use in treating, preventing, and/or ameliorating
viral
infections caused by a picornavirus, e.g. by a rhinovirus.
[033] One embodiment of the invention relates to pharmaceutical preparations
containing as active substance one or more compounds of general formula I as
described herein, optionally in the form of the tautomers, the racemates, the
enantiomers, the diastereomers, hydrates, isotopes, and mixtures thereof, or
the
pharmacologically acceptable salt thereof, or the pharmacologically acceptable
salts
thereof, optionally in combination with conventional excipients and/or
carriers.
[034] One embodiment of the invention relates to pharmaceutical preparations
comprising a compound of general formula I as described herein, wherein the
compounds are optionally present in the form of the tautomers, racemates,
enantiomers, diastereomers, hydrates, isotopes, and mixtures thereof, or also
as the
respective pharmacologically acceptable salts of all the above mentioned
forms, and at
least one further active substance different from formula I.
Definitions
[035] As used herein, the following definitions apply, unless stated
otherwise:
[036] Unless specified otherwise, the term "alkyl", when used alone or in
combination
with other groups or atoms, refers to a saturated straight or branched chain
consisting
solely of 1 to 6 hydrogen-substituted carbon atoms, and includes methyl,
ethyl, propyl,
isopropyl, n-butyl, 1-methylpropyl, isobutyl, t-butyl, 2,2-dimethylbutyl, 2,2-
dimethyl-
propyl, n-pentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, n-hexyl and
the like.
[037] Unless specified otherwise, the term "alkenyl" refers to a partially
unsaturated
straight or branched chain consisting solely of 2 to 6 hydrogen-substituted
carbon
atoms that contains at least one double bond, and includes vinyl, allyl, 2-
methylprop-1-
enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, penta-1,3-dienyl,
penta-2,4-
dienyl, 2-methylbut-1-enyl, 2-methylpent-1-enyl, 4-methylpent-1-enyl, 4-
methylpent-2-
enyl, 2-methylpent-2-enyl, 4-methylpenta-1,3-dienyl, hexen-1-yland the like.
[038] Unless specified otherwise, the term "alkynyl" refers to a partially
unsaturated
straight or branched chain consisting solely of 2 to 6 hydrogen-substituted
carbon
atoms that contains at least one triple bond, and includes ethynyl, 1-
propynyl, 2-
propynyl, 2-methylprop-1-ynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1,3-
butadiynyl, 3-
methylbut-1-ynyl, 4-methylbut-ynyl, 4-methylbut-2-ynyl, 2-methylbut-1-ynyl, 1-
pentynyl,

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
9
2-pentynyl, 3-pentynyl, 4-pentynyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 3-
methylpent-1-
ynyl, 4-methylpent-2-ynyl, 4-methylpent-2-ynyl, 1-hexynyl, and the like.
[039] Unless specified otherwise, the term "cycloalkyl", when used alone or in
combination with other groups or atoms, refers to monocyclic hydrocarbon
rings,
bicyclic hydrocarbon rings or spirohydrocarbon rings, which each may be either
saturated or unsaturated (cycloalkenyl). The term unsaturated means that in
the ring
system in question there is at least one double bond, but no aromatic system
is
formed. In bicyclic hydrocarbon rings two rings are linked such that they have
at least
two carbon atoms in common. In spirohydrocarbon rings one carbon atom
(spiroatom)
is shared by two rings. If a cycloalkyl is substituted, the substitution may
be mono- or
polysubstitution in each case, at all the hydrogen-carrying carbon atoms,
independently of one another. Cycloalkyl itself may be linked to the molecule
as
substituent via any suitable position of the ring system.
[040] Typical examples of individual sub-groups are listed below.
Monocyclic saturated hydrocarbon rings: cyclopropyl; cyclobutyl; cyclopentyl;
cyclohexyl; cycloheptyl, etc.
[041] Monocyclic unsaturated hydrocarbon rings: cycloprop-1-enyl; cycloprop-2-
enyl;
cyclobut-1-enyl; cyclobut-2-enyl; cyclopent-1-enyl; cyclopent-2-enyl;
cyclopent-3-enyl;
cyclohex-1-enyl; cyclohex-2-enyl; cyclohex-3-enyl; cyclohept-1-enyl; cyclohept-
2-enyl;
cyclohept-3-enyl; cyclohept-4-enyl; cyclobuta-1,3- dienyl; cyclopenta-1,4-
dienyl;
cyclopenta-1,3-dienyl; cyclopenta-2,4-dienyl; cyclohexa-1,3- dienyl; cyclohexa-
1,5-
dienyl; cyclohexa-2,4-dienyl; cyclohexa-1 ,4-dienyl; cyclohexa-2,5- dienyl,
etc.
Saturated and unsaturated bicyclic hydrocarbon rings: bicyclo[2.2.0]hexyl;
bicyclo[3.2.0]heptyl; bicyclo[3.2.1]octyl; bicyclo[2.2.2]octyl;
bicyclo[4.3.0]nonyl
(octahydroindenyl); bicyclo[4.4.0]decyl (decahydronaphthalene);
bicyclo[2,2,1]heptyl
(norbornyl); (bicyclo[2.2.1]hepta-2,5-dienyl (norborna-2,5-dienyl);
bicyclo[2,2,1]hept-2-
enyl (norbornenyl); bicyclo[4.1.0]heptyl (norcaranyl); bicyclo- [3.1.1]heptyl
(pinanyl),
etc.
[042] Saturated and unsaturated spirohydrocarbon rings: spiro[2.5]octyl,
spiro[3.3]heptyl, spiro[4.5]dec-2-ene, etc.
[043] "Cycloalkylalkyl" denotes the combination of the above-defined groups
alkyl,
alkenyl, alkynyl, and cycloalkyl, in each case in their broadest sense. The
alkyl group
as substituent is directly linked to the molecule and is in turn substituted
by a cycloalkyl

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
group. The alkyl and cycloalkyl may be linked in both groups via any carbon
atoms
suitable for this purpose. The respective sub-groups of alkyl and cycloalkyl
are also
included in the combination of the two groups.
[044] Unless specified otherwise, the term "aryl" refers to an aromatic mono-
or
bicyclic group containing from 6 to 14 carbon atoms, preferably 6 to 10 carbon
atoms,
that may be optionally fused with a fully or partially saturated or
unsaturated
carbocyclic ring and may optionally be substituted with one or more, identical
or
different substituents, suitably one to three substituents. Examples of aryl
groups
include phenyl, naphthyl, indanyl, and the like.
[045] "Arylalkyl" denotes the combination of the groups alkyl, alkenyl,
alkynyl and aryl
as hereinbefore defined, in each case in their broadest sense. The alkyl group
as
substituent is directly linked to the molecule and is in turn substituted by
an aryl group.
The alkyl and aryl may be linked in both groups via any carbon atoms suitable
for this
purpose. Typical examples include benzyl, 1-phenylethyl, 2-phenylethyl,
phenylvinyl,
phenylallyl, etc.
[046] Unless specified otherwise, the term "heteroaryl" refers to an aromatic
mono- or
bicyclic group containing from 5 to 14 carbon atoms, preferably 5 to 12 carbon
atoms,
of which one to five is replaced with a heteroatom selected from N, S and 0,
that may
optionally be reduced to a non-aromatic heterocycle and may optionally be
substituted
with one or more, identical or different substituents. Examples of heteroaryl
groups
include pyrrolyl, dihydropyrrolyl, pyrrolidinyl, oxopyrrolidinyl, indolyl,
isoindolyl,
indolizinyl, imidazolyl, pyrazolyl, benzimidazolyl, imidazo(1,2-a)pyridinyl,
indazolyl,
purinyl, pyrrolo(2,3-c)pyridinyl, pyrrolo(3,2-c)pyridinyl, pyrrolo(2,3-
b)pyridinyl,
pyrazolo(1,5-a)pyridinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl,
oxazolyl, 1,2 oxazolyl,
isoxazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-
oxadiazolyl,
thiazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,4-
thiadiazolyl, 1,2,3-
thiadiazolyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, benzofuranyl,
isobenzofuranyl,
thiophenyl, dihydrothiophenyl, tetrahydrothiophenyl, benzothiophenyl,
benzoisothiophenyl, pyridyl, piperidinyl, quinolinyl, isoquinolinyl,
tetrahydroisoqinolinyl,
quinolizinyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyranyl, tetrahydropyranyl,
1,2,3-
triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, chromenyl, morpholinyl,
diazepinyl,
benzodiazepinyl, and the like.

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
11
[047] "Heteroarylalkyl" denotes the combination of the alkyl, alkenyl,
alkynyl, and
heteroaryl groups defined hereinbefore, in each case in their broadest sense.
The alkyl
group as substituent is directly linked to the molecule and is in turn
substituted by a
heteroaryl group. The linking of the alkyl and heteroaryl may be achieved on
the alkyl
side via any carbon atoms suitable for this purpose and on the heteroaryl side
by any
carbon or nitrogen atoms suitable for this purpose.
[048] By the term "heterocycloalkyl" are meant groups which are derived from
cycloalkyl as hereinbefore defined if in the hydrocarbon rings one or more of
the
groups ¨CH2¨ are replaced independently of one another by the groups -0-, -S-
or -
NH- or one or more of the groups =CH- are replaced by the group =N-, while not
more
than five heteroatoms may be present in total, there must be at least one
carbon atom
between two oxygen atoms and between two sulphur atoms or between one oxygen
and one sulphur atom and the group as a whole must be chemically stable.
Heteroatoms may simultaneously be present in all the possible oxidation stages
(sulphur -> sulphoxide -SO-, sulphone -SO2-; nitrogen -> N-oxide). It is
immediately
apparent from the indirect definition/derivation from cycloalkyl that
heterocycloalkyl is
made up of the sub-groups monocyclic hetero-rings, bicyclic hetero-rings and
spirohetero-rings, while each sub-group can also be further subdivided into
saturated
and unsaturated (heterocycloalkenyl). The term unsaturated means that in the
ring
system in question there is at least one double bond, but no aromatic system
is
formed. In bicyclic hetero-rings two rings are linked such that they have at
least two
atoms in common. In spirohetero-rings one carbon atom (spiroatom) is shared by
two
rings. If a heterocycloalkyl is substituted, the substitution may be mono- or
polysubstitution in each case, at all the hydrogen-carrying carbon and/or
nitrogen
atoms, independently of one another. Heterocycloalkyl itself as substituent
may be
linked to the molecule via any suitable position of the ring system.
[049] The term "heterocyclic group" as used herein refers to a
heterocycloalkyl group
which optionally may be fused to an aromatic aryl or heteroaryl group.
[050] Typical examples of individual sub-groups are listed below:
Monocyclic heterorings (saturated and unsaturated): oxolane, pyrrolidinyl,
pyrrolinyl,
imidazolidinyl, thiazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl,
piperidinyl,
piperazinyl, oxiranyl, aziridinyl, azetidinyl, 1,4-dioxanyl, azepanyl,
diazepanyl,
morpholinyl, thiomorpholinyl, homomorpholinyl, homopiperidinyl,
homopiperazinyl,

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
12
homothiomorpholinyl, thiomorpholinyl-S-oxide, thiomorpholinyl-S,S-dioxide, 1,3-
dioxolanyl, oxane, tetrahydrothiopyranyl, 1,4-oxazepanyl, tetrahydrothienyl,
homothiomorpholinyl-S,S-dioxide, oxazolidinonyl, dihydropyrazolyl,
dihydropyrrolyl,
dihydropyrazinyl, dihydropyridyl, dihydro-pyrimidinyl, dihydrofuryl,
dihydropyranyl,
tetrahydrothienyl-S-oxide, tetrahydrothienyl-S,S-dioxide, homothiomorpholinyl-
S-oxide,
2,3-dihydroazet, 2H-pyrrolyl, 4H-pyranyl, 1,4- dihydropyridinyl, etc;
Bicyclic heterorings (saturated and unsaturated): 8-azabicyclo[3.2.1]octyl,
8-azabicyclo[5.1.0]octyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 8-oxa- 3-aza-
bicyclo[3.2.1]octyl, 3,8-diaza-bicyclo[3.2.1]octyl, 2,5-diaza-bicyclo-
[2.2.1]heptyl, 1-aza-
bicyclo[2.2.2]octyl, 3,8-diaza-bicyclo[3.2.1]octyl, 3,9-diaza-
bicyclo[4.2.1]nonyl, 2,6-
diaza-bicyclo[3.2.2]nonyl, hexahydro-furo[3,2-b]furyl, etc;
Spiro-heterorings (saturated and unsaturated): 1,4-dioxa-spiro[4.5]decyl; 1-
oxa-3,8-
diaza-spiro[4.5]decyl; 2,6-diaza-spiro[3.3]heptyl; 2,7-diaza-spiro[4.4]nonyl;
2,6-diaza-
spiro[3.4]octyl; 3,9-diaza-spiro[5.5]undecyl; 2,8-diaza- spiro[4.5]decyl, etc.
[051] "Heterocycloalkylalkyl" denotes the combination of the alkyl, alkenyl,
alkynyl,
and heterocycloalkyl groups defined hereinbefore, in each case in their
broadest
sense. The alkyl group as substituent is directly linked to the molecule and
is in turn
substituted by a heterocycloalkyl group. The linking of the alkyl and
heterocycloalkyl
may be achieved on the alkyl side via any carbon atoms suitable for this
purpose and
on the heterocycloalkyl side by any carbon or nitrogen atoms suitable for this
purpose.
[052] By the term "suitable substituent" is meant a substituent that on the
one hand is
fitting on account of its valency and on the other hand leads to a system with
chemical
stability.
[053] It is intended that the definition of any substituent or variable at a
particular
location in a molecule be independent of its definitions elsewhere in that
molecule. It is
understood that substituents and substitution patterns on the compounds of
this
invention can be selected by one of ordinary skill in the art to provide
compounds that
are chemically stable and that can be readily synthesized by techniques known
in the
art as well as those methods set forth herein.
[054] The term "tautomers" refer to compounds that are interchangeable forms
of a
particular compound structure, and that vary in the displacement of hydrogen
atoms
and electrons. Thus, two structures may be in equilibrium through the movement
of 7

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
13
electrons and an atom (usually H). For example, enols and ketones are
tautomers
because they are rapidly interconverted by treatment with either acid or base.
[055] It is also to be understood that compounds (e.g., dihydro bases
described
herein) that have the same molecular formula but differ in the nature or
sequence of
bonding of their atoms or the arrangement of their atoms in space are termed
"isomers". Isomers that differ in the arrangement of their atoms in space are
termed
"stereoisomers".
[056] Stereoisomers that are not mirror images of one another are termed
"diastereomers" and those that are non-superimposable mirror images of each
other
are termed "enantiomers". When a compound has an asymmetric center, for
example,
it is bonded to four different groups, a pair of enantiomers is possible. An
enantiomer
can be characterized by the absolute configuration of its asymmetric center
and is
described by the R- and S-sequencing rules of Cahn and Prelog, or by the
manner in
which the molecule rotates the plane of polarized light and designated as
dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively).
[057] A 50:50 mixture of enantiomers is referred to as a racemic mixture or a
racemate, which may occur where there has been no stereoselection or
stereospecificity in a chemical reaction or process. The terms "racemic
mixture" and
"racemate" refer to an equimolar mixture of two enantiomeric species, devoid
of optical
activity.
[058] The term "hydrate" refers to a compound which is associated with water.
Typically, the number of the water molecules contained in a hydrate of a
compound is
in a definite ratio to the number of the compound molecules in the hydrate.
[059] Any formula or structure given herein, including Formula I compounds, is
also
intended to represent unlabeled forms as well as isotopically-labeled forms of
the
compounds. Isotopically-labeled compounds have structures depicted by the
formulas
given herein except that one or more atoms are replaced by an atom having a
selected
atomic mass or mass number. Examples of isotopes that can be incorporated into
compounds of the invention include isotopes of hydrogen, carbon, nitrogen,
oxygen,
phosphorous, fluorine, and chlorine, such as, but not limited to 2H
(deuterium, D), 3H
(tritium), 11C, 13C, 14C, 15N, 18F, 31P, 32P, 35S, 36CI, and 125J.
[060] The term "pharmacologically acceptable" means compatible with the
treatment
of animals, in particular, humans. The term pharmacologically acceptable salt
includes

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
14
both pharmacologically acceptable acid addition salts and pharmacologically
acceptable basic addition salts.
[061] The term" pharmacologically acceptable acid addition salt" as used
herein
means any non-toxic organic or inorganic salt of any base compound of the
disclosure,
or any of its intermediates. Basic compounds of the disclosure that may form
an acid
addition salt include, for example, compounds that contain a basic nitrogen
atom.
Illustrative inorganic acids which form suitable salts include hydrochloric,
hydrobromic,
sulfuric and phosphoric acids, as well as metal salts such as sodium
monohydrogen
orthophosphate and potassium hydrogen sulfate. Illustrative organic acids that
form
suitable salts include mono-, di-, and tricarboxylic acids such as glycolic,
lactic,
pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric,
ascorbic, maleic,
benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids
such as p-
toluene sulfonic and methanesulfonic acids. Either the mono-, di- or the
triacid salts
can be formed, and such salts may exist in either a hydrated, solvated or
substantially
anhydrous form. In general, the acid addition salts of the compounds of the
disclosure
are more soluble in water and various hydrophilic organic solvents, and
generally
demonstrate higher melting points in comparison to their free base forms. The
selection of the appropriate salt will be known to one skilled in the art.
Other non-
pharmacologically acceptable acid addition salts, e.g. oxalates, may be used,
for
example, in the isolation of the compounds of the disclosure, for laboratory
use, or for
subsequent conversion to a pharmacologically acceptable acid addition salt.
[062] The term "pharmacologically acceptable basic salt" as used herein means
any
non-toxic organic or inorganic basic addition salt of any acid compound of the
invention, or any of its intermediates, which are suitable for or compatible
with the
treatment of animals, in particular humans. Acidic compounds of the invention
that may
form a basic addition salt include, for example compounds that contain
carboxylic acid,
sulfonic acid, sulfinic acid, sulfonamide, N-unsubstituted tetrazole,
phosphoric acid
ester, or sulfuric acid ester. Illustrative inorganic bases which form
suitable salts
include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide.
Illustrative organic bases which form suitable salts include aliphatic,
alicyclic or
aromatic organic amines such as methylamine, trimethylamine and picoline or
ammonia. The selection of the appropriate salt will be known to a person
skilled in the
art. Other non-pharmacologically acceptable basic addition salts, may be used,
for

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
example, in the isolation of the compounds of the invention, for laboratory
use, or for
subsequent conversion to a pharmacologically acceptable basic addition salt.
The
formation of a desired compound salt is achieved using standard techniques.
For
example, the neutral compound is treated with a base in a suitable solvent and
the
formed salt is isolated by filtration, extraction or any other suitable
method.
[063] The term "therapeutically effective amount", "effective amount" or
"sufficient
amount" of a compound of the present invention is a quantity sufficient to,
when
administered to the subject, including a mammal, for example a human, effect
beneficial or desired results, including clinical results, and, as such, an
effective
amount or synonym thereof depends upon the context in which it is being
applied.
Abbreviations
AcOH acetic acid
atm atmosphere
Boc20 boc anhydride
CHCI3 chloroform
CO2 carbon dioxide
conc. concentrated
C52CO3 cesium carbonate
Cu(l)l copper (I) iodide
CV column volume
1,2-DCE 1,2-dichloroethane
DCM dichloromethane
DIPEA /V,N-diisopropyl-N-ethylamine
DMF /V,N-dimethylformamide
DMP Dess-Martin periodinane
DMSO dimethylsulfoxide
D20 deuterium oxide
ee enantiomeric excess
ELS Evaporative Light Scattering
ESI electron-spray ionisation
Et20 diethyl ether
Et0Ac ethyl acetate
Et0H ethanol

CA 03075812 2020-03-13
WO 2019/068841
PCT/EP2018/077072
16
FCC flash column chromatography
FP final product
g gram
h hour
H20 water
H2SO4 sulfuric acid
HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium
3-oxid hexafluorophosphate
HCI hydrochloric acid
HPLC high-performance liquid chromatography
I intermediate
IPA Isopropanol
K2CO3 potassium carbonate
KI potassium iodide
LC liquid chromatography
LiOH lithium hydroxide
m-CPBA meta-chloroperoxybenzoic acid
MeCN acetonitrile
Me0H methanol
mHz Mega Hertz
min minute
mL milliliter
NaBH4 sodium borohydride
NaBr sodium bromide
NaH sodium hydride
NaHCO3 sodium bicarbonate
NaOH sodium hydroxide
NaNO2 sodium nitrite
Na0Et sodium ethoxide
NaOH sodium hydroxide
Na2S203 sodium thiosulfate
Na2S03 sodium sulfite
Na2SO4 sodium sulfate

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
17
NH40I ammonium chloride
NiCl2 nickel chloride
NMR nuclear magnetic resonance
Pd/C palladium on charcoal
Pt02 platinum dioxide
ppm parts per million
RT room temperature
Rt retention time
sat. saturated
sec second
SFC supercritical fluid chromatography
STAB sodium triacetoxyborohyd ride
T3P propylphosphonic anhydride
TBME tert-butyl methyl ether
THF tetrahydrofuran
UV ultraviolet
weight
Examples
[064] The Examples which follow are set forth to aid in the understanding of
the
invention but are not intended to, and should not be construed to limit the
scope of the
invention in any way. The Examples do not include detailed descriptions of
conventional methods. Such methods are well known to those of ordinary skill
in the
art.
GENERAL EXPERIMENTAL DETAILS
[065] Commercially available reagents and solvents (HPLC grade) were used
without
further purification. 1H NMR spectra were recorded on a Bruker DRX 500 MHz
spectrometer or a Bruker DPX 250 MHz spectrometer in deuterated solvents.
Chemical shifts (5) are in parts per million.
[066] Compounds were purified by FCC on normal phase silica on Biotage Isolera
systems using the appropriate SNAP cartridge and gradient. Alternatively,
compounds
were purified on reverse phase silica using Biotage 'solera systems with the
appropriate SNAP C18 cartridges and reverse phase eluent or by preparative LC
(if
stated otherwise).

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
18
Reverse phase chromatography using acidic pH, standard elution method
[067] Purifications by FCC on reverse phase silica (acidic pH, standard
elution
method) were performed on Biotage lsolera systems using the appropriate SNAP
C18
cartridge and a gradient of 10% B (A= 0.1% formic acid in water; B= 0.1%
formic acid
in acetonitrile) over 1.7 CV then 10-100% B over 19.5 CV and 100% B for 2 CV.
Preparative LC using acidic pH, standard elution method
[068] Purifications by preparative LC (acidic pH, standard elution method)
were
performed on a Gilson LC system using a Waters Sunfire C18 column (30 mm x 10
mm, 10 pM; temperature: RT) and a gradient of 30-95% B (A= 0.1% formic acid in
water; B= 0.1% formic acid in acetonitrile) over 11.00 min then 95% B for 2.10
min,
with an injection volume of 1500 pL and a flow rate of 40 mL/min. UV spectra
were
recorded at 215 nm using a Gilson detector.
Preparative LC using acidic pH, early elution method
[069] Purifications by preparative LC (acidic pH, early elution method) were
performed
on a Gilson LC system using a Waters Sunfire C18 column (30 mm x 100 mm, 10
pM;
temperature: RT) and a gradient of 10-95% B (A= 0.1% formic acid in water; B=
0.1%
formic acid in acetonitrile) over 14.44 min then 95% B for 2.11 min, with an
injection
volume of 1500 pL and a flow rate of 40 mL/min. UV spectra were recorded at
215 nm
using a Gilson detector.
Method METCR0990
[070] Analytical METCR0990 HPLC-MS were performed on a Agilent G1312A system
with Waters PDA and ELS detectors using a Phenomenex Gemini-NX C18 column
(2.0 mm x 50 mm, 3 pM; temperature: 40 C) and a gradient of 1-100% (A= 2 mM
ammonium bicarbonate, buffered to pH 10 with ammonium hydroxide solution; B =
acetonitrile) over 1.8 min then 100% B for 0.3 min, with an injection volume
of 3 pL and
a flow rate of 1.0 mL/min. UV spectra were recorded at 215 nm using a Waters
2996
photo diode array detector. Mass spectra were obtained over the range m/z 150
to 850
at a sampling rate of 5 scans per sec using a Waters ZQ. Data were integrated
and
reported using Waters MassLynx and OpenLynx software.
Method METCR1410
[071] Analytical METCR1410 HPLC-MS were performed on Shimadzu LCMS-2010EV
systems using reverse phase Kinetex Core shell C18 columns (2.1 mm x 50 mm, 5
pm; temperature: 40 C) and a gradient of 5-100% B (A= 0.1% formic acid in
water; B=

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
19
0.1% formic acid in acetonitrile) over 1.2 min then 100% B for 0.1 min, with
an injection
volume of 3 pL and a flow rate of 1.2 mL/min. UV spectra were recorded at 215
nm
using a SPD-M20A photo diode array detector. Mass spectra were obtained over
the
range m/z 150 to 850 at a sampling rate of 2 scans per sec using a LCMS2010EV.
Data were integrated and reported using Shimadzu LCMS-Solutions and PsiPort
software.
Method METCR1603
[072] Analytical METCR1603 HPLC-MS were performed on a Agilent G1312A system
with Waters 2996 PDA detector and Waters 2420 ELS detector using a Phenomenex
Gemini ¨NX C18 column (2.0 x 100mm, 3!.trn column; temperature: 40 C) and a
gradient of 5-100% (A= 2 mM ammonium bicarbonate, buffered to pH 10; B =
acetonitrile) over 5.5 min then 100% B for 0.4 min, with an injection volume
of 3 pL and
a flow rate of 0.6 mL/min. UV spectra were recorded at 215 nm using a Waters
Acquity
photo diode array detector. Mass spectra were obtained over the range m/z 150
to 850
at a sampling rate of 5 scans per sec using a Waters ZQ mass detector. Data
were
integrated and reported using Waters MassLynx and OpenLynx software.
Method MET-uHPLC-AB-101
[073] Analytical MET-uHPLC-AB-101 HPLC-MS were performed on a Waters Acquity
uPLC system with Waters PDA and ELS detectors using a Phenomenex Kinetex-XB
C18 column (2.1 mm x 100 mm, 1.7 pM; temperature: 4000) and a gradient of 5-
100%
B (A = 0.1% formic acid in water; B = 0.1% formic acid in acetonitrile) over
5.3 min
then 100% B for 0.5 min, with an injection solution of 3 pL and a flow rate of
0.6
mL/min. UV spectra were recorded at 215 nm using a Waters Acquity photo diode
array detector. Mass spectra were obtained over the range m/z 150 to 850 at a
sampling rate of 5 scans per sec using a Waters SOD. Data were integrated and
reported using Waters MassLynx and OpenLynx software.
Method MET-uHPLC-AB-102
[074] Analytical MET-uHPLC-AB-102 HPLC-MS were performed on a Waters Acquity
uPLC system with Waters PDA and ELS detectors using a Waters uPLC CSH 018
column (2.1 mm x 100 mm, 1.7 pM; temperature: 40 C) and a gradient of 5-100%
(A=
2 mM ammonium bicarbonate, buffered to pH 10 with ammonium hydroxide solution;
B
= acetonitrile) over 5.3 min then 100% B for 0.5 min a flow rate of 0.6
mL/min. UV
spectra were recorded at 215 nm using a Waters Acquity photo diode array
detector.

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
Mass spectra were obtained over the range m/z 150 to 850 at a sampling rate of
5
scans per sec using a Waters Quatro Premier XE. Data were integrated and
reported
using Waters MassLynx and OpenLynx software.
MET-uHPLC-1704
[075] Analytical MET-uHPLC-1704 HPLC-MS were performed on a Waters Acquity
uPLC system with Waters PDA and ELS detectors using a Waters uPLC CSH 018
column (2.1 mm x 100 mm, 1.7 pM; temperature: 40 C) and a gradient of 5-100% B
(A = 0.1% formic acid in water; B = 0.1% formic acid in acetonitrile) over 1.1
min then
100% B for 0.25 min, with an injection solution of 2 pL and a flow rate of 0.9
mL/min.
UV spectra were recorded at 215 nm using a Waters Acquity photo diode array
detector. Mass spectra were obtained over the range m/z 150 to 850 at a
sampling
rate of 5 scans per sec using a Waters SOD. Data were integrated and reported
using
Waters MassLynx and OpenLynx software.
Method CAM-1
[076] Analytical chiral SFC were performed on a Waters Resolution SFC system
using Chiralpak AS-H columns (4.6 mm x 250 mm, 5 pm; temperature: 40 C) and
an
isocratic eluent of 7.5/2.5 002/IPA over 10 min, with an injection volume of
10 pL and a
flow rate of 4 mL/min. UV spectra were recorded at 215 nm using a Waters 2998
photo
diode array detector. Data were integrated using Waters MassLynx and OpenLynx
software.
Method CAM-2
[077] Analytical CAM-2 chiral LC were performed on a Waters LC system using
Chiralpak AS-H columns (4.6 mm x 250 mm, 5 pm; temperature: RT) and an
isocratic
eluent of acetonitrile over 15 min, with an injection volume of 20 pL and a
flow rate of 1
mL/min. UV spectra were recorded at 215 nm using a Waters 2996 photo diode
array
detector. Data were integrated and reported using Waters MassLynx and OpenLynx
software.
Method CAM-3
[078] Analytical CAM-3 chiral SFC were performed on a Waters Investigator SFC
system using Chiralcel OD-H columns (4.6 mm x 250 mm, 5 pm; temperature: 40
C)
and an isocratic eluent of 7.5/2.5 002:MeCN over 10 min, with an injection
volume of
10 pL and a flow rate of 4 mL/min. UV spectra were recorded at 240 nm using a

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
21
Waters 2998 photo diode array detector. Data were integrated and reported
using
Waters MassLynx and OpenLynx software.
Method CAM-4
[079] Analytical CAM-4 chiral LC were performed on a Waters LC system using
Cellulose-4 columns (4.6 mm x 250 mm, 5 pm; temperature: RT) and an isocratic
eluent of MeCN over 15 min, with an injection volume of 20 pL and a flow rate
of 1
mL/min. UV spectra were recorded at 215 nm using a Waters 2996 photo diode
array
detector. Data were integrated using Waters MassLynx and OpenLynx software.
Method CAM-5
[080] Analytical CAM-5 chiral LC were performed on a Waters LC system using
Cellulose-4 columns (4.6 mm x 250 mm, 5 pm; temperature: RT) and an isocratic
eluent of MeCN over 40 min, with an injection volume of 20 pL and a flow rate
of 0.5
mL/min. UV spectra were recorded at 215 nm using a Waters 2996 photo diode
array
detector. Data were integrated using Waters MassLynx and OpenLynx software.
Method CAM-6
[081] Analytical CAM-6 chiral LC were performed on a Waters LC system using
Amylose-2 columns (4.6 mm x 250 mm, 5 pm; temperature: RT) and an isocratic
eluent of MeCN over 12 min, with an injection volume of 20 pL and a flow rate
of 1
mL/min. UV spectra were recorded at 215 nm using a Waters 2996 photo diode
array
detector. Data were integrated using Waters MassLynx and OpenLynx software.
[082] All compounds displayed a purity >95% as determined by these methods
unless
otherwise stated.
[083] Compound names were generated using ChemAxon software: Instant JChem
Excel IUPAC Name function.
[084] Note:1-(Cyanomethyl)thiolan-1-ium bromide was synthesized by the
procedure
described in W02014/154829

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
22
GENERAL SCHEME 1:
1) Diazotsation/
Bro =)(()R
rninabon N N
NH,
Genera' Br 0 0 I I
procedure 1
OH Alloylation
R3 _____________ 0' FVly R ___________ I R ).1r)..(0.õ._
-0 'II
2) Esterification Genera'
0 0
General procedure 3 R3 0
procedure 2 R= Me, Et
1
Nitrinleerarel duction
re 4
H
0 R.
RR. H, Boc
R,, )=ycr0 = me, B
0 R
R3 0
Cyclisation Cyclisation
General General
procedure 58 procedure
51:1/5c
H
R/
IrC...\ 1/-1
o)rnirõ0 0
e0
0 R3 0 R3
AND ENANTIOMER
R= Me, Et
Hydrolysis
EpimerisationiHydrelysis
General General
procedure 6a procedure fib
Irec NI-;
0
HO
71
0 F.T3
AND ENANTIOMER
IYlide formation
General
procedural
& ) NH
18 0
0 ri3
AND ENANTIOME R
GENERAL PROCEDURE 1 (GENERAL SCHEME 1): Diazotisation/bromination
2-Bromo-3-phenylpropanoic acid (1-1)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
23
[085] To an ice-cooled stirred suspension of phenylalanine (5.0 g, 30.27 mmol)
in
water (35 mL) was added H2SO4 (5.0 mL, 93.80 mmol) and NaBr (10.9 g, 105.94
mmol). A solution of NaNO2 (2.61 g, 37.83 mmol) in water (40 mL) was added
dropwise over 15 min and the reaction was stirred at 0 00 for 1 h then allowed
to warm
and stirred at RT for 5 h. The mixture was extracted with Et0Ac (3 x 100 mL)
and the
combined organic extracts washed with brine (100 mL), dried over Na2SO4and
concentrated in vacuo to give 7.64 g of 2-bromo-3-phenylpropanoic acid as a
pale
yellow liquid (61% purity, 67%) which was used in the next step without
further
purification.
[086] LC-MS (METCR1410): 61% (UV), Rt= 1.04 min, m/z (ESI+)= 226.8/228.8 [M-H]-
[087] 1H NMR (250 MHz, Chloroform-o) 63.25 (dd, J =7 .2, 14.2 Hz, 1H), 3.48
(dd, J
=8.1, 14.2 Hz, 1H), 4.43 (dd, J =7 .3, 8.1 Hz, 1H), 7.26 (s, 5H)
GENERAL PROCEDURE 2 (GENERAL SCHEME 1): Esterification
Ethyl 2-bromo-3-phenylpropanoate (1-2)
[088] To a solution of 2-bromo-3-phenylpropanoic acid (1-1) (61% purity, 7.64
g, 20.34
mmol) in Et0H (100 mL) was added H2SO4 (610 pL, 11.44 mmol) and the mixture
heated at reflux for 1.5 h, cooled to RT and concentrated in vacuo. The
residue was
dissolved in Et20 (100 mL), washed with sat. NaHCO3 (100 mL) and brine (100
mL)
and the organic phase dried over Na2SO4and concentrated in vacuo. The residue
was
purified by FCC on normal phase silica (100 g SNAP KP-SIL cartridge, 0-30%
Et0Ac
in heptane gradient) to afford 5.22 g of ethyl 2-bromo-3-phenylpropanoate as a
colourless oil (97% purity, 97%).
[089] LC-MS (METCR1410): 97% (UV), Rt= 1.26 min, m/z (ESI-)= 256.9/258.9
[090] 1H NMR (500 MHz, Chloroform-a) 6 1.25 (t, J =7 .1 Hz, 3H), 3.27 (dd, J =
14.1,
7.1 Hz, 1H), 3.48 (dd, J = 14.1, 8.5 Hz, 1H), 4.16 - 4.24 (m, 2H), 4.41 (dd, J
= 8.5 , 7.1
Hz, 1H), 7.22 - 7.26 (m, 2H), 7.28 - 7.35 (m, 3H)
Methyl 2-bromo-3-phenylpropanoate (1-3)
[091] To a solution of 2-bromo-3-phenylpropanoic acid (1-1) (25 g, 109.14
mmol) in
Me0H (225 mL) was added H2504 (3.25 mL, 63.79 mmol) and the mixture heated at
reflux for 2 h, cooled to RT and concentrated in vacuo. The residue was
dissolved in
Et20 (220 mL), washed with sat. NaHCO3 (160 mL) and brine (160 mL) and the
organic phase dried over Na2SO4and concentrated in vacuo. The residue was
purified

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
24
by FCC on normal phase silica (340 g SNAP KP-SIL cartridge, 0-20% Et0Ac in
heptane gradient) to afford 23.3 g of methyl 2-bromo-3-phenylpropanoate as a
clear
yellow free-flowing oil (98% purity, 86%).
[092] LC-MS (METCR1410): 98% (UV), Rt= 1.17 min, no ionisation.
[093] 1H NMR (500 MHz, Chloroform-a) 63.25 (dd, J= 7.1, 14.1 Hz, 1H), 3.47
(dd, J
= 8.4, 14.1 Hz, 1H), 3.73 (s, 3H), 4.41 (dd, J= 7.1, 8.4 Hz, 1H), 7.19 - 7.23
(m, 2H),
7.24 - 7.29 (m, 1H), 7.29 - 7.34 (m, 2H)
Ethyl 2-bromo-2-(4-fluorophenyl)acetate (1-4)
[094] To a solution of 2-bromo-2-(4-fluorophenyl)acetic acid (10 g, 41.2 mmol)
in
Et0H (30 mL) was added conc. HC1(354 pL, 4.24 mmol) and the reaction was
heated
at 50 0C for 2 h, stirred at RT for 2 h, cooled and concentrated in vacuo. The
residue
was purified by FCC on normal phase silica (100 g SNAP KP-SIL cartridge, 0-
100%
Et0Ac in heptane gradient) to afford 9.9 g ethyl 2-bromo-2-(4-
fluorophenyl)acetate_as
a colourless free-flowing oil (100% purity, 92%).
[095] LC-MS (METCR1410): 100% (UV), Rt= 1.19 min, no ionisation.
[096] 1H NMR (250 MHz, Chloroform-a) 61.28 (t, 3H), 4.16 - 4.32 (m, 2H), 5.32
(s,
1H), 6.98 - 7.13 (m, 2H), 7.43 - 7.60 (m, 2H)
GENERAL PROCEDURE 3 (GENERAL SCHEME 1): Alkylation
1,4-Diethyl 2-benzy1-3-cyanobutanedioate (1-5)
[097] To a solution of ethyl cyanoacetate (2.14 mL, 20.11 mmol) in Et0H (80
mL) was
added 21% w/w Na0Et in ethanolic solution (7.85 mL, 21.02 mmol) and the
mixture
stirred at RT for 15 min. A solution of ethyl 2-bromo-3-phenylpropanoate (1-2)
(4.7 g,
18.28 mmol) in Et0H (80 mL) was added slowly and the mixture heated at reflux
for
1.5 h. The reaction was cooled to RT, quenched with AcOH (3 mL), diluted with
water
(200 mL) and neutralised by portionwise addition of solid NaHCO3. The mixture
was
extracted with DCM (3 x 150 mL) and the combined organic extracts dried over
Na2SO4and concentrated in vacuo. The residue was purified by FCC on normal
phase
silica (100 g SNAP KP-SIL cartridge, 0-50% Et0Ac in heptane gradient) to
afford 3.29
g of 1,4-diethyl 2-benzy1-3-cyanobutanedioate as a pale yellow oil (97%
purity, 60%).
[098] LC-MS (METCR1410): 97% (UV), Rt= 1.20 min, m/z (ES14-)= 290.0 [M+H].#
1,4-Diethyl 2-cyano-3-phenylbutanedioate (1-6)
[099] The title compound was synthesized from ethyl 2-bromo-2-phenylacetate in
a
similar manner to general procedure 3 (general scheme 1) as a pale yellow
viscous oil

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
(24.3 g, 95% purity, 82%) after purification by FCC on normal phase silica
(340 g
SNAP KP-SIL cartridge, 0-30% Et0Ac in heptane gradient).
[0100] LC-MS (METCR1410): 95% (UV), Rt= 1.20 min, m/z (ES14-)= 276.1 [M-FH]4-
[0101] 1H NMR (500 MHz, Chloroform-o) 6 1.16 - 1.35 (m, 6H), 3.92 - 4.36 (m,
6H),
7.29 - 7.42 (m, 5H)
1,4-Diethyl 2-cyano-3-(4-fluorophenyl)butanedioate (1-7)
[0102] The title compound was synthesized from ethyl 2-bromo-2-(4-
fluorophenyl)acetate (1-4) in a similar manner to general procedure 3 (general
scheme
1) as an orange oil (7.9 g, 98% purity, 70%) after purification by FCC on
normal phase
silica (340 g SNAP KP-SIL cartridge, 0-30% Et0Ac in heptane gradient).
[0103] LC-MS (METCR1410): 98% (UV), Rt= 1.77 min, m/z (ES14-)= 294.1 [M+H]4-
[0104] 1H NMR (500 MHz, Chloroform-d) 6 1.37 - 1.57 (m, 6H), 4.14 - 4.62 (m,
6H),
7.23 - 7.34 (m, 2H), 7.48 - 7.60 (m, 2H)
1,4-Dimethyl 2-benzy1-3-cyanobutanedioate (1-8)
[0105] To a solution of methyl 2-cyanoacetate (10 mL, 107.28 mmol) in Me0H
(150
mL) was added 21% w/w Na0Et in ethanolic solution (41 mL, 109.82 mmol) and the
mixture stirred at RT for 30 min. A solution of methyl 2-bromo-3-
phenylpropanoate (1-3)
(98% purity, 23.3 g, 93.85 mmol) in Me0H (150 mL) was added slowly and the
mixture
heated at reflux for 5 h. The reaction was cooled to RT, concentrated to 100
mL,
quenched with AcOH (5 mL), diluted with water (200 mL) and neutralised by
portionwise addition of solid NaHCO3. The mixture was extracted with DCM (3 x
250
mL) and the combined organic extracts dried over Na2SO4and concentrated in
vacuo.
The residue was purified by FCC in 2 batches on normal phase silica (340 g
SNAP
KP-SIL cartridge, 0-25% Et0Ac in heptane gradient) to afford 9.2 g of 1,4-
dimethyl 2-
benzy1-3-cyanobutanedioate as a yellow oil (94% purity, 35%).
[0106] LC-MS (METCR1410): 94% (UV), Rt= 1.09 min, m/z (ESI+)= 262.1 [M+H]4-
[0107] 1H NMR (500 MHz, Chloroform-a) 62.89 (dd, J= 10.9, 13.5 Hz, 1H), 3.17 -
3.91 (m, 1H), 3.36 - 3.51 (m, 2H), 3.67 - 3.81 (m, 6H), 3.89 (d, J= 7.3 Hz,
OH), 7.17 -
7.37 (m, 5H)
GENERAL PROCEDURE 4 (GENERAL SCHEME 1): Nitrile reduction
Method A: Hydrogenation using Pt02
1,4-Diethyl 2-(aminomethyl)-3-phenylbutanedioate (1-9)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
26
[0108] To a solution of 1,4-diethyl 2-cyano-3-phenylbutanedioate (1-6) (96%
purity,
10.49 g, 36.58 mmol) in Et0H (100 mL) were added 12M HCl (15 mL) and Pt02
(0.83
g, 3.66 mmol) and the suspension stirred under an atmosphere of hydrogen for
18 h.
The reaction was filtered through a plug of Celite and the resultant cake
washed with
Et0H. The combined filtrates were concentrated in vacuo and the residue
dissolved in
water (100 mL) and extracted with toluene (50 mL). The aqueous phase was
neutralised by portionwise addition of solid NaHCO3 and extracted with 0HC13
(3 x 150
mL). The combined organic extracts were dried over Na2SO4and concentrated in
vacuo to give 10.35 g of 1,4-diethyl 2-(aminomethyl)-3-phenylbutanedioate as a
pale
yellow oil (69% purity, 70%) which was used in the next step without further
purification. The compound contained 1,4-diethyl 2-(aminomethyl)-3-
cyclohexylbutane-
dioate as a minor by-product.
[0109] LC-MS (METCR1410): 69% (UV), Rt= 0.83 min, m/z (ES14-)= 280.0 [M+H].#
Method B: Hydrogenation using Pd/C
1,4-Diethyl 2-(aminomethyl)-3-benzylbutanedioate (1-10)
[0110] To a solution of 1,4-diethyl 2-benzy1-3-cyanobutanedioate (1-5) (2.8 g,
9.68
mmol) in Et0H (100 mL) were added 12M HC1(4.24 mL) and 10% Pd/C (0.21 g, 1.94
mmol) and the suspension stirred under an atmosphere of hydrogen for 24 h. The
reaction was filtered through a plug of Celite and the resultant cake washed
with Et0H.
The combined filtrates were concentrated in vacuo and the residue dissolved in
water
(80 mL) and extracted with toluene (50 mL). The aqueous phase was neutralised
by
portionwise addition of solid NaHCO3 and extracted with CHC13 (2 x 80 mL) then
3:1
CHC13/1PA (3 x 80 mL). The combined organic extracts were dried over Na2SO4and
concentrated in vacuo to give 2.56 g of 1,4-diethyl 2-(aminomethyl)-3-
benzylbutanedioate as a yellow oil (71% purity, 64%) which was used in the
next step
without further purification.
[0111] LC-MS (METCR1410): 71% (UV), Rt= 0.94 min, m/z (ES14-)= 294.0 [M+H].
1,4-Diethyl 2-(aminomethyl)-3-phenylbutanedioate (1-9)
[0112] The title compound was synthesized from 1,4-diethyl 2-cyano-3-
phenylbutanedioate (1-6) in a similar manner to method B, general procedure 4
(general scheme 1) as a pale yellow viscous oil (2.75 g, 91% purity, 49%)
which was
used in the next step without further purification.
[0113] LC-MS (METCR0990): 91% (UV), Rt= 1.61 min, m/z (ES1+)= 280.3 [M+H].

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
27
1,4-Dimethyl 2-(aminomethyl)-3-benzylbutanedioate (1-11)
[0114] The title compound was synthesized from 1,4-dimethyl 2-cyano-3-
phenylbutanedioate (1-8) in a similar manner to method B, general procedure 4
(general scheme 1) as a yellow oil (844 mg, 64% purity, 12%) which was used in
the
next step without further purification.
[0115] LC-MS (METCR1410): 64% (UV), Rt= 0.92 min, m/z (ES1)= 266.1 [M+H]
Method C: Reduction using NaBF14 in the presence of NiC12
1,4-Diethyl 2-({[(tert-butoxy)carbonyl]amino}methyl)-3-(4-
fluorophenyl)butanedioate (I-
12)
[0116] To a solution of 1,4-diethyl 2-cyano-3-(4-fluorophenyl)butanedioate (1-
7) (7.2 g,
22.83 mmol) in Et0H (300 mL) were added Boc20 (12.46 g, 57.08 mmol) and
NiC12.6H20 (8.14 g, 34.25 mmol). The suspension was cooled to 0 0C and NaB1-14
(8.64
g, 228.30 mmol) added portionwise over 2 min. The mixture was stirred at 15 00
for 1.5
h, cooled to 0 0C and ethylene diamine (50 mL) added. The reaction was stirred
at 0 00
for 1 h sat. NaHCO3 (200 mL) added and the mixture stirred at RT for 10 min.
Et0Ac
(200 mL) was added and the black suspension transferred to a large conical
flask,
diluted with sat. NaHCO3 (200 mL), Et0Ac (200 mL) and ethylene diamine (100
mL).
Additional ethylene diamine (100 mL) was added and the suspension stirred
until a
solution was obtained. Brine (200 mL) was added and the two phases separated.
The
aqueous layer was extracted with Et0Ac (3 x 300 mL) and the combined organic
extracts washed with brine (2 x 200 mL), dried over MgSat and concentrated in
vacuo
to afford 8.0 g of 1,4-diethyl 2-({[(tert-butoxy)carbonyl]aminolmethyl)-3-(4-
fluorophenyl)butane-dioate as a light orange viscous oil (91% purity by 1H
NMR, 80%)
which was used in the next step without further purification.
[0117] LC-MS (METCR0990): 97% (UV), Rt= 1.95 min, m/z (ESI+)= 398.2 [M+H]+
[0118] 1H NMR (500 MHz, Chloroform-a) 60.91 ¨ 1.32 (m, 6H), 1.33¨ 1.47 (m,
9H),
2.73 ¨ 3.54 (m, 4H), 3.77 ¨ 4.24 (m, 4H), 4.52 ¨ 4.94 (m, 1H), 6.94 ¨ 7.06 (m,
2H), 7.23
¨ 7.32 (m, 2H)
GENERAL PROCEDURE 5a (GENERAL SCHEME 1): Cyclisation
Rac-ethyl (3R,4R)-4-benzy1-5-oxopyrrolidine-3-carboxylate (1-13) and
Rac-ethyl (3R,4S)-4-benzy1-5-oxopyrrolidine-3-carboxylate (1-14)
[0119] 1,4-Diethyl 2-(aminomethyl)-3-benzylbutanedioate (I-10)(71% purity,
2.56 g,
8.73 mmol) was dissolved in toluene (50 mL) and the reaction mixture heated at
reflux

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
28
for 2 h, cooled to RT and concentrated in vacuo. The residue was purified by
FCC on
normal phase silica (50 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane
gradient)
to afford 345 mg of rac-ethyl (3R,4R)-4-benzy1-5-oxopyrrolidine-3-carboxylate
as a
pale yellow solid (95% purity, 15%) and 543 mg of rac-ethyl (3R,45)-4-benzy1-5-
oxopyrrolidine-3-carboxylate as an off-white solid (96% purity, 24%).
Rac-ethyl (3R,4R)-4-benzy1-5-oxopyrrolidine-3-carboxylate (1-13)
[0120] LC-MS (METCR1410): 95% (UV), Rt= 0.97 min, m/z (ES14-)= 248.0 [M+H]4-
[0121] 1H NMR (500 MHz, Chloroform-o) 6 1.20 (t, J =7 .1 Hz, 3H), 2.97 ¨ 3.11
(m,
3H), 3.19 (dd, J = 12.8, 3.6 Hz, 1H), 3.35 (t, J=8.7 Hz, 1H), 3.46 (dd, J =
9.4 , 7.8 Hz,
1H), 4.04 (qq, J = 10.8, 7.1 Hz, 2H), 5.44 (s, 1H), 7.20 ¨ 7.35 (m, 5H)
Rac-ethyl (3R,45)-4-benzy1-5-oxopyrrolidine-3-carboxylate (1-14)
[0122] LC-MS (METCR1410): 96% (UV), Rt= 0.96 min, m/z (ES14-)= 248.0 [M+H]4-
[0123] 1H NMR (500 MHz, Chloroform-o) 6 1.08 (t, J =7 .1 Hz, 3H), 2.75 (dd, J
= 14.6,
9.8 Hz, 1H), 2.94 (ddd, J =9.6 , 8.6, 4.4 Hz, 1H), 3.16 (dd, J = 14.6, 4.3 Hz,
1H), 3.20 ¨
3.28 (m, 1H), 3.33 ¨ 3.41 (m, 2H), 3.79 ¨ 3.88 (m, 1H), 3.95 ¨ 4.06 (m, 1H),
6.37 (s,
1H), 7.10 ¨ 7.17 (m, 3H), 7.17 ¨ 7.24 (m, 2H)
Rac-ethyl (3R,45)-4-pheny1-5-oxopyrrolidine-3-carboxylate (1-15) and
Rac-ethyl (3R,4R)-4-phenyl-5-oxopyrrolidine-3-carboxylate (1-16)
[0124] The title compounds were synthesized from crude 1,4-diethyl 2-
(aminomethyl)-
3-phenylbutanedioate (1-9) prepared from method A, general procedure 4
(general
scheme 1) in a similar manner to general procedure 5a (general scheme 1) as
off-
white solids after purification by FCC on normal phase silica (340 g SNAP KP-
SIL
cartridge, 0-100% Et0Ac in heptane gradient) to give 3.11 g of rac-ethyl
(3R,45)-4-
pheny1-5-oxopyrrolidine-3-carboxylate (88% purity, 32%) and 1.05 g of rac-
ethyl
(3R,4R)-4-phenyl-5-oxopyrrolidine-3-carboxylate (83% purity, 10%). Both
compounds
contained a minor cyclohexyl by-product (8% and 10% by LC/MS respectively).
Rac-ethyl (3R,45)-4-pheny1-5-oxopyrrolidine-3-carboxylate (1-15)
[0125] LC-MS (METCR1410): 88% (UV), Rt= 0.92 min, m/z (ES14-)= 234.1 [M+H]4-
Rac-ethyl (3R,4R)-4-phenyl-5-oxopyrrolidine-3-carboxylate (1-16)
[0126] LC-MS (METCR1410): 83% (UV), Rt= 0.88 min, m/z (ES1)= 234.1 [M+H]4-

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
29
GENERAL PROCEDURE 5b (GENERAL SCHEME 1): Cyclisation
Ethyl 5-oxo-4-phenylpyrrolidine-3-carboxylate (1-17)
[0127] 1,4-Diethyl 2-(aminomethyl)-3-phenylbutanedioate (1-9) (4.5 g, 16.11
mmol)
prepared from method B, general procedure 4 (general scheme 1) was heated on a
rotary evaporator at 50 C under 15 mbar for 15 h then cooled to RT to afford
3.55 g of
ethyl 5-oxo-4-phenylpyrrolidine-3-carboxylate as a pale yellow solid (93%
purity, 88%,
-2:1 cis:trans mixture) which was used in the next step without further
purification.
[0128] LC-MS (METCR0990): 63% + 30% (UV), Rt= 1.40 min + 1.45 min, miz (ESI)=
234.2 [M+H]4-
Methyl 4-benzy1-5-oxopyrrolidine-3-carboxylate (1-18)
[0129] 1,4-Dimethyl 2-(aminomethyl)-3-benzylbutanedioate (1-11) (64% purity,
844
mg, 2.04 mmol) was dissolved in toluene (15 mL) and the reaction mixture
heated at
reflux for 2 h, cooled to RT and concentrated in vacuo. The residue was
purified by
FCC on normal phase silica (50 g SNAP KP-SIL cartridge, 0-100% Et0Ac in
heptane
gradient) to afford 544 mg of methyl 4-benzy1-5-oxopyrrolidine-3-carboxylate
as a dark
orange solid (94% purity, quantitative).
[0130] LC-MS (METCR1410): 94% (UV), Rt= 0.91 min, rniz (ES1)= 234.2 [M+H]+
[0131] 1H NMR (500 MHz, Chloroform-a) 5 2.72 - 3.48 (m, 6H), 3.53 - 3.57 (m,
3H),
5.64- 5.77 (m, 1H), 7.17- 7.24 (m, 3H), 7.26 -7.30 (m, 2H).
GENERAL PROCEDURE 5c (GENERAL SCHEME 1): Cyclisation after Boc
deprotection
Ethyl 4-(4-fluoropheny1)-5-oxopyrrolidine-3-carboxylate (1-19)
[0132] To a solution of 1,4-diethyl 2-({[(tert-butoxy)carbonyl]aminolmethyl)-3-
(4-
fluorophenyl)butanedioate (1-12) (7.99 g, 19.5 mmol) in DCM (20 mL) was added
4N
HC1 in 1,4-dioxane (35 mL, 140 mmol) and the reaction stirred at RT for 3 h.
The
mixture was concentrated in vacuo and the residue partitioned between water
(30 mL)
and DCM (30 mL) The aqueous phase was neutralised with solid NaHCO3, DCM (50
mL) added and the two phases separated. The aqueous layer was extracted with
DCM
(3 x 30 mL) and the combined organic extracts washed with brine (30 mL), dried
over
MgSO4 and concentrated in vacuo. The material obtained was dissolved in MeCN
(20
mL) and the solution heated at 80 C for 3 h, cooled to RT and concentrated in
vacuo.
The residue was suspended in Et20 (10 mL) and the suspension sonicated for 5
min.
The resulting solid was collected by filtration and the filtrate concentrated
in vacuo. The

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
trituration process was repeated on the material obtained from the filtrate
until no
further solid was obtained. The solid crops were combined to afford 3.5 g
ethyl 4-(4-
fluoropheny1)-5-oxopyrrolidine-3-carboxylate as an off-white powder (100%
purity,
71%, -2:1 cis:trans mixture) which was used in the next step without further
purification.
[0133] LC-MS (METCR0990): 63% + 37% (UV), Rt= 1.43 min + 1.48 min, m/z (ES14-
)=
252.2 [M+H]4-
[0134] 1H NMR (500 MHz, Chloroform-d) 60.81 -1.70 (m, 3H), 3.28 - 4.72 (m,
6H),
6.99 - 8.17 (m, 5H)
GENERAL PROCEDURE 6a (GENERAL SCHEME 1): Hydrolysis of trans-racemic
mixture
Rac-(3R,4R)-4-benzy1-5-oxopyrrolidine-3-carboxylic acid (1-20)
[0135] To a solution of rac-ethyl (3R,4R)-4-benzy1-5-oxopyrrolidine-3-
carboxylate (I-
13) (345 mg, 1.40 mmol) in THF (10 mL) was added 2M NaOH (1.7 mL, 3.35 mmol)
and the reaction stirred at RT for 16 h then concentrated in vacuo. The
residue was
diluted with water (20 mL) and extracted with Et20. The aqueous phase was
acidified
with 2M HCI and extracted with 3:1 0H013:1PA (3 x 30 mL). The combined organic
extracts were dried over Na2SO4and concentrated in vacuo to give 276 mg of rac-
(3R,4R)-4-benzy1-5-oxopyrrolidine-3-carboxylic acid as a pale yellow solid
(90% purity,
81%) which was used in the next step without purification.
[0136] LC-MS (METCR1410): 90% (UV), Rt= 0.80 min, m/z (ES1)= 220.2 [M+H]4-
[0137] 1H NMR (250 MHz, Chloroform-o) 6 2.99 - 3.18 (m, 4H), 3.34 (t, J=9.0
Hz,
1H), 3.42 - 3.57 (m, 1H), 6.49 (s, 1H), 7.26 (s, 5H)
Rac-(3R,4S)-5-oxo-4-phenylpyrrolidine-3-carboxylic acid (1-21)
[0138] The title compound was synthesized from crude rac-ethyl (3R,4S)-4-
pheny1-5-
oxopyrrolidine-3-carboxylate (1-15) in a similar manner to general procedure
6a
(general scheme 1) as an off-white solid (1.13 g, 80% purity by 1H NMR, 68%)
obtained after work-up and used in the next step without further purification.
The
compound contained rac-(3R,4R)-4-cyclohexy1-5-oxopyrrolidine-3-carboxylic acid
as a
minor by-product.
[0139] LC-MS (METCR1410): 97% (UV), Rt= 0.69 min, m/z (ES14-)= 206.2 [M+H]+
[0140] 1H NMR (250 MHz, Chloroform-a) 6 3.29 - 3.44 (m, 1H), 3.54 - 3.78 (m,
2H),
3.95 (d, J= 8.8 Hz, 1H), 6.80 (s, 1H), 7.18 - 7.34 (m, 5H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
31
GENERAL PROCEDURE 6b (GENERAL SCHEME 1): Epimerisation/hydrolysis of
diastereoisomeric mixture
Rac-(3R,4S)-5-oxo-4-phenylpyrrolidine-3-carboxylic acid (1-21)
[0141] To a solution of ethyl 5-oxo-4-phenylpyrrolidine-3-carboxylate (1-17)
(3.55 g,
15.22 mmol) in 3:2 MeOH:water (25 mL) was added 2M NaOH (12 mL, 24 mmol) and
the mixture stirred at 60 C for 3 h then concentrated in vacuo. The residue
was diluted
with water (20 mL), acidified to pH -3 with 2N HCI and the precipitate
filtered and dried
in a vacuum oven at 40 C to afford 2.6 g of rac-(3R,4S)-5-oxo-4-
phenylpyrrolidine-3-
carboxylic acid as an off-white solid (92% purity, 77%) which was used in the
next step
without further purification.
[0142] LC-MS (METCR1410): 92% (UV), Rt= 0.72 min, m/z (ES14-)= 206.0 [M+H]4-
[0143] 1H NMR (500 MHz, Chloroform-a) 6 3.38 - 3.46 (m, 1H), 3.63 - 3.68 (m,
1H),
3.73 - 3.79 (m, 1H), 4.03 (d, J= 8.7 Hz, 1H), 7.26 - 7.32 (m, 3H), 7.33 - 7.39
(m, 2H)
Ethyl 4-(4-fluorophenyI)-5-oxopyrrolidine-3-carboxylate (1-22)
[0144] The title compound was synthesized from ethyl 4-(4-fluorophenyI)-5-
oxopyrrolidine-3-carboxylate (1-19) in a similar manner to general procedure
6b
(general scheme 1) as an off-white solid (810 mg, 97% purity, 88%) obtained
after
work-up and used in the next step without further purification.
[0145] LC-MS (MET-uHPLC-AB-101): 97% (UV), Rt= 1.38 min, m/z (ES14-)= 224.1
[M+H]
[0146] 1H NMR (500 MHz, DMSO-d6) 6 3.30 - 3.38 (m, 2H), 3.52 - 3.59 (m, 1H),
3.72
-3.80 (m, 1H), 7.06 - 7.20 (m, 2H), 7.20 - 7.37 (m, 2H), 7.95 (s, 1H), 12.56
(s, 1H).
GENERAL PROCEDURE 7 (GENERAL SCHEME 1): Ylide formation
Rac-3-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-2-(1X4-thiolan-1-ylidene)-3-oxo-
propanenitrile (1-23)
[0147] To a solution of rac-(3R,4R)-4-benzy1-5-oxopyrrolidine-3-carboxylic
acid (1-20)
(90% purity, 276 mg, 1.26 mmol) and DIPEA (658 pL, 3.78 mmol) in DCM (20 mL)
was
added HATU (527 mg, 1.38 mmol) and 1-(cyanomethyl)thiolan-1-ium bromide (90%
purity, 349 mg, 1.51 mmol, synthesized by the procedure outlined in Note 1,
general
experimental details) and the mixture stirred at RT for 1.5 h. The reaction
was
quenched with sat. NH4CI (30 mL), the aqueous phase extracted with DCM (3 x 50
mL)
and the combined organic phases dried over Na2SO4and concentrated in vacuo.
The
residue was purified by FCC on normal phase silica (10 g SNAP Ultra cartridge,
0-20%

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
32
Me0H in Et0Ac gradient) to afford 424 mg of rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-
3-yI]-2-(1X4-thiolan-1-ylidene)-3-oxopropanenitrile as an off-white solid (98%
purity,
100%).
[0148] LC-MS (METCR1410): 98% (UV), Rt= 0.82 min, m/z (ESI+)= 329.0 [M+H].#
[0149] 1H NMR (250 MHz, Chloroform-a) 6 1.88 ¨ 2.10 (m, 2H), 2.37 ¨ 2.59 (m,
2H),
2.67 (dd, J= 13.8, 10.1 Hz, 1H), 2.85 ¨ 3.06 (m, 2H), 3.10 ¨ 3.30 (m, 4H),
3.31 ¨3.46
(m, 2H), 3.50 ¨ 3.66 (m, 1H), 5.46 (s, 1H), 7.14 ¨ 7.36 (m, 5H)
Rac-3-oxo-3-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-y1]-2-(1A4-thiolan-1-
ylidene)propane-
nitrile (1-24)
[0150] The title compound was synthesized from rac-(3R,4S)-5-oxo-4-
phenylpyrrolidine-3-carboxylic acid (1-21) prepared from general procedure 6b
(general
scheme 1) in a similar manner to general procedure 7 (general scheme 1) as an
off-
white solid (2.20 g, 100% purity, 55%) obtained after trituration in DCM.
[0151] LC-MS (METCR1410): 100% (UV), Rt= 0.79 min, m/z (ESI-)= 315.0 [M-FH]4-
[0152] 1H NMR (500 MHz, Chloroform-o) 6 1.98 ¨ 2.11 (m, 2H), 2.47 ¨ 2.62 (m,
2H),
3.18 ¨ 3.35 (m, 2H), 3.35 ¨ 3.47 (m, 3H), 3.71 (t, J= 8.9 Hz, 1H), 3.79 ¨ 3.90
(m, 1H),
4.11 (d, J= 9.4 Hz, 1H), 6.31 (s, 1H), 7.25 ¨ 7.29 (m, 3H), 7.29 ¨ 7.39 (m,
2H)
[0153] Note: Crude batches of rac-3-oxo-3-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
y1]-2-
(1)1/44-thiolan-1-ylidene)propane-nitrile (1-24) prepared from rac-(3R,4S)-5-
oxo-4-
phenylpyrro-lidine-3-carboxylic acid (1-21) synthesized according to general
procedure
6a (general scheme 1) contained rac-3-[(3R,4R)-4-cyclohexy1-5-oxopyrrolidin-3-
y1]-3-
oxo-2-(110-thiolan-1-ylidene)propanenitrile as a minor by-product.
Rac-3-[(3R,4S)-4-(4-fluoropheny1)-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propanenitrile (1-25)
[0154] The title compound was synthesized from ethyl 4-(4-fluorophenyI)-5-
oxopyrrolidine-3-carboxylate (1-22) in a similar manner to general procedure 7
(general
scheme 1) as an off-white powder (1.08 g, 96% purity, 91%) after purification
by FCC
on normal phase silica (25 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane
gradient followed by 0-50% Me0H in Et0Ac gradient).
[0155] LC-MS (METCR1410): 100% (UV), Rt= 0.79 min, m/z (ESI+)= 315.0 [M+H]4-
[0156] 1H NMR (500 MHz, Chloroform-a) 6 1.98 ¨ 2.15 (m, 2H), 2.46 ¨ 2.59 (m,
2H),
3.16¨ 3.29(m, 2H), 3.32 ¨ 3.42 (m, 3H), 3.65(t, J= 9.0 Hz, 1H), 3.75 (q, 1H),
4.08 (d,
J= 9.8 Hz, 1H), 6.88 (s, 1H), 6.97 ¨ 7.03 (m, 2H), 7.18 ¨ 7.25 (m, 2H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
33
GENERAL SCHEME 2:
Nicc
Boc
N
Bac proteclion 0 Alkylation
_____________ 0 ________
General 113C
General H C
procedure 1
0 0 procedure 2
0 R3
AND ENAN11OMER
Boc deprotection
General
procedure 3
0 NH Nirec
0 Ylide formation _____ 0 Hydrolysis 0
HO 0
.s General General H3C
Ft3 procedure 5 0 F--4-3 procedure 4
AND ENANTIOMER AND ENANTIOMER AND ENANTIOMER
GENERAL PROCEDURE 1 (GENERAL SCHEME 2): Boc protection
1-tert-butyl 3-methyl 5-oxopyrrolidine-1,3-dicarboxylate (1-26)
[0157] To a stirred solution of methyl 5-oxopyrrolidine-3-carboxylate (20 g,
139.72
mmol) in DCM (200 mL) was added TEA (58.4 mL, 419.16 mmol) and DMAP (1.7 g,
13.97 mmol). The mixture was stirred for 15 min at RT then Boc20 (61.0 g,
279.44
mmol) was added and the reaction stirred at RT for 17 h. The solution was
diluted with
water (150 mL) and acidified slowly to pH 4 with 1N HCI. The aqueous layer was
separated and extracted with DCM (200 mL) and the combined organic extracts
washed with brine (150 mL), dried over Na2SO4, filtered and concentrated in
vacuo.
The crude material was purified by FCC on normal phase silica in two batches
(340 g
SNAP Ultra cartridge, 0-73% Et0Ac in heptane gradient) to afford 31.6 g of 1-
tert-butyl
3-methyl 5-oxopyrrolidine-1,3-dicarboxylate as a light yellow solid (98%
purity, 91%).
[0158] LC-MS (METCR1410): 98% (UV), Rt= 0.94 min, m/z (ES1+)= 188.4 [M+H-tBu]#
[0159] 1H NMR (500 MHz, Chloroform-a) 6 1.52 (s, 9H), 2.74 (dd, J= 9.5, 17.7
Hz,
1H), 2.85 (dd, J= 8.0, 17.7 Hz, 1H), 3.19 (p, J= 8.8 Hz, 1H), 3.75 (s, 3H),
3.90 (dd, J=
7.0, 11.2 Hz, 1H), 3.97 (dd, J= 8.8, 11.2 Hz, 1H)
GENERAL PROCEDURE 2 (GENERAL SCHEME 2): Alkylation
Rac-1-tert-butyl 3-methyl (3R,4R)-4-[(4-fluorophenyl)methy1]-5-oxopyrrolidine-
1,3-
dicarboxylate (1-27)
[0160] To a stirring solution of 1-tert-butyl 3-methyl 5-oxopyrrolidine-1,3-
dicarboxylate
(1-26) (98% purity, 5.43 g, 21.88 mmol) in dry THF (35 mL) under nitrogen at -
78 C
was added 1M LHMDS in THF (24.0 mL, 24.06 mmol) dropwise over 15 min. The

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
34
mixture was stirred at -78 C for 1 h, 1-(bromomethyl)-4-fluorobenzene (2.9
mL, 23.28
mmol) in dry THF (10 mL) was added dropwise over 5 min and the reaction
stirred at -
78 C for 2.5 h. The reaction was quenched with sat. NH401(40 mL) at -78 C
and
extracted with Et0Ac (3 x 25 mL). The combined organic phases were washed with
brine (15 mL), dried over Na2SO4, filtered and concentrated in vacuo to -25
mL. The
thick emulsion was diluted with heptane (50 mL) and the product collected by
filtration,
washed with heptane (50 mL) and dried in vacuo in a vacuum oven at 50 C for
15 h to
afford 4.66 g of rac-1-tert-butyl 3-methyl (3R,4R)-4-[(4-fluorophenyl)methy1]-
5-
oxopyrrolidine-1,3-dicarboxylate as an off-white solid (99% purity, 60%).
[0161] LC-MS (METCR1410): 99% (UV), Rt= 1.22 min, m/z (ES14-)= 252.0 [M+H-Bu]+
[0162] 1H NMR (500 MHz, Chloroform-a) 5 1.52 (s, 9H), 2.84 (q, 1=9.2 Hz, 1H),
2.96
-3.04 (m, 1H), 3.10 - 3.18 (m, 2H), 3.61 (s, 3H), 3.63 - 3.69 (m, 1H), 3.76 -
3.83 (m,
1H), 6.93 - 7.00 (m, 2H), 7.15 - 7.20 (m, 2H)
Rac-1-tert-butyl 3-methyl (3R,4R)-4-benzy1-5-oxopyrrolidine-1,3-dicarboxylate
(1-28)
[0163] The title compound was synthesized from 1-tert-butyl 3-methyl 5-
oxopyrrolidine-1,3-dicarboxylate (1-26) in a similar manner to general
procedure 2
(general scheme 2) as an off-white solid (20.1 g, 96% purity, 49%) after work-
up and
used in the next step without further purification.
[0164] LC-MS (METCR1410): 96% (UV), Rt= 1.16 min, no ionisation
[0165] 1H NMR (500 MHz, Chloroform-d) 5 1.51 (s, 9H), 2.82 - 2.90 (m, 1H),
2.94 -
3.01 (m, 1H), 3.15 - 3.22 (m, 2H), 3.55 (s, 3H), 3.66 (dd, J = 8.8, 11.0 Hz,
1H), 3.74 -
3.80 (m, 1H), 7.18 - 7.24 (m, 3H), 7.26 - 7.30 (m, 2H)
Rac-1-tert-butyl 3-methyl (3R,4R)-5-oxo-4-[(pyridin-2-yl)methyl]pyrrolidine-
1,3-
dicarboxylate (1-29)
[0166] The title compound was synthesized from 1-tert-butyl 3-methyl 5-
oxopyrrolidine-1,3-dicarboxylate (1-26) in a similar manner to general
procedure 2
(general scheme 2) as a yellow solid (1.46 g, 88% purity, 48%) after
purification by
FCC on normal phase silica (25 g SNAP Ultra cartridge, 0-60% Et0Ac in heptane
gradient).
[0167] LC-MS (METCR1410): 88% (UV), Rt= 0.85 min, m/z (ES1+)= 335.1 [M-FH]-
[0168] 1H NMR (500 MHz, Chloroform-a) 5 1.52 - 1.53 (m, 9H), 3.07 - 3.14 (m,
1H),
3.20 (q, J= 9.0 Hz, 1H), 3.37 - 3.44 (m, 2H), 3.57 - 3.61 (m, 3H), 3.72 (dd,
J= 8.6,

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
11.0 Hz, 1H), 3.87 -3.92 (m, 1H), 7.09 - 7.14 (m, 1H), 7.22 (d, J= 7.8 Hz,
1H), 7.59
(td, J= 1.8, 7.7 Hz, 1H), 8.45 - 8.52 (m, 1H)
GENERAL PROCEDURE 3 (GENERAL SCHEME 2): Boc deprotection
Rac-methyl (3R,4R)-4-[(4-fluorophenyl)methy1]-5-oxopyrrolidine-3-carboxylate
(1-30)
[0169] To a solution of rac-1-tert-butyl 3-methyl (3R,4R)-4-benzy1-5-
oxopyrrolidine-
1,3-dicarboxylate (1-27) (99% purity, 4.66 g, 13.14 mmol) in DCM (35 mL) was
added
TFA (3.0 mL, 39.42 mmol) and the mixture stirred at RT for 4 h. The reaction
was
quenched carefully with sat. NaHCO3 (30 mL) to neutral pH and extracted with
DCM
(50 mL). The combined organic phases were washed with sat. NaHCO3 (25 mL) and
brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo to give
3.24 g of
rac-methyl (3R,4R)-4-[(4-fluorophenyl)methy1]-5-oxopyrrolidine-3-
carboxylate_as an off-
white solid (100% purity; 98%).
[0170] LC-MS (METCR1410): 100% (UV), Rt= 0.96 min, m/z (ES14-)= 252.1 [M+H].#
[0171] 1H NMR (500 MHz, Chloroform-a) 6 2.95 - 3.05 (m, 3H), 3.06 - 3.14 (m,
1H),
3.31 - 3.38 (m, 1H), 3.40 - 3.48 (m, 1H), 3.61 (s, 3H), 5.64 (s, 1H), 6.94 -
7.00 (m,
2H), 7.19 (ddd, J= 2.5, 5.3, 8.4 Hz, 2H)
Rac-methyl (3R,4R)-4-benzy1-5-oxopyrrolidine-3-carboxylate (1-31)
[0172] The title compound was synthesized from rac-1-tert-butyl 3-methyl
(3R,4R)-4-
benzy1-5-oxopyrrolidine-1,3-dicarboxylate (1-28) in a similar manner to
general
procedure 3 (general scheme 2) as an off-white solid (13.3 g, 98% purity, 97%)
after
work-up and used in the next step without further purification.
[0173] LC-MS (METCR1410): 98% (UV), Rt= 0.91 min, m/z (ES14-)= 234.2 [M-'-H]
[0174] 1H NMR (500 MHz, Chloroform-a) 6 2.97 - 3.08 (m, 3H), 3.15 (dd, J= 3.7,
13.0 Hz, 1H), 3.30 - 3.36 (m, 1H), 3.40 - 3.46 (m, 1H), 3.57 (s, 3H), 5.75 (s,
1H), 7.18
- 7.25 (m, 3H), 7.26 - 7.31 (m, 2H)
Rac-methyl (3R,4R)-5-oxo-4-[(pyridin-2-yl)methyl]pyrrolidine-3-carboxylate
(TFA salt)
(1-32)
[0175] The title compound was synthesized from rac-1-tert-butyl 3-methyl
(3R,4R)-5-
oxo-4-[(pyridin-2-yl)methyl]pyrrolidine-1,3-dicarboxylate (1-29) in a similar
manner to
general procedure 3 (general scheme 2) as a dark oil (2.1 g, 98% purity,
quantitative)
after work-up and used in the next step without further purification.
[0176] LC-MS (METCR1410): 98% (UV), Rt= 1.22 min, m/z (ES14-)= 235.2 [M+H]

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
36
GENERAL PROCEDURE 4 (GENERAL SCHEME 2): Hydrolysis
Rac-(3R,4R)-4-[(4-fluorophenyl)methyI]-5-oxopyrrolidine-3-carboxylic acid (1-
33)
[0177] A solution of methyl rac-(3R,4R)-4-[(4-fluorophenyl)methy1]-5-oxo-
pyrrolidine-3-
carboxylate (1-30) (99% purity, 1.75 g, 6.90 mmol) in 2:1 Me0H/water (30 mL)
was
treated with 2M NaOH (7.6 mL), 15.20 mmol) and stirred at RT for 0.5 h. The
mixture
was concentrated in vacuo and the residue diluted with water (30 mL) and
extracted
with Et20 (2 x 30 mL). The aqueous layer was separated, acidified to pH 1
using 6M
HCI and the resulting precipitate was collected by filtration, washed with
water (10 mL)
and dried in a vacuum oven at 40 C to afford 1.5 g of rac-(3R,4R)-4-[(4-
fluoropheny1)-
methy1]-5-oxo-pyrrolidine-3-carboxylic acid as an off-white solid (96% purity,
88%).
[0178] LC-MS (METCR1410): 96% (UV), Rt= 0.83 min, m/z (ES14-)= 238.2 [M+H]4-
[0179] 1H NMR (500 MHz, DMSO-d6) 6 2.75 - 2.86 (m, 3H), 2.93 (dd, J= 4.5, 13.4
Hz, 1H), 3.17 (dd, J= 7.2, 9.6 Hz, 1H), 3.23 - 3.27 (m, 1H), 7.05 - 7.12 (m,
2H), 7.20 -
7.27 (m, 2H), 7.72 (s, 1H), 12.49 (br. s, 1H)
Rac-(3R,4R)-5-oxo-4-[(pyridin-2-yl)methyl]pyrrolidine-3-carboxylic acid (HCI
salt) (1-34)
[0180] The title compound was synthesized from rac-methyl (3R,4R)-5-oxo-4-
[(pyridin-2-yl)methyl]pyrrolidine-3-carboxylate (TFA salt) (1-32) in a similar
manner to
general procedure 4 (general scheme 2) as a brown solid (2.8 g, 90% purity by
1H
NMR, quantitative) after work-up and used in the next step without further
purification.
[0181] LC-MS (METCR1410): 100% (ELS), Rt= 0.16 min, m/z (ES1+)= 221.0 [M+H]4-
[0182] 1H NMR (500 MHz, D20) 6 3.34 - 3.45 (m, 3H), 3.54 - 3.65 (m, 2H), 3.71 -
3.77 (m,
1H), 7.97- 8.02 (m, 1H), 8.06 (d, J= 8.1 Hz, 1H), 8.57 (td, J= 1.5, 8.0 Hz,
1H), 8.71 -8.76
(m, 1H)
GENERAL PROCEDURE 5 (GENERAL SCHEME 2): Ylide formation
Rac-3-[(3R,4R)-4-[(4-fluorophenyl)methyl]-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-
thiolan-1-
ylidene)propanenitrile (1-35)
[0183] To a stirred solution of rac-(3R,4R)-4-[(4-fluorophenyl)methy1]-5-oxo-
pyrrolidine-3-carboxylic acid (1-33) (96% purity, 1.49 g, 6.03 mmol) and DIPEA
(3.4 mL,
19.52 mmol) in DCM (30 mL) was added HATU (2.52 g, 6.63 mmol) and 1-
(cyanomethyl)thiolan-1-ium bromide (90% purity, 1.81 g, 7.83 mmol, synthesized
by
the procedure outlined in Note 1, general experimental details) and the
mixture was
stirred at RT under nitrogen for 1 h. The reaction was diluted with DCM (30
mL) and
quenched with a sat. NH40I (50 mL). The aqueous layer was extracted with DCM
(30

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
37
mL) and the combined organic layers was dried over Na2SO4 and concentrated in
vacuo. The residue was purified by FCC on normal phase silica (50 g SNAP KP-
SIL
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-20% Me0H in Et0Ac)
to
afford 2.5 g of rac-3-[(3R,4R)-4-[(4-fluorophenyl)methyl]-5-oxopyrrolidin-3-
y1]-3-oxo-2-
(1A4-thiolan-1-ylidene)propanenitrile as an off-white gum (84% purity by 1H
NMR,
99%).
[0184] LC-MS (METCR1410): 97% (UV), Rt= 0.86 min, m/z (ES1)= 347.1 [M+H]
[0185] 1H NMR (500 MHz, Chloroform-0 6 1.95 - 2.07 (m, 2H), 2.39 - 2.53 (m,
2H),
2.62 (dd, J= 10.2, 14.0 Hz, 1H), 2.90 - 2.98 (m, 1H), 2.99 - 3.07 (m, 1H),
3.09 - 3.26
(m, 4H), 3.30 (dd, J= 4.3, 14.0 Hz, 1H), 3.35 - 3.41 (m, 1H), 3.50 (q, J= 8.7
Hz, 1H),
5.72 (s, 1H), 6.91 - 6.98 (m, 2H), 7.21 - 7.28 (m, 2H)
Rac-3-oxo-3-[(3R,4R)-5-oxo-4-[(pyridin-2-yl)methyl]pyrrolidin-3-y1]-2-(1A4-
thiolan-1-
ylidene)propanenitrile (I-36)
[0186] The title compound was synthesized from rac-(3R,4R)-5-oxo-4-[(pyridin-2-
yl)methyl]pyrrolidine-3-carboxylic acid (HCl salt) (1-34) in a similar manner
to general
procedure 5 (general scheme 2) as a brown gum (1 g, 76% purity by 1H NMR, 71%)
after purification by ion-exchange flash chromatography (25 g Isolute Si II
cartridge, 0-
20% Me0H in Et0Ac gradient then 0-10% 7N methanolic ammonia in Et0Ac
gradient).
[0187] LC-MS (METCR1410): 100% (UV), Rt= 1.16 min, m/z (ESII= 330.2 [M+H]
[0188] 1H NMR (500 MHz, Chloroform-0 6 1.97 - 2.06 (m, 2H), 2.49 - 2.58 (m,
2H),
3.03 (dd, J= 8.1, 14.0 Hz, 1H), 3.10 (q, J= 7.5 Hz, 1H), 3.14 - 3.22 (m, 1H),
3.22 -
3.31 (m, 3H), 3.34 - 3.47 (m, 3H), 3.63 - 3.71 (m, 1H), 5.54 (s, 1H), 7.08 -
7.13 (m,
1H), 7.30 (d, J= 7.8 Hz, 1H), 7.59 (td, J= 1.8, 7.7 Hz, 1H), 8.48 - 8.53 (m,
1H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
38
GENERAL SCHEME 3:
e'yCh'
0 Ra
len Me, El
IAklubsOullon on order &
General procedure 9b
Ra
,...y. . __ _.
H.....irizo ----.......iyo ...._ .......).y..c,..
R = *Substitution on ester & Vide ronnallon _....,
*Substitution on yllde
0 10 Hydrolysis Lr. General procedure 4 ej....,
?.... Omen, procedure 5 se ....."
General procedure 3a 0 313 o is. o
k3
AND ENANDOMER
AND ENANTIOMLNI AND steternomap
AND ENANTIOVER
R. Me. El
AcSubtelluelon on fester HYdlalYsls
I General procedure 6
Genenil General
procedure 1 procedure 2
R2
in 0 R2u H
_______________________ 6 leOlter ITH, Me 0,A1* ________________ < 41

Ceddation
a General
procedure 6
ris
0
AND ENAINTIOSER AND ENANI1OSER
General procedure 7a
I
R2 R2
72
0 0 0 N
0 = Ri....)ly 0 41-- R.,.....N _______ . o I
procedure e H =. General
procedure 70
0 ii-3 0 H3 0 k3
No ENANTIOMER
GENERAL PROCEDURE 1 (GENERAL SCHEME 3): ALSubstitution of trans racemic
ester
Method A: N-Alkylation using C52CO3 in MeCN at reflux
Rac-methyl (3R,4R)-4-benzy1-1-Roxan-4-y1)methylj-5-oxopyrrolidine-3-
carboxylate (1-
37)
[0189] To a stirring solution of rac-methyl (3R,4R)-4-benzy1-5-oxopyrrolidine-
3-
carboxylate (1-31) (98% purity, 1 g, 4.22 mmol) in MeCN (30 mL) was added 4-
(bromomethyl)oxane (1.1 mL, 8.35 mmol), C52CO3(5.5 g, 16.88 mmol), and K1 (350
mg, 2.11 mmol) and the suspension stirred at reflux for 48 h. Further 4-
(bromomethyl)-
oxane (0.4 mL, 3.04 mmol) was added and the reaction stirred at reflux for 6.5
h.
Further C52CO3(6.8 g, 21.1 mmol) was added over time and the mixture stirred
at
reflux for 46 h. The suspension was filtered and the inorganics washed with
MeCN.
The combined filtrates were concentrated in vacuo to afford 2.38 g of rac-
methyl

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
39
(3R,4R)-4-benzy1-1-[(oxan-4-yl)methyl]-5-oxopyrrolidine-3-carboxylate as a
pale yellow
gum (31% purity, 53%) which was used in the next step without further
purification.
[0190] LC-MS (METCR1410): 31% (UV), Rt= 1.07 min, m/z (ES14-)= 332.1 [M+H].
Rac-methyl (3R,4R)-4-benzy1-1-[(3-methy1-1,2,4-oxadiazol-5-y1)methyl]-5-
oxopyrrolidine-3-carboxylate (1-38)
[0191] The title compound was synthesized from rac-methyl (3R,4R)-4-benzy1-5-
oxopyrrolidine-3-carboxylate (1-31) in a similar manner to method A, general
procedure
1 (general scheme 3) as an orange solid (4.57 g, 50% purity, 66%) after work-
up and
used in the next step without further purification.
[0192] LC-MS (METCR1410): 50% (UV), Rt= 1.02 min, m/z (ES14-)= 329.9 [M+H]4-
Method B: N-Alkylation using NaH in DMF at RT
Rac-methyl (3R,4R)-4-benzy1-5-oxo-1-[(pyrimidin-2-yl)methylipyrrolidine-3-
carboxylate
(1-39)
[0193] To an ice-cooled stirring solution of rac-methyl (3R,4R)-4-benzy1-5-
oxopyrrolidine-3-carboxylate (1-31) (98% purity, 1 g, 4.2 mmol) in dry DMF (30
mL) was
added NaH (60% in mineral oil, 350 mg, 8.75 mmol) under nitrogen and the
mixture
was stirred at 0 C for 30 min. 2-(Chloromethyl)pyrimidine (850 mg, 6.61 mmol)
in dry
DMF (3 mL) was added dropwise over 10 min followed by K1(350 mg, 2.11 mmol).
The suspension was stirred at RT under nitrogen for 1 h then quenched with
0.5M HC1
and extracted with DCM (4 x 30 mL). The combined organic layers were washed
with
water (30 mL) and brine (30 mL), dried over Na2SO4and concentrated in vacuo to
afford 1.69 g of rac-methyl (3R,4R)-4-benzy1-5-oxo-1-[(pyrimidin-2-
yl)methyl]pyrrolidine
-3-carboxylate as an orange gum (70% purity by 1H NMR, 87%).
[0194] LC-MS (MET0R1410): 75% (UV), Rt= 1.00 min, m/z (ES14-)= 326.1 [M+H]-
[0195] 1H NMR (500 MHz, Chloroform-a) 6 2.99 - 3.04 (m, 2H), 3.20- 3.27 (m,
2H),
3.44 - 3.50 (m, 1H), 3.54 (s, 3H), 3.58 - 3.62 (m, 1H), 4.68 (d, J= 16.8 Hz,
1H), 4.75 -
4.79 (m, 1H), 7.15 - 7.31 (m, 6H), 8.67 (d, J= 4.9 Hz, 2H)
Rac-methyl (3R,4R)-4-benzy1-5-oxo-1-[(pyrimidin-4-yl)methyl]pyrrolidine-3-
carboxylate
(1-40)
[0196] The title compound was synthesized from rac-methyl (3R,4R)-4-benzy1-5-
oxopyrrolidine-3-carboxylate (1-31) in a similar manner to method B, general
procedure
1 (general scheme 3) as a brown gum (1.17 g, 24% purity, 26%) after work-up
and
used in the next step without further purification.

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
[0197] LC-MS (METCR1410): 24% (UV), Rt= 0.94 min, rn/z (ES14-)= 326.0 [M+H]
GENERAL PROCEDURE 2 (GENERAL SCHEME 3): Hydrolysis
Rac-(3R,4R)-4-benzy1-1-[(oxan-4-yl)methyl]-5-oxopyrrolidine-3-carboxylic acid
(1-41)
[0198] A solution of rac-methyl (3R,4R)-4-benzy1-1-[(oxan-4-yl)methyl]-5-oxo-
pyrrolidine-3-carboxylate (1-37) (31% purity, 2.38 g, 2.22 mmol) in 2:1
Me0H/water (75
mL) was treated with 2M NaOH (4.4 mL) and stirred at RT for 1.5 h. The mixture
was
concentrated in vacuo and the residue diluted with water (50 mL) and extracted
with
Et20 (50 mL). The aqueous layer was separated, acidified to pH 1-2 using 2M
HCI and
extracted with 3:1 0H013/1PA (3 x 50 mL). The combined organic layers were
dried
over Na2SO4and concentrated in vacuo to give 1.63 g of rac-(3R,4R)-4-benzy1-1-
[(oxan-4-yl)methyl]-5-oxopyrrolidine-3-carboxylic acid as an orange oil (50%
purity by
1H NMR, quantitative).
[0199] LC-MS (METCR1410): 65% (UV), Rt= 0.93 min, rn/z (ES14-)= 318.1 [M+H].#
[0200] 1H NMR (500 MHz, Chloroform-a) 5 1.23 - 1.44 (m, 2H), 1.62- 1.68 (m,
1H),
1.71 - 1.84 (m, 1H), 2.91 - 2.98 (m, 1H), 3.02 - 3.08 (m, 1H), 3.09 - 3.22 (m,
3H), 3.27
-3.34 (m, 2H), 3.40 (td, J= 2.1, 11.9 Hz, 1H), 3.45 - 3.49 (m, 1H), 3.51 (d,
J= 6.4 Hz,
1H), 3.89 - 3.96 (m, 2H), 3.97 - 4.02 (m, 1H), 7.18 - 7.31 (m, 5H).
Rac-(3R,4R)-4-benzy1-1-[(3-methy1-1,2,4-oxadiazol-5-yl)methyl]-5-
oxopyrrolidine-3-
carboxylic acid (1-42)
[0201] The title compound was synthesized from rac-methyl (3R,4R)-4-benzy1-1-
[(3-
methy1-1,2,4-oxadiazol-5-y1)methyl]-5-oxopyrrolidine-3-carboxylate (1-38) in a
similar
manner to general procedure 2 (general scheme 3) as an orange gum (3.5 g, 39%
purity, 62%) obtained after work-up and used in the next step without further
purification.
[0202] LC-MS (MET0R1410): 39% (UV), Rt= 0.92 min, rn/z (ES14-)= 316.0 [M+H].
Rac-(3R,4R)-4-benzy1-5-oxo-1-[(pyrimidin-2-yl)methyl]pyrrolidine-3-carboxylic
acid (I-
43)
[0203] The title compound was synthesized from rac-methyl (3R,4R)-4-benzy1-5-
oxo-
1-[(pyrimidin-2-yl)methyl]pyrrolidine-3-carboxylate (1-39) in a similar manner
to general
procedure 2 (general scheme 3) as an orange gum (1.6 g, 76% purity,
quantitative)
obtained after work-up and used in the next step without further purification.
[0204] LC-MS (METCR1410): 76% (UV), Rt= 0.87 min, rn/z (ES14-)= 312.1 [M+H]

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
41
[0205] 1H NMR (500 MHz, Chloroform-o) 5 2.99 ¨ 3.08 (m, 1H), 3.15¨ 3.19 (m,
2H),
3.24 ¨ 3.30 (m, 1H), 3.41 (t, J= 9.2 Hz, 1H), 3.63 (dd, J= 7.1, 9.6 Hz, 1H),
4.60 (d, J=
16.9 Hz, 1H), 4.85 (d, J= 16.9 Hz, 1H), 7.17 ¨ 7.24 (m, 2H), 7.26 (d, J= 4.4
Hz, 4H),
8.69 (d, J= 4.9 Hz, 2H)
Rac-(3R,4R)-4-benzy1-5-oxo-1-[(pyrimidin-4-yl)methyl]pyrrolidine-3-carboxylic
acid (I-
44)
[0206] The title compound was synthesized from rac-methyl (3R,4R)-4-benzy1-5-
oxo-
1-[(pyrimidin-4-yl)methyl]pyrrolidine-3-carboxylate (1-40) in a similar manner
to general
procedure 2 (general scheme 3) as an orange gum (1.18 g, 48% purity,
quantitative)
obtained after work-up and used in the next step without further purification.
[0207] LC-MS (METCR1410): 48% (UV), Rt= 0.86 min, m/z (ES14-)= 312.0 [M+H]+
GENERAL PROCEDURE 3a (GENERAL SCHEME 3): N-Substitution of trans racemic
ester and Hydrolysis
Rac-(3R,4S)-1-methy1-5-oxo-4-phenylpyrrolidine-3-carboxylic acid (1-45)
[0208] To an ice-cooled solution of crude rac-ethyl (3R,4S)-4-pheny1-5-
oxopyrrolidine-
3-carboxylate (1-15) (1.0 g, 4.29 mmol) in THF (30 mL) was added NaH (60%
dispersion in oil, 0.51 g, 12.86 mmol) and the mixture stirred at 0 C for 10
min.
lodomethane (534 pL, 8.57 mmol) was added and the mixture stirred for a
further 30
min. The reaction was slowly quenched with water (30 mL), stirred for 15 min
and
extracted with Et20 (30 mL). The aqueous phase was acidified with 6M HCI and
extracted with 3:1 0HC13/IPA (3 x 50 mL). The combined organic extracts were
dried
over Na2SO4and concentrated in vacuo. The residue was purified by FCC on
normal
phase silica (50 g SNAP Ultra cartridge, 0-5% Me0H in DCM gradient) to afford
835
mg of rac-(3R,45)-1-methy1-5-oxo-4-phenylpyrrolidine-3-carboxylic acid as a
yellow
gum (52% purity, 46%). The compound contained rac-(3R,4R)-4-cyclohexy1-1-
methyl-
5-oxopyrrolidine-3-carboxylic acid as a minor by-product (10% by LC/MS).
[0209] LC-MS (METCR1410): 52% (UV), Rt= 0.76 min, m/z (ES14-)= 220.2 [M+H]4-
GENERAL PROCEDURE 3b (GENERAL SCHEME 3): Al-Substitution of
diastereoisomeric ester mixture and Epimerisation/hydrolysis
Rac-(3R,4R)-4-benzy1-1-(2-methoxyethyl)-5-oxopyrrolidine-3-carboxylic acid (1-
46)
[0210] To an ice-cooled solution of methyl 4-benzy1-5-oxopyrrolidine-3-
carboxylate (I-
18) (94% purity, 544 mg, 2.19 mmol) in dry DMF (8 mL) was added portionwise
NaH
(60% dispersion in oil, 100 mg, 2.50 mmol) and the suspension stirred at 0 C
for 25

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
42
min. 2-Bromoethyl methyl ether (230 pL, 2.45 mmol) was added dropwise over 10
min
and the reaction stirred at RT for 18 h. Further NaH (90 mg, 2.19 mmol) was
added
and the mixture stirred at RT for 30 min. Further 2-bromoethyl methyl ether
(45 pL,
0.48 mmol) was added and the solution stirred at RT for 1 h. The reaction was
quenched with 0.5M HC1(10 mL) and extracted with 3:1 0H013/J.= (4 x 10 mL).
The
combined organic layers were washed with water (10 mL) and brine (5 mL), dried
over
Na2SO4and concentrated in vacuo to afford 672 mg of rac-(3R,4R)-4-benzy1-1-(2-
methoxyethyl)-5-oxopyrrolidine-3-carboxylic acid as an orange gum (42% purity,
46%)
which was used in the next step without further purification.
[0211] LC-MS (METCR1410): 42% (UV), Rt= 0.89 min, m/z (ESI-)= 278.1 [M+H]4-
Rac-(3R,4R)-4-benzy1-1-(carbamoylmethyl)-5-oxopyrrolidine-3-carboxylic acid (1-
47)
[0212] The title compound was synthesized from methyl 4-benzy1-5-
oxopyrrolidine-3-
carboxylate (1-18) in a similar manner to general procedure 3b (general scheme
3) as
an orange gum (701 mg, 61% purity, 67%) obtained after work-up and used in the
next
step without further purification.
[0213] LC-MS (METCR1410): 61% (UV), Rt= 0.77 min, m/z (ESI)= 277.1 [M+H]-
GENERAL PROCEDURE 4 (GENERAL SCHEME 3): Ylide formation
Rac-3-[(3R,4R)-4-benzy1-1-[(oxan-4-yl)methyl]-5-oxopyrrolidin-3-y1]-3-oxo-2-
(1A4-
thiolan-1-ylidene)propanenitrile (1-48)
[0214] To a solution of rac-(3R,4R)-4-benzy1-1-[(oxan-4-yl)methyl]-5-
oxopyrrolidine-3-
carboxylic acid (1-41) (1.55 g, 2.44 mmol) and DIPEA (2 mL, 11.43 mmol) in DCM
(50
mL) was added HATU (1.39 g, 3.66 mmol) and 1-(cyanomethyl)thiolan-1-ium
bromide
(90%, 850 mg, 3.68 mmol, synthesized by the procedure outlined in Note 1,
general
experimental details) and the mixture stirred at RT for 1 h. The reaction was
quenched
with sat. NH4C1(30 mL), the aqueous phase extracted with DCM (3 x 40 mL) and
the
combined organic phases dried over Na2SO4, filtered and concentrated in vacuo.
The
residue was purified by FCC on normal phase silica (100 g SNAP Ultra
cartridge, 0-
100% Et0Ac in heptane gradient followed by 0-25% Me0H in Et0Ac gradient) to
afford to afford 900 mg of rac-3-[(3R,4R)-4-benzy1-1-[(oxan-4-yl)methyl]-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile as an orange
gum
(89% purity by 1H NMR, 77%).
[0215] LC-MS (METCR1410): 95% (UV), Rt= 0.92 min, m/z (ESI)= 427.1 [M+H]

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
43
[0216] 1H NMR (500 MHz, Chloroform-o) 5 1.28 - 1.36 (m, 2H), 1.46- 1.54 (m,
2H),
1.76- 1.86 (m, 1H), 1.94 -2.03 (m, 2H), 2.40 - 2.53 (m, 2H), 2.68 (dd, J= 9.7,
13.9
Hz, 1H), 2.91 - 3.02 (m, 2H), 3.09 - 3.21 (m, 4H), 3.21 - 3.29 (m, 3H), 3.29 -
3.37 (m,
3H), 3.39 - 3.46 (m, 1H), 3.90 - 3.98 (m, 2H), 7.12 - 7.18 (m, 1H), 7.20 -
7.30 (m, 4H)
Rac-3-[(3R,4R)-4-benzy1-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-5-
oxopyrrolidin-3-
y1]-3-oxo-2-(110-thiolan-1-ylidene)propanenitrile (1-49)
[0217] The title compound was synthesized from ac-(3R,4R)-4-benzy1-1-[(3-
methy1-
1,2,4-oxadiazol-5-y1)methyl]-5-oxopyrrolidine-3-carboxylic acid (1-42) in a
similar
manner to general procedure 4 (general scheme 3) as a brown gum (1.47 g, 80%
purity by 1H NMR, 64%) after purification by by FCC on normal phase silica
(340 g
SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient followed by 0-30% Me0H
in
Et0Ac gradient).
[0218] LC-MS (METCR1410): 99% (UV), Rt= 0.91 min, m/z (ES14-)= 425.0 [M+H]4-
[0219] 1H NMR (500 MHz, Chloroform-U) 5 1.95 - 2.03 (m, 2H), 2.39 (s, 3H),
2.41 -
2.49 (m, 2H), 2.68 (dd, J= 10.0, 13.9 Hz, 1H), 2.87 - 3.00 (m, 2H), 3.12 -
3.21 (m,
2H), 3.28 - 3.35 (m, 2H), 3.35 - 3.41 (m, 1H), 3.44 - 3.54 (m, 2H), 4.61 (d,
J= 16.6
Hz, 1H), 4.77 (d, J= 16.6 Hz, 1H), 7.13 -7.18 (m, 1H), 7.22 - 7.29 (m, 4H)
Rac-3-[(3R,4R)-4-benzy1-5-oxo-1-[(pyrimidin-2-yl)methyl]pyrrolidin-3-y1]-3-oxo-
2-(1A4-
thiolan-1-ylidene)propanenitrile (1-50)
[0220] The title compound was synthesized from rac-(3R,4R)-4-benzy1-5-oxo-1-
[(pyrimidin-2-yl)methyl]pyrrolidine-3-carboxylic acid (1-43) in a similar
manner to
general procedure 4 (general scheme 3) as an orange gum (1.74 g, 80% purity by
1H
NMR, 88%) after purification by by FCC on normal phase silica (100 g SNAP
Ultra
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-25% Me0H in Et0Ac
gradient).
[0221] LC-MS (METCR1410): 98% (UV), Rt= 0.87 min, m/z (ES14-)= 421.2 [M+H]-
[0222] 1H NMR (500 MHz, Chloroform-d) 5 1.90 - 2.01 (m, 2H), 2.43 (dp, J= 7.2,
20.2 Hz, 2H), 2.66 (dd, J= 10.6, 13.8 Hz, 1H), 2.84 - 2.96 (m, 2H), 3.06 -
3.16 (m,
2H), 3.31 -3.42 (m, 2H), 3.42 - 3.48 (m, 1H), 3.49 - 3.57 (m, 2H), 4.66 (d, J=
16.6
Hz, 1H), 4.80 (d, J= 16.6 Hz, 1H), 7.12 -7.19 (m, 2H), 7.21 -7.26 (m, 2H),
7.29 -
7.33 (m, 2H), 8.69 (d, J= 4.9 Hz, 2H)
Rac-3-[(3R,4R)-4-benzy1-5-oxo-1-[(pyrimidin-411)methyl]pyrrolidin-3-y1]-3-oxo-
2-(110-
thiolan-1-ylidene)propanenitrile (1-51)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
44
[0223] The title compound was synthesized from rac-(3R,4R)-4-benzy1-5-oxo-1-
[(pyrimidin-4-yl)methyl]pyrrolidine-3-carboxylic acid (1-44) in a similar
manner to
general procedure 4 (general scheme 3) as a yellow solid (1.74 g, 75% purity
by 1H
NMR, 59%) after purification by by FCC on normal phase silica (600 mgg SNAP
Ultra
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-25% Me0H in Et0Ac
gradient).
[0224] LC-MS (METCR1410): 77% (UV), Rt= 0.86 min, m/z (ESI)= 421.0 [M+H]4-
[0225] 1H NMR (500 MHz, Chloroform-a) 6 1.96 ¨ 2.03 (m, 2H), 2.41 ¨2.54 (m,
2H),
2.79 (dd, J= 9.0, 13.4 Hz, 1H), 2.94 ¨ 3.04 (m, 2H), 3.16 ¨ 3.24 (m, 2H), 3.28
(d, J=
8.2 Hz, 2H), 3.30 ¨ 3.37 (m, 2H), 3.50 (q, J= 8.1 Hz, 1H), 4.48 ¨4.59 (m, 2H),
7.16 ¨
7.21 (m, 2H), 7.24 ¨ 7.32 (m, 4H), 8.66 (d, J= 5.2 Hz, 1H), 9.12 (d, J= 1.2
Hz, 1H)
Rac-3-[(3R,4R)-4-cyclohexy1-1-methyl-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-
thiolan-1-
ylidene)propanenitrile (1-52)
[0226] The title compound was synthesized from crude rac-(3R,45)-1-methy1-5-
oxo-4-
phenylpyrrolidine-3-carboxylic acid (1-45) containing rac-(3R,4R)-4-cyclohexy1-
1-
methy1-5-oxopyrrolidine-3-carboxylic acid as a minor by-product in a similar
manner to
general procedure 4 (general scheme 3) as an off-white solid (531 mg, 91%
purity,
38%) after purification by FCC on reverse phase silica (60 g SNAP Ultra C18
cartridge,
acidic pH, standard elution method).
[0227] LC-MS (METCR1410): 91% (UV), Rt= 0.90 min, m/z (ES14-)= 335.0 [M+H]-
[0228] 1H NMR (500 MHz, Chloroform-a) 6 1.05 (qd, J= 3.4, 12.5 Hz, 1H), 1.12 ¨
1.34 (m, 3H), 1.45¨ 1.53 (m, 1H), 1.60¨ 1.76 (m, 5H), 1.86¨ 1.96 (m, 1H), 2.03
¨ 2.16
(m, 2H), 2.57 ¨ 2.67 (m, 2H), 2.80 ¨ 2.86 (m, 4H), 3.18 ¨ 3.25 (m, 1H), 3.30 ¨
3.44 (m,
4H), 3.45 ¨ 3.53 (m, 2H)
Rac-3-[(3R,4R)-4-benzy1-1-(2-methoxyethyl)-5-oxopyrrolidin-3-y1]-3-oxo-2-(110-
thiolan-
1-ylidene)propanenitrile (1-53)
[0229] The title compound was synthesized from crude rac-(3R,4R)-4-benzy1-1-(2-
methoxyethyl)-5-oxopyrrolidine-3-carboxylic acid (1-46) in a similar manner to
general
procedure 4 (general scheme 3) as an orange gum (582 mg, 60% purity, 89%)
after
purification by FCC on normal phase silica (100 g SNAP KP-SIL cartridge, 0-
100%
Et0Ac in heptane gradient followed by 0-30% Me0H in Et0Ac gradient).
[0230] LC-MS (METCR1410): 60% (UV), Rt= 0.89 min, m/z (ES14-)= 387.1 [M+H].#

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
Rac-2-[(3R,4R)-3-benzy1-412-cyano-2-(110-thiolan-1-ylidene)acety1]-2-
oxopyrrolidin-1-
yl]acetamide (1-54)
[0231] The title compound was synthesized from crude rac-(3R,4R)-4-benzy1-1-
(carbamoylmethyl)-5-oxopyrrolidine-3-carboxylic acid (1-47) in a similar
manner to
general procedure 4 (general scheme 3) as an orange gum (771 mg, 60% purity
estimated by 1H NMR, 78%) after purification by FCC on normal phase silica
(100 g
SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed by 0-30% Me0H
in Et0Ac gradient).
[0232] LC-MS (METCR1410): 93% (UV), Rt= 0.81 min, m/z (ES14-)= 386.1 [M+H]-
GENERAL PROCEDURE 5 (GENERAL SCHEME 3): N=Substitution of ylide
Method A: N-Alkylation using NaH in DMF at RT
Rac-3-[(3R,4R)-4-benzy1-1-[(5-methyl-1,2-oxazol-3-yl)methyl]-5-oxopyrrolidin-3-
y1]-3-
oxo-2-(110-thiolan-1-ylidene)propanenitrile (1-55)
[0233] To a cold stirred solution of rac-3-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-
y1]-3-
oxo-2-(110-thiolan-1-ylidene)propanenitrile (1-23) (85% purity by 1H NMR, 600
mg, 1.55
mmol) in dry DMF (12 mL) was added NaH (60% in mineral oil, 90 mg, 2.25 mmol)
in
one portion under nitrogen and the suspension stirred at 0 C for 30 min. 3-
(bromo-
methyl)-5-methyl-isoxazole (300 mg, 1.7 mmol) in dry DMF (1 mL) was added over
3
min and the mixture stirred at RT under nitrogen for 1 h. The reaction was
quenched
with water (30 mL) and extracted into Et0Ac (2 x 30 mL). The combined organic
extracts were washed with brine (20 mL), dried over Na2SO4,filtered and
concentrated
in vacuo. The residue was purified by FCC on normal phase silica (10 g SNAP KP-
SIL
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-15% Me0H in Et0Ac)
to
afford 536 mg of rac-3-[(3R,4R)-4-benzy1-1-[(5-methy1-1,2-oxazol-3-yl)methyl]-
5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile as a brown
oil (86%
purity by 1H NMR, 70%).
[0234] LC-MS (METCR1410): 100% (UV), Rt= 0.94 min, m/z (ES14-)= 424.0 [M+H]+
[0235] 1H NMR (500 MHz, Chloroform-o) 6 1.92 - 2.01 (m, 2H), 2.37 - 2.41 (m,
3H),
2.41 - 2.52 (m, 2H), 2.67 (dd, J= 9.9, 13.9 Hz, 1H), 2.89 - 2.99 (m, 2H), 3.10
- 3.19
(m, 3H), 3.23 - 3.32 (m, 2H), 3.36 (dd, J= 4.1, 13.9 Hz, 1H), 3.42 (q, J= 8.7
Hz, 1H),
4.42 (d, J= 15.0 Hz, 1H), 4.50 (d, J= 15.0 Hz, 1H), 5.87 - 5.91 (m, 1H), 7.13 -
7.18
(m, 1H), 7.22 - 7.30 (m, 4H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
46
Rac-3-[(3R,4R)-4-benzy1-1-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-5-
oxopyrrolidin-3-
y1]-3-oxo-2-(110-thiolan-1-ylidene)propanenitrile (1-56)
[0236] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-oxo-
pyrrolidin-3-y1]-3-oxo-2-(110-thiolan-1-ylidene)propanenitrile (1-23) in a
similar manner
to method A, general procedure 5 (general scheme 3) as an off-white solid (462
mg,
98% purity by 1H NMR, 67%) after purification by FCC on normal phase silica
(10 g
SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed by 0-20% Me0H
in Et0Ac gradient).
[0237] LC-MS (METCR1410): 100% (UV), Rt= 2.89 min, rniz (ES14-)= 424.1 [M+H]-
[0238] 1H NMR (500 MHz, Chloroform-d) 6 1.94 ¨ 2.02 (m, 2H), 2.40 ¨ 2.53 (m,
2H),
2.70 (dd, J= 9.5, 13.7 Hz, 1H), 2.89 ¨ 3.01 (m, 2H), 3.12 ¨ 3.21 (m, 3H), 3.22
¨ 3.28
(m, 1H), 3.29 ¨ 3.37 (m, 2H), 3.42 (q, J= 8.4 Hz, 1H), 3.90 (s, 3H), 4.55 ¨
4.67 (m,
2H), 7.14 ¨ 7.19 (m, 1H), 7.21 ¨7.27 (m, 4H), 7.77 (s, 1H)
Rac-2-[(3R,4R)-3-benzy1-442-cyano-2-(110-thiolan-1-ylidene)acetyl]-2-
oxopyrrolidin-1-
y11-N-methylacetamide (1-57)
[0239] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method A, general procedure 5 (general scheme 3) as a pale yellow
gum
(603 mg, 83% purity by 1H NMR, 77%) after purification by FCC on normal phase
silica
(50 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed by 0-
25%
Me0H in Et0Ac gradient).
[0240] LC-MS (METCR1410): 100% (UV), Rt= 0.84 min, rniz (ESI+)= 400.0 [M+H]4-
[0241] 1H NMR (500 MHz, Chloroform-a) 6 2.05 ¨ 2.13 (m, 2H), 2.50 ¨ 2.61 (m,
2H),
2.67 (dd, J= 7.5, 9.5 Hz, 1H), 2.78 (d, J= 4.7 Hz, 3H), 2.92 ¨ 2.98 (m, 1H),
3.06 (dd, J
= 6.5, 13.7 Hz, 1H), 3.12 ¨ 3.25 (m, 3H), 3.27 (dd, J= 3.3, 9.6 Hz, 1H), 3.33
¨ 3.44 (m,
4H), 4.26 (d, J= 16.8 Hz, 1H), 7.17 ¨ 7.30 (m, 6H)
Rac-2-[(3R,4R)-3-benzy1-4-[2-cyano-2-(1A4-thiolan-1-ylidene)acety1]-2-
oxopyrrolidin-1-
y1]-/VA-dimethylacetamide (1-58)
[0242] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method A, general procedure 5 (general scheme 3) as a pale yellow
gum
(710 mg, 83% purity by 1H NMR, 88%) after purification by FCC on normal phase
silica

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
47
(50 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed by 0-
25%
Me0H in Et0Ac gradient).
[0243] LC-MS (METCR1410): 99% (UV), Rt= 0.85 min, m/z (ES14-)= 414.0 [M-FH]-
[0244] 1H NMR (500 MHz, Chloroform-a) 6 1.90 ¨ 2.02 (m, 2H), 2.40 ¨ 2.52 (m,
2H),
2.65 (dd, J= 10.0, 13.5 Hz, 1H), 2.90 ¨ 2.99 (m, 5H), 3.01 (s, 3H), 3.10 ¨
3.18 (m, 2H),
3.28¨ 3.40 (m, 3H), 3.48 (q, J= 8.4 Hz, 1H), 3.54 (t, J= 8.7 Hz, 1H), 4.04 (d,
J= 15.7
Hz, 1H), 4.15 (d, J= 15.7 Hz, 1H), 7.12 ¨ 7.17 (m, 1H),7.21 ¨7.31 (m, 4H)
Rac-4-{[(3R,4R)-3-benzy1-442-cyano-2-(110-thiolan-1-ylidene)acetyl]-2-
oxopyrrolidin-1-
yllmethyl}benzamide (1-59)
[0245] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method A, general procedure 5 (general scheme 3) as an off-white
solid
(588 mg, 87% purity, 82%) after purification by FCC on normal phase silica (50
g
SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient followed by 0-25% Me0H
in
Et0Ac gradient).
[0246] LC-MS (METCR1410): 87% (UV), Rt= 0.89 min, m/z (ESI+)= 461.9 [M+H].
[0247] 1H NMR (500 MHz, Chloroform-o) 6 1.92 ¨ 2.02 (m, 2H), 2.40 ¨ 2.50 (m,
2H),
2.74 (dd, J= 9.6, 13.8 Hz, 1H), 2.90 ¨ 2.98 (m, 2H), 3.05 ¨ 3.11 (m, 1H), 3.11
¨3.20
(m, 3H), 3.27 ¨ 3.33 (m, 1H), 3.35 ¨ 3.46 (m, 2H), 4.44 ¨ 4.53 (m, 2H), 5.55
(bs, 1H),
6.05 (bs, 1H), 7.13 ¨ 7.20 (m, 1H), 7.23 ¨ 7.28 (m, 4H), 7.28 ¨ 7.31 (m, 2H),
7.72 ¨
7.78 (m, 2H)
Rac-3-[(3R,4R)-4-benzy1-1-[(3-methyl-1,2-oxazol-5-y1)methyl]-5-oxopyrrolidin-3-
y1]-3-
oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-60)
[0248] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1M-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method A, general procedure 5 (general scheme 3) as a brown viscous
oil
(367 mg, 90% purity by 1H NMR, 55%) after purification by FCC on normal phase
silica
(10 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed by 0-
20%
Me0H in Et0Ac gradient).
[0249] LC-MS (METCR1410): 99% (UV), Rt= 0.95 min, m/z (ES14-)= 424.0 [M+H].#
[0250] 1H NMR (500 MHz, Chloroform-a) 6 1.94 ¨ 2.03 (m, 2H), 2.27 (s, 3H),
2.41 ¨
2.52 (m, 2H), 2.70 (dd, J= 9.7, 13.8 Hz, 1H), 2.92 ¨ 3.02 (m, 2H), 3.14 ¨ 3.21
(m, 2H),

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
48
3.23 ¨ 3.28 (m, 2H), 3.31 ¨ 3.38 (m, 2H), 3.45 (q, J= 8.5 Hz, 1H), 4.52 (s,
2H), 5.96 (s,
1H), 7.13 ¨ 7.20 (m, 1H), 7.22 ¨ 7.30 (m, 4H)
Rac-3-[(3R,4R)-4-benzy1-5-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]pyrrolidin-3-
y1]-3-oxo-2-
(1A4-thiolan-1-ylidene)propanenitrile (1-61)
[0251] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method A, general procedure 5 (general scheme 3) as a pale yellow
gum
(598 mg, 85% purity by 1H NMR, 71%) after purification by FCC on normal phase
silica
(50 g SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient followed by 0-30%
Me0H in Et0Ac gradient).
[0252] LC-MS (METCR1410): 89% (UV), Rt= 0.87 min, rrilz (ES14-)= 440.0 [M+H]4-
[0253] 1H NMR (500 MHz, Chloroform-a) 6 1.93 ¨ 2.03 (m, 4H), 2.26 ¨ 2.40 (m,
2H),
2.42 ¨ 2.54 (m, 2H), 2.64 (dd, J= 9.6, 13.6 Hz, 1H), 2.97 ¨ 3.07 (m, 2H), 3.14
¨ 3.20
(m, 2H), 3.20 ¨ 3.25 (m, 1H), 3.25 ¨ 3.30 (m, 2H), 3.31 ¨ 3.41 (m, 5H), 3.41 ¨
3.49 (m,
2H), 3.49 ¨ 3.54 (m, 1H), 7.13 ¨ 7.17 (m, 1H), 7.22 ¨ 7.29 (m, 4H)
Rac-3-[(3R,4R)-4-benzy1-1-(2,2-difluoroethyl)-5-oxopyrrolidin-3-y1]-3-oxo-2-
(1A4-thiolan-
1-ylidene)propanenitrile (1-62)
[0254] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method A, general procedure 5 (general scheme 3) as a pale yellow
solid
(634 mg, 93% purity by 1H NMR, 71%) after purification by FCC on normal phase
silica
(25 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed by 0-
20%
Me0H in Et0Ac gradient).
[0255] LC-MS (METCR1410): 100% (UV), Rt= 0.93 min, rrilz (ESI+)= 393.0 [M+H]4-
[0256] 1H NMR (500 MHz, Chloroform-a) 6 1.95 ¨ 2.03 (m, 2H), 2.39 ¨ 2.52 (m,
2H),
2.68 (dd, J= 9.7, 13.8 Hz, 1H), 2.90 ¨ 3.02 (m, 2H), 3.17 ¨ 3.23 (m, 2H), 3.23
¨ 3.29
(m, 1H), 3.30 ¨ 3.37 (m, 2H), 3.37 ¨ 3.50 (m, 2H), 3.53 ¨ 3.71 (m, 2H), 5.84
(tt, J= 4.2,
55.7 Hz, 1H), 7.14 ¨ 7.21 (m, 1H), 7.23 ¨ 7.29 (m, 4H)
Rac-3-[(3R,4R)-4-[(4-fluorophenyl)methy1]-1-[(1-methy1-1H-1,2,4-triazol-3-
y1)methyl]-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1/0-thiolan-1-ylidene)propanenitrile (1-63)
[0257] The title compound was synthesized from rac-3-[(3R,4R)-4-[(4-
fluorophenyl)methy1]-5-oxopyrrolidin-3-y1]-3-oxo-2-(1P-thiolan-1-
ylidene)propanenitrile
(1-35) in a similar manner to method A, general procedure 5 (general scheme 3)
as an

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
49
off-white solid (352 mg, 100% purity, 30%) after purification by FCC on normal
phase
silica (10 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed
by 0-
20% Me0H in Et0Ac gradient).
[0258] LC-MS (MET0R1410): 100% (UV), Rt= 0.90 min, rrilz (ESI+)= 442.6 [M+H]4-
[0259] 1H NMR (500 MHz, Chloroform-o) 6 1.95 - 2.04 (m, 2H), 2.40 - 2.50 (m,
2H),
2.61 (dd, J= 10.5, 14.0 Hz, 1H), 2.88 - 3.02 (m, 2H), 3.14 - 3.30 (m, 4H),
3.35 - 3.43
(m, 2H), 3.47 (t, J= 8.8 Hz, 1H), 3.88 (s, 3H), 4.42 (d, J= 15.3 Hz, 1H), 4.69
(d, J=
15.3 Hz, 1H), 6.90 - 6.96 (m, 2H), 7.21 - 7.26 (m, 2H), 7.94 (s, 1H)
Rac-3-[(3R,4R)-4-[(4-fluorophenyl)methy1]-1-[(1-methy1-1H-1,2,4-triazol-5-
y1)methyl]-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-64)
[0260] The title compound was synthesized from rac-3-[(3R,4R)-4-[(4-
fluorophenyl)methy1]-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propanenitrile
(1-35) in a similar manner to method A, general procedure 5 (general scheme 3)
as an
off-white solid (991 mg, 100% purity, 95%) after purification by FCC on normal
phase
silica (25 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed
by 0-
50% Me0H in Et0Ac gradient).
[0261] LC-MS (METCR1410): 100% (UV), Rt= 0.87 min, rrilz (ES14-)= 442.4 [M+H]+
[0262] 1H NMR (500 MHz, Chloroform-a) 6 1.92 - 2.02 (m, 2H), 2.37 - 2.47 (m,
2H),
2.61 (dd, J= 9.5, 13.7 Hz, 1H), 2.88 - 3.01 (m, 2H), 3.08 - 3.15 (m, 1H), 3.15
- 3.27
(m, 4H), 3.29 - 3.38 (m, 2H), 3.86 (s, 3H), 4.54 (d, J= 15.2 Hz, 1H), 4.58 (d,
J= 15.2
Hz, 1H), 6.85 - 6.92 (m, 2H), 7.13 - 7.19 (m, 2H), 7.73 (s, 1H)
Method B: N-Arylation using Pd2(dba)3 and Xantphos
Rac-3-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1]-3-oxo-2-(1A4-
thiolan-1-
ylidene)propanenitrile (1-65)
[0263] To a degassed solution of rac-3-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-
3-oxo-
2-(1A4-thiolan-1-ylidene)propanenitrile (1-23) (80% purity by 1H NMR, 500 mg,
1.22
mmol) in 1,4-dioxane (10 mL) was added 5-bromopyrimidine (235 mg, 1.48 mmol),
Cs2CO3 (555 mg, 1.7 mmol), Pd2(dba)3 (56 mg, 0.06 mmol) and Xantphos (106 mg,
0.18 mmol). Nitrogen was bubbled through the suspension for 5 min and the
reaction
heated at 100 C for 5.5 h. The suspension was cooled to RT, diluted with DCM
(10
mL) and filtered through Celite. The Celite was washed with DCM (3 x 15 mL)
and the
combined filtrates concentrated in vacuo. The residue was purified by FCC on
normal
phase silica (50 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient
followed

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
by 0-20% Me0H in Et0Ac gradient) to afford 385 mg of rac-3-[(3R,4R)-4-benzy1-5-
oxo-
1-(pyrimidin-5-yl)pyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propanenitrile as a pale
yellow gum (90% purity by 1H NMR, 70%).
[0264] LC-MS (METCR1410): 100% (UV), Rt= 0.90 min, m/z (ESI+)= 407.0 [M+H]-
[0265] 1H NMR (500 MHz, Chloroform-o) 5 1.96 ¨ 2.07 (m, 2H), 2.42 ¨ 2.55 (m,
2H),
2.79 ¨ 2.88 (m, 1H), 2.93 ¨ 3.08 (m, 2H), 3.16 ¨ 3.27 (m, 2H), 3.39 ¨ 3.49 (m,
2H), 3.62
(q, J= 8.4 Hz, 1H), 3.66 ¨ 3.74 (m, 2H), 7.16 ¨ 7.22 (m, 1H), 7.24 ¨ 7.32 (m,
4H), 8.99
(s, 1H), 9.06 (s, 2H)
Rac-3-[(3R,4R)-4-benzy1-5-oxo-1-(pyrazin-2-yl)pyrrolidin-3-y1]-3-oxo-2-(1A4-
thiolan-1-
ylidene)propanenitrile (1-66)
[0266] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-3-oxo-2-(110-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method B, general procedure 5 (general scheme 3) as a brown viscous
oil
(310 mg, 82% purity by 1H NMR, 58%) after purification by FCC on normal phase
silica
(25 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed by 0-
20%
Me0H in Et0Ac gradient).
[0267] LC-MS (METCR1410): 91% (UV), Rt= 0.97 min, m/z (ESI+)= 407.0 [M+H]4-
[0268] 1H NMR (500 MHz, Chloroform-a) 5 1.96 ¨ 2.03 (m, 2H), 2.42 ¨ 2.54 (m,
2H),
2.76 ¨ 2.83 (m, 1H), 2.95 ¨ 3.04 (m, 2H), 3.14 ¨ 3.24 (m, 2H), 3.39 ¨ 3.46 (m,
1H), 3.53
¨3.61 (m, 2H), 3.69 ¨ 3.76 (m, 1H), 4.14 ¨4.19 (m, 1H), 7.15 ¨ 7.20 (m, 1H),
7.24 ¨
7.33 (m, 4H), 8.25 ¨ 8.28 (m, 1H), 8.30 (d, J= 2.6 Hz, 1H), 9.75 (d, J= 1.4
Hz, 1H)#
Rac-3-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-2-yl)pyrrolidin-3-y1]-3-oxo-2-(1A4-
thiolan-1-
ylidene)propanenitrile (1-67)
[0269] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method B, general procedure 5 (general scheme 3) as an orange gum
(626
mg, 70% purity by 1H NMR, 40%) after purification by FCC on normal phase
silica (100
g SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient followed by 0-25%
Me0H
in Et0Ac gradient).
[0270] LC-MS (METCR1410): 98% (UV), Rt= 0.90 min, m/z (ES14-)= 407.0 [M+H].#
[0271] 1H NMR (500 MHz, Chloroform-0 5 1.92 ¨ 2.03 (m, 2H), 2.40 ¨ 2.55 (m,
2H),
2.79 (dd, J= 9.4, 14.0 Hz, 1H), 2.92 ¨ 3.04 (m, 2H), 3.10 ¨ 3.22 (m, 2H), 3.47
(dd, J=
4.0, 13.9 Hz, 1H), 3.50 ¨ 3.60 (m, 2H), 3.79 (dd, J= 8.9, 10.7 Hz, 1H), 4.18
(dd, J=

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
51
8.4, 10.7 Hz, 1H), 7.02 (t, J= 4.8 Hz, 1H), 7.13 ¨7.20 (m, 1H), 7.23¨ 7.28 (m,
2H),
7.29 ¨ 7.35 (m, 2H), 8.67 (d, J= 4.8 Hz, 2H)
Rac-3-[(3R,4R)-4-benzy1-1-(2-chloropyrimidin-4-y1)-5-oxopyrrolidin-3-y1]-3-oxo-
2-(1A4-
thiolan-1-ylidene)propanenitrile (1-68)
[0272] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method B, general procedure 5 (general scheme 3) as a pale yellow
viscous
oil (411 mg, 96% purity, 84%) after purification by FCC on normal phase silica
(25 g
SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed by 0-50% Me0H
in Et0Ac gradient).
[0273] LC-MS (METCR1410): 96% (UV), Rt= 1.04 min, m/z (ES14-)= 441.4/443.1
[M+H]4-
[0274] 1H NMR (500 MHz, Chloroform-o) 6 1.94 ¨ 2.04 (m, 2H), 2.41 ¨2.52 (m,
2H),
2.75 (dd, J= 9.2, 13.9 Hz, 1H), 2.95 ¨ 3.03 (m, 2H), 3.14 ¨ 3.23 (m, 2H), 3.36
(dd, J=
4.2, 13.9 Hz, 1H), 3.49 ¨ 3.60 (m, 2H), 3.69 (dd, J= 8.5, 11.2 Hz, 1H), 4.21
(dd, J=
8.5, 11.2 Hz, 1H), 7.14 ¨ 7.20 (m, 1H), 7.23 ¨ 7.26 (m, 4H), 8.33 (d, J= 5.8
Hz, 1H),
8.44 (d, J= 5.8 Hz, 1H)
Rac-3-[(3R,4R)-4-benzy1-1-(6-chloropyridazin-3-y1)-5-oxopyrrolidin-3-y1]-3-oxo-
2-(1A4-
thiolan-1-ylidene)propanenitrile (1-69)
[0275] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method B, general procedure 5 (general scheme 3) as a pale yellow
powder
(362 mg, 98% purity, 75%) after purification by FCC on normal phase silica (25
g
SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed by 0-50% Me0H
in Et0Ac gradient).
[0276] LC-MS (METCR1410): 98% (UV), Rt= 1.02 min, m/z (ESI+)= 441.0/443.1
[M+H].
[0277] 1H NMR (500 MHz, Chloroform-0 6 1.95 ¨ 2.04 (m, 2H), 2.43 ¨ 2.57 (m,
2H),
2.74 ¨ 2.84 (m, 1H), 2.96 ¨ 3.10 (m, 2H), 3.14 ¨ 3.26 (m, 2H), 3.37 ¨ 3.45 (m,
1H), 3.54
¨3.63 (m, 2H), 3.82 ¨ 3.92 (m, 1H), 4.29 ¨ 4.37 (m, 1H), 7.16 ¨ 7.22 (m, 1H),
7.26 ¨
7.30 (m, 4H), 7.48 (d, J= 9.4 Hz, 1H), 8.73 (d, J= 9.4 Hz, 1H)
Rac-3-oxo-3-[(3R,45)-5-oxo-4-pheny1-1-(pyrimidin-5-yl)pyrrolidin-3-y1]-2-(110-
thiolan-1-
ylidene)propanenitrile (1-70)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
52
[0278] The title compound was synthesized from rac-3-oxo-3-[(3R,4S)-5-oxo-4-
phenylpyrrolidin-3-y1]-2-(1A4-thiolan-1-ylidene)propanenitrile (1-24) in a
similar manner
to method B, general procedure 5 (general scheme 3) as a yellow viscous oil
(233 mg,
92% purity, 38%) after purification by FCC on normal phase silica (25 g SNAP
KP-SIL
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-50% Me0H in Et0Ac
gradient).
[0279] LC-MS (METCR1410): 92% (UV), Rt= 0.87 min, rniz (ES14-)= 393.2 [M+H]
[0280] 1H NMR (500 MHz, Chloroform-a) 6 2.02 ¨ 2.09 (m, 2H), 2.45 ¨ 2.56 (m,
2H),
3.17 ¨ 3.31 (m, 2H), 3.33 ¨ 3.42 (m, 2H), 3.86 ¨ 3.96 (m, 2H), 4.09 ¨ 4.14 (m,
1H), 4.31
(d, J= 9.5 Hz, 1H), 7.26 ¨ 7.29 (m, 3H), 7.31 ¨7.36 (m, 2H), 8.97 (s, 1H),
9.11 (s, 2H)
Rac-5-[(3R,4R)-3-benzy1-4-[2-cyano-2-(1A4-thiolan-1-ylidene)acetyl]-2-
oxopyrrolidin-1-
yl]pyrimidine-4-carbonitrile (1-71)
[0281] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-yI]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method B, general procedure 5 (general scheme 3) as a pale yellow
powder
(328 mg, 94% purity by 1H NMR, 83%) after purification by FCC on normal phase
silica
(25 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed by 0-
50%
Me0H in Et0Ac gradient).
[0282] LC-MS (METCR1410): 96% (UV), Rt= 0.96 min, rniz (ES14-)= 432.0 [M+H]
[0283] 1H NMR (500 MHz, Chloroform-o) 6 1.96 ¨ 2.09 (m, 2H), 2.45 ¨ 2.57 (m,
2H),
2.91 (dd, J= 9.0, 14.0 Hz, 1H), 3.00 ¨ 3.11 (m, 2H), 3.19 ¨ 3.29 (m, 2H), 3.39
(dd, J=
4.5, 14.0 Hz, 1H), 3.46 ¨ 3.53 (m, 1H), 3.65 (q, J= 8.2 Hz, 1H), 3.75 ¨ 3.85
(m, 1H),
3.98 (dd, J= 8.0, 8.9 Hz, 1H), 7.20 ¨ 7.24 (m, 1H), 7.27 ¨ 7.34 (m, 4H), 9.07
(s, 1H),
9.14 (s, 1H)
Rac-3-[(3R,4R)-4-benzy1-1-(4-methylpyrimidin-5-y1)-5-oxopyrrolidin-3-y1]-3-oxo-
2-(110-
thiolan-1-ylidene)propanenitrile (1-72)
[0284] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-3-oxo-2-(110-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method B, general procedure 5 (general scheme 3) as an orange
viscous oil
(374 mg, 90% purity by 1H NMR, 60%) after purification by FCC on normal phase
silica
(25 g SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient followed by 0-30%
Me0H in Et0Ac gradient).
[0285] LC-MS (METCR1410): 94% (UV), Rt= 0.89 min, rniz (ESI+)= 421.1 [M+H].

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
53
[0286] 1H NMR (500 MHz, Chloroform-o) 6 1.97 ¨2.07 (m, 2H), 2.43 (s, 3H), 2.44
¨
2.55 (m, 2H), 2.92 (dd, J= 8.1, 13.4 Hz, 1H), 2.99 ¨ 3.09 (m, 2H), 3.20 ¨ 3.28
(m, 2H),
3.31 ¨ 3.42 (m, 2H), 3.42 ¨ 3.47 (m, 1H), 3.60 ¨ 3.69 (m, 2H), 7.20 ¨ 7.24 (m,
1H), 7.28
¨ 7.34 (m, 4H), 8.37 (s, 1H), 8.98 (s, 1H)
Rac-3-[(3R,4R)-4-benzy1-146-(benzyloxy)pyridin-2-y1]-5-oxopyrrolidin-3-y1]-3-
oxo-2-
(110-thiolan-1-ylidene)propanenitrile (1-73)
[0287] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-23) in a
similar
manner to method B, general procedure 5 (general scheme 3) as a yellow viscous
oil
(342 mg, 95% punt, 61%) after purification by FCC on normal phase silica (25 g
SNAP
Ultra cartridge, 0-100% Et0Ac in heptane gradient followed by 0-20% Me0H in
Et0Ac
gradient).
[0288] LC-MS (METCR1410): 95% (UV), Rt= 1.26 min, miz (ES14-)= 512.2 [M+H]4-
[0289] 1H NMR (500 MHz, Chloroform-a) 6 1.93 ¨ 2.03 (m, 2H), 2.40 ¨ 2.53 (m,
2H),
2.69 ¨ 2.76 (m, 1H), 2.91 ¨3.03 (m, 2H), 3.13 ¨ 3.21 (m, 2H), 3.46 (dd, J=
3.7, 13.9
Hz, 1H), 3.48 ¨ 3.57 (m, 2H), 3.70 ¨ 3.78 (m, 1H), 4.18 ¨4.27 (m, 1H), 5.29
(s, 2H),
6.53 (d, J= 8.0 Hz, 1H), 7.14 ¨ 7.19 (m, 1H), 7.24 ¨ 7.29 (m, 2H), 7.29 ¨ 7.33
(m, 3H),
7.33 ¨ 7.38 (m, 2H), 7.40 ¨ 7.44 (m, 2H), 7.61 (t, J= 8.0 Hz, 1H), 7.97 (d, J=
7.9 Hz,
1H)
Method C: N-Arylation using Cs2CO3 and Cu(I)I
Rac-3-[(3R,4R)-4-benzy1-1-(1-methy1-1H-pyrazol-4-y1)-5-oxopyrrolidin-3-y1]-3-
oxo-2-
(1M-thiolan-1-ylidene)propanenitrile (1-74)
[0290] To a solution of rac-3-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-3-oxo-2-
(110-
thiolan-1-ylidene)propanenitrile (1-23) (71% purity by 1H NMR, 500 mg, 1.08
mmol) and
4-bromo-1-methyl-1H-pyrazole (157 mg, 0.975 mmol) in 1,4-dioxane (10 mL) was
added Cs2CO3 (635 mg, 1.95 mmol), Cu(I)I (19 mg, 0.10 mmol) and N,N-dimethyl-
ethylenediamine (9 mg, 0.10 mmol) then the suspension was heated at 90 C in a
pressure tube for 3 h. Further 4-bromo-1-methyl-1H-pyrazole (157 mg, 0.98
mmol),
Cs2CO3 (635 mg, 1.95 mmol), Cu(I)I (19 mg, 0.10 mmol) and N,N-dimethylethylene-
diamine (9 mg, 0.10 mmol) were added and the reaction heated at 90 0C for 3 h.
The
mixture was cooled to RT, diluted with DCM (20 mL) and filtered. The filter
cake was
washed with DCM (20 mL) and the combined filtrates concentrated in vacuo. The
residue was purified by FCC on normal phase silica (25 g SNAP KP-SIL
cartridge, 0-

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
54
100% Et0Ac in heptane gradient followed by 0-50% Me0H in Et0Ac gradient) to
afford 248 mg of rac-3-[(3R,4R)-4-benzy1-1-(1-methy1-1H-pyrazol-4-y1)-5-
oxopyrrolidin-
3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile as a pale yellow gum (90%
purity by
1H NMR, 56%).
[0291] LC-MS (MET-uHPLC-1704): 100% (UV), Rt= 0.61 min, m/z (ES14-)= 409.2
[M+H]
[0292] 1H NMR (500 MHz, DMSO-a) 6 1.92 ¨ 2.06 (m, 2H), 2.15 ¨ 2.29 (m, 2H),
2.72 ¨2.81
(m, 2H), 2.93 ¨ 2.99 (m, 1H), 3.07 (dd, J= 4.6, 13.6 Hz, 1H), 3.10 ¨ 3.16 (m,
1H), 3.35 ¨ 3.56
(m, 5H), 3.80 (s, 3H), 7.16 ¨7.22 (m, 3H), 7.22 ¨ 7.31 (m, 2H), 7.56 (s, 1H),
7.96 (s, 1H)
GENERAL PROCEDURE 6 (GENERAL SCHEME 3): Oxidation
Method A: Oxone oxidation to ketoacid
Rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-75)
[0293] To an ice-cooled solution of rac-3-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-
y1]-2-
(12,4-thiolan-1-ylidene)-3-oxopropanenitrile (1-23) (0.42 g, 1.29 mmol) in 3:2
THF:water
(25 mL) was added Oxone (1.57 g, 2.57 mmol) and the mixture stirred at 000 for
1 h.
The reaction was quenched with 1M HCI, stirred vigorously for 5 min and
extracted
with Et0Ac (3 x 80 mL). The combined organic extracts were dried over
Na2SO4and
concentrated in vacuo to give 490 mg of rac-2-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-
2-oxoacetic acid as a pale yellow oil (70% purity by 1H NMR, 100%) which was
used in
the next step without further purification.
[0294] LC-MS (MET0R1410): 91% (UV), Rt= 0.67 min, m/z (ES1+)= 247.9 [M+H]4-
[0295] 1H NMR (500 MHz, Chloroform-a) 52.94 (dd, J =7 .4, 13.4 Hz, 2H), 3.15 ¨
3.27 (m, 2H), 3.31 ¨ 3.42 (m, 2H), 3.86 ¨ 3.97 (m, 1H), 7.26 (s, 5H)
Rac-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-yl]acetic acid (1-76)
[0296] The title compound was synthesized from pure rac-3-oxo-3-[(3R,4S)-5-oxo-
4-
phenylpyrrolidin-3-y1]-2-(110-thiolan-1-ylidene)propanenitrile (1-24) in a
similar manner
to method A, general procedure 6 (general scheme 3) as a pale yellow viscous
oil (550
mg, 50% purity, 39%) obtained after work-up and used in the next step without
further
purification.
[0297] LC-MS (MET0R1410): 50% (UV), Rt= 0.20 ¨ 0.50 min, m/z (ES1)= 234.1
[M+H]
[0298] Note: Batches of rac-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
yl]acetic acid
(1-76) prepared from crude rac-3-oxo-3-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-y1]-
2-(110-

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
thiolan-1-ylidene)propanenitrile (1-24) contained rac-2-[(3R,4R)-4-cyclohexy1-
5-
oxopyrrolidin-3-y1]-2-oxoacetic acid as a minor by-product.
Rac-2-[(3R,4S)-4-(4-fluoropheny1)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-
77)
[0299] The title compound was synthesized from rac-3-[(3R,4S)-4-(4-
fluoropheny1)-5-
oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-25) in a
similar
manner to method A, general procedure 6 (general scheme 3) as a yellow viscous
oil
(750 mg, 50% purity, 64%) obtained after work-up and used in the next step
without
further purification.
[0300] LC-MS (METCR1410): 50% (UV), Rt= 0.35 min, m/z (ES1)= 252.0 [M+H]
Rac-2-[(3R,4R)-4-[(4-fluorophenyl)methy1]-5-oxopyrrolidin-3-y1]-2-oxoacetic
acid (1-78)
[0301] The title compound was synthesized from rac-3-[(3R,4R)-4-[(4-
fluorophenyl)methy1]-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propanenitrile
(1-35) in a similar manner to method A, general procedure 6 (general scheme 3)
as a
yellow viscous oil (2.1 g, 60% purity estimated by 1H NMR, 60%) obtained after
work-
up and used in the next step without further purification.
[0302] LC-MS (METCR1410): 89% (UV), Rt= 0.72 min, m/z (ES1)= 266.0 [M+H]+
[0303] 1H NMR (500 MHz, DMSO-d6) 6 2.80 - 2.86 (m, 2H), 2.89 - 2.95 (m, 1H),
3.13
-3.17 (m, 1H), 3.18 - 3.23 (m, 1H), 3.63 - 3.69 (m, 1H), 7.04 - 7.11 (m, 2H),
7.21 -
7.26 (m, 2H), 7.69 - 7.75 (m, 1H)
Rac-2-[(3R,4R)-4-benzy1-1-[(oxan-4-yl)methyl]-5-oxopyrrolidin-3-y1]-2-
oxoacetic acid (1-
79)
[0304] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-1-
[(oxan-4-
yl)methyl]-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile
(1-48) in a
similar manner to method A, general procedure 6 (general scheme 3) as a yellow
viscous oil (810 mg, 60% purity estimated by 1H NMR, 71%) obtained after work-
up
and used in the next step without further purification.
[0305] LC-MS (METCR1410): 75% (UV), Rt= 0.84 min, m/z (ES1)= 346.2 [M+H]+
[0306] 1H NMR (250 MHz, Chloroform-d) 6 1.31 - 1.49 (m, 3H), 1.68- 1.90 (m,
1H),
3.05 - 3.22 (m, 7H), 3.25 - 3.45 (m, 3H), 3.75 - 3.86 (m, 1H), 3.88 - 4.02 (m,
2H), 7.16
- 7.32 (m, 5H)
Rac-2-[(3R,4R)-4-benzy1-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-5-
oxopyrrolidin-3-
y1]-2-oxoacetic acid (1-80)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
56
[0307] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-1-[(3-
methyl-1,2,4-oxadiazol-5-yl)methyl]-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-
1-
ylidene)propanenitrile (1-49) in a similar manner to method A, general
procedure 6
(general scheme 3) as a yellow viscous oil (209 mg, 50% purity estimated by 1H
NMR,
86%) obtained after work-up and used in the next step without further
purification.
[0308] LC-MS (MET0R1410): 92% (UV), Rt= 0.82 min, m/z (ES14-)= 344.0 [M+H]4-
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-[(pyrimidin-2-yl)methyl]pyrrolidin-3-y1]-2-
oxoacetic
acid (1-81)
[0309] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-oxo-1-
[(pyrimidin-2-yl)methyl]pyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propanenitrile (I-
50) in a similar manner to method A, general procedure 6 (general scheme 3) as
a
yellow gum (850 mg, 40% purity estimated by 1H NMR, 53%) obtained after work-
up
and used in the next step without further purification.
[0310] LC-MS (MET0R1410): 70% (UV), Rt= 0.78 min, m/z (ES14-)= 340.1 [M+H]f
[0311] 1H NMR (250 MHz, Chloroform-o) 6 3.08 ¨ 3.26 (m, 3H), 3.37 ¨ 3.45 (m,
1H),
3.53 ¨ 3.62 (m, 1H), 3.70 ¨ 3.82 (m, 1H), 4.40 (d, J= 16.9 Hz, 1H), 5.02 (d,
J= 17.0
Hz, 1H), 7.20 ¨ 7.35 (m, 6H), 8.82 (d, J= 4.7 Hz, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-[(pyrimidin-4-yl)methyl]pyrrolidin-3-y1]-2-
oxoacetic
acid (1-82)
[0312] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-oxo-1-
[(pyrimidin-4-yl)methyl]pyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propanenitrile (I-
51) in a similar manner to method A, general procedure 6 (general scheme 3) as
a
pale yellow gum (201 mg, 50% purity estimated by 1H NMR, 83%) obtained after
work-
up and used in the next step without further purification.
[0313] LC-MS (METCR1410): 75% (UV), Rt= 0.76 min, m/z (ES14-)= 340.0 [M-FH]+
Rac-2-[(3R,4R)-4-cyclohexy1-1-methyl-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-
83)
[0314] The title compound was synthesized from rac-3-[(3R,4R)-4-cyclohexy1-1-
methyl-5-oxopyrrolidin-3-y1]-3-oxo-2-(1M-thiolan-1-ylidene)propanenitrile (1-
52) in a
similar manner to method A, general procedure 6 (general scheme 1) as a
colourless
oil (721 mg, 50% purity estimated by 1H NMR, 90%) obtained after work-up and
used
in the next step without further purification.
[0315] LC-MS (METCR1410): 89% (UV), Rt= 0.75 min, m/z (ESI+)= 254.0 [M-FH].#

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
57
Rac-2-[(3R,4R)-4-benzy1-1-(2-methoxyethyl)-5-oxopyrrolidin-3-y1]-2-oxoacetic
acid (I-
84)
[0316] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-1-(2-
methoxyethyl)-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propanenitrile (1-53)
in a similar manner to method A, general procedure 6 (general scheme 3) as a
yellow
gum (555 mg, 25% purity estimated by 1H NMR, 50%) obtained after work-up and
used in the next step without further purification.
[0317] LC-MS (METCR1410): 54% (UV), Rt= 0.79 min, m/z (ES14-)= 306.1 [M+H]
[0318] 1H NMR (500 MHz, Chloroform-0 6 2.93 - 2.98 (m, 1H), 3.16 - 3.22 (m,
3H),
3.28 (s, 3H), 3.35- 3.39 (m, 2H), 3.41 - 3.49 (m, 5H), 7.16 - 7.24 (m, 3H),
7.24 -7.31
(m, 2H).
Rac-2-[(3R,4R)-4-benzy1-1-(carbamoylmethyl)-5-oxopyrrolidin-3-y1]-2-oxoacetic
acid (I-
85)
[0319] The title compound was synthesized from rac-2-[(3R,4R)-3-benzy1-442-
cyano-
2-(1A4-thiolan-1-ylidene)acetyl]-2-oxopyrrolidin-1-yllacetamide (1-54) in a
similar
manner to method A, general procedure 6 (general scheme 3) as a yellow gum
(563
mg, 10% purity estimated by 1H NMR, 15%) and used in the next step without
further
purification.
[0320] LC-MS (METCR1410): 20% (UV), Rt= 0.68 min, m/z (ES1)= 305.2 [M+H]4-
Rac-2-[(3R,4R)-4-benzy1-1-[(5-methyl-1,2-oxazol-3-y1)methyl]-5-oxopyrrolidin-3-
y1]-2-
oxoacetic acid (1-86)
[0321] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-1-[(5-
methyl-1,2-oxazol-3-yl)methyl]-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propanenitrile (1-55) in a similar manner to method A, general
procedure 6
(general scheme 3) as a brown oil (419 mg, 65% purity estimated by 1H NMR,
77%)
and used in the next step without further purification.
[0322] LC-MS (METCR1410): 83% (UV), Rt= 0.89 min, m/z (ESI+)= 343.0 [M+H]-
[0323] 1H NMR (500 MHz, Chloroform-o) 6 2.39 - 2.41 (m, 3H), 2.97 - 3.06 (m,
1H),
3.16 - 3.26 (m, 3H), 3.28 - 3.34 (m, 1H), 3.74 - 3.82 (m, 1H), 4.44 - 4.46 (m,
2H), 5.83
-5.88 (m, 1H), 7.14 - 7.19 (m, 2H), 7.20 - 7.27 (m, 3H)
Rac-2-[(3R,4R)-4-benzy1-1-[(1-methyl-1H-1,2,4-triazol-5-y1)methyl]-5-
oxopyrrolidin-3-
y1]-2-oxoacetic acid (1-87)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
58
[0324] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-1-[(1-
methyl-1H-1,2,4-triazol-5-yl)methyl]-5-oxopyrrolidin-3-y1]-3-oxo-2-(110-
thiolan-1-
ylidene)propanenitrile (1-56) in a similar manner to method A, general
procedure 6
(general scheme 3) as a colourless viscous oil (298 mg, 49% purity, 42%) and
used in
the next step without further purification.
[0325] LC-MS (METCR1410): 49% (UV), Rt= 0.75 min, m/z (ES14-)= 343.0 [M+H]-
Rac-2-[(3R,4R)-4-benzy1-1-[(methylcarbamoyl)methyl]-5-oxopyrrolidin-3-y1]-2-
oxoacetic
acid (1-88)
[0326] The title compound was synthesized from rac-2-[(3R,4R)-3-benzy1-4-[2-
cyano-
2-(1A4-thiolan-1-ylidene)acetyl]-2-oxopyrrolidin-1-y1FN-methylacetamide (1-57)
in a
similar manner to method A, general procedure 6 (general scheme 3) as a pale
yellow
gum (544 mg, 45% purity by 1H NMR, 62%) and used in the next step without
further
purification.
[0327] LC-MS (METCR1410): 79% (UV), Rt= 0.71 min, m/z (ES1-)= 319.0 [M+H]4-
[0328] 1H NMR (500 MHz, Chloroform-o) 6 2.78 (d, J= 4.4 Hz, 3H), 3.08 ¨ 3.20
(m,
4H), 3.39 ¨ 3.46 (m, 1H), 3.66 ¨ 3.83 (m, 2H), 4.02 (d, J= 15.9 Hz, 1H), 6.29
(s, 1H),
7.17 ¨7.33 (m, 5H)
Rac-2-[(3R,4R)-4-benzy1-1-[(dimethylcarbamoyl)methyl]-5-oxopyrrolidin-3-y1]-2-
oxoacetic acid (1-89)
[0329] The title compound was synthesized from rac-2-[(3R,4R)-3-benzy1-442-
cyano-
2-(1A4-thiolan-1-ylidene)acetyl]-2-oxopyrrolidin-1-y1]-N,/V-dimethylacetamide
(1-58) in a
similar manner to method A, general procedure 6 (general scheme 3) as a pale
yellow
gum (670 mg, 40% purity by 1H NMR, 57%) and used in the next step without
further
purification.
[0330] LC-MS (METCR1410): 86% (UV), Rt= 0.79 min, m/z (ES14-)= 333.1 [M+H]4-
[0331] 1H NMR (500 MHz, Chloroform-o) 62.94 (s, 3H), 2.96 ¨ 3.00 (m, 1H), 3.01
(s,
3H), 3.15 ¨3.23 (m, 1H), 3.27 ¨ 3.36 (m, 1H), 3.51 (dd, J= 4.4, 7.9 Hz, 2H),
3.67 ¨
3.80 (m, 1H), 3.95 (d, J= 16.1 Hz, 1H), 4.21 (d, J= 16.2 Hz, 1H), 7.14 ¨7.25
(m, 5H)
Rac-2-[(3R,4R)-4-benzy1-1-[(4-carbamoylphenyl)methyl]-5-oxopyrrolidin-3-y1]-2-
oxoacetic acid (1-90)
[0332] The title compound was synthesized from rac-4-{[(3R,4R)-3-benzy1-4-[2-
cyano-
2-(1A4-thiolan-1-ylidene)acety1]-2-oxopyrrolidin-1-yl]methyllbenzamide (1-59)
in a
similar manner to method A, general procedure 6 (general scheme 3) as a yellow
gum

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
59
(248 mg, 50% purity estimated by 1H NMR, 71%) and used in the next step
without
further purification.
[0333] LC-MS (METCR1410): 83% (UV), Rt= 0.80 min, rrilz (ES14-)= 381.2 [M+H]4-
Rac-2-[(3R,4R)-4-benzy1-1-[(3-methy1-1,2-oxazol-5-y1)methyl]-5-oxopyrrolidin-3-
y1]-2-
oxoacetic acid (1-91)
[0334] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-1-[(3-
methyl-1,2-oxazol-5-yl)methyl]-5-oxopyrrolidin-3-y1]-3-oxo-2-(110-thiolan-1-
ylidene)propanenitrile (1-60) in a similar manner to method A, general
procedure 6
(general scheme 3) as a yellow oil (370 mg, 64% purity by 1H NMR, 90%) and
used in
the next step without further purification.
[0335] LC-MS (MET0R1410): 90% (UV), Rt= 0.86 min, rrilz (ES14-)= 343.1 [M+H]-
[0336] 1H NMR (500 MHz, Chloroform-a) 62.28 (s, 3H), 2.96 ¨ 3.00 (m, 1H), 3.15
¨
3.23 (m, 2H), 3.25 ¨ 3.30 (m, 1H), 3.39 (dd, J= 6.0, 9.9 Hz, 1H), 3.81 ¨3.87
(m, 1H),
4.51 (s, 2H), 5.95 (s, 1H), 7.14 ¨7.18 (m, 2H), 7.20 ¨ 7.28 (m, 3H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]pyrrolidin-3-
y1]-2-
oxoacetic acid (1-92)
[0337] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-oxo-1-
[2-
(2-oxopyrrolidin-1-yl)ethyl]pyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propanenitrile
(1-61) in a similar manner to method A, general procedure 6 (general scheme 3)
as a
yellow gum (547 mg, 50% purity estimated by 1H NMR, 66%) and used in the next
step
without further purification.
[0338] LC-MS (METCR1410): 77% (UV), Rt= 0.79 min, rrilz (ES14-)= 359.1 [M+H]4-
[0339] 1H NMR (500 MHz, Chloroform-a) 6 1.83 ¨ 2.10 (m, 6H), 2.20 ¨ 2.37 (m,
5H),
2.36 ¨ 2.45 (m, 1H), 2.92 (dd, J= 7.6, 13.9 Hz, 1H), 3.03 (s, 6H), 3.05 ¨ 3.17
(m, 2H),
3.18¨ 3.25 (m, 2H), 3.32 ¨ 3.44 (m, 2H), 3.59¨ 3.72 (m, 3H), 3.75 (s, 5H),
7.14 ¨7.30
(m, 5H)
Rac-2-[(3R,4R)-4-benzy1-1-(2,2-difluoroethyl)-5-oxopyrrolidin-3-y1]-2-
oxoacetic acid (I-
93)
[0340] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-1-(2,2-
difluoroethyl)-5-oxopyrrolidin-3-y1]-3-oxo-2-(1/0-thiolan-1-
ylidene)propanenitrile (1-62) in
a similar manner to method A, general procedure 6 (general scheme 3) as a pale
yellow oil (346 mg, 87% purity, 64%) and used in the next step without further
purification.

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
[0341] LC-MS (MET0R1410): 87% (UV), Rt= 0.86 min, rrilz (ES14-)= 312.0 [M+H]
Rac-2-[(3R,4R)-4-[(4-fluorophenyl)methyl]-1-[(1-methy1-1H-1,2,4-triazol-3-
y1)methyl]-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-94)
[0342] The title compound was synthesized from rac-3-[(3R,4R)-4-[(4-
fluorophenyl)methy1]-1-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-5-
oxopyrrolidin-3-y1]-3-
oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-63) in a similar manner to
method A,
general procedure 6 (general scheme 3) as a colourless gum (241 mg, 35%
purity,
30%) and used in the next step without further purification.
[0343] LC-MS (METCR1410): 35% (UV), Rt= 0.80 min, rrilz (ES14-)= 361.0 [M+H].#
Rac-2-[(3R,4R)-4-[(4-fluorophenyl)methy1]-1-[(1-methy1-1H-1,2,4-triazol-5-
y1)methyl]-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-95)
[0344] The title compound was synthesized from rac-3-[(3R,4R)-4-[(4-
fluorophenyl)methy1]-1-[(1-methy1-1H-1,2,4-triazol-5-yl)methyl]-5-
oxopyrrolidin-3-y1]-3-
oxo-2-(1A4-thiolan-1-ylidene)propanenitrile (1-64) in a similar manner to
method A,
general procedure 6 (general scheme 3) as a yellow oil (851 mg, 40% purity
estimated
by 1H NMR, 44%) and used in the next step without further purification.
[0345] LC-MS (METCR1410): 51% (UV), Rt= 0.78 min, rrilz (ES14-)= 361.1 [M+H]-
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1]-2-oxoacetic
acid (1-96)
[0346] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-oxo-1-
(pyrimidin-5-yl)pyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile
(1-65) in a
similar manner to method A, general procedure 6 (general scheme 3) as a pale
yellow
gum (305 mg, 50% purity estimated by 1H NMR, 55%) and used in the next step
without further purification.
[0347] LC-MS (METCR1410): 84% (UV), Rt= 0.80 min, rrilz (ES14-)= 344.0 [M+H]+
[0348] 1H NMR (500 MHz, Chloroform-a) 63.11 ¨3.21 (m, 1H), 3.23 ¨ 3.31 (m,
1H),
3.35¨ 3.42 (m, 1H), 3.62 ¨ 3.69 (m, 1H), 3.81 (dd, J= 6.3, 9.6 Hz, 1H), 3.94
¨4.01 (m,
1H), 7.17 ¨ 7.30 (m, 5H), 8.98 ¨ 9.04 (m, 1H), 9.05 ¨ 9.13 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrazin-2-yl)pyrrolidin-3-y1]-2-oxoacetic
acid (1-97)
[0349] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-oxo-1-
(pyrazin-2-yl)pyrrolidin-3-y1]-3-oxo-2-(1M-thiolan-1-ylidene)propanenitrile (1-
66) in a
similar manner to method A, general procedure 6 (general scheme 3) as a brown
viscous oil (206 mg, 70% purity by 1H NMR, 77%) and used in the next step
without
further purification.

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
61
[0350] LC-MS (METCR1410): 92% (UV), Rt= 0.87 min, m/z (ES14-)= 326.0 [M+H]
[0351] 1H NMR (500 MHz, Chloroform-a) 5 3.00 ¨ 3.06 (m, 1H), 3.33 (dd, J= 5.0,
13.9 Hz, 1H), 3.49 (td, J= 5.0, 8.1 Hz, 1H), 3.91 (dd, J= 7.1, 11.0 Hz, 1H),
3.97 ¨4.03
(m, 1H), 4.08 ¨ 4.15 (m, 1H), 7.17 ¨ 7.24 (m, 3H), 7.25 ¨ 7.30 (m, 2H), 8.31
¨8.33 (m,
1H), 8.34 (d, J= 2.6 Hz, 1H), 9.74 (d, J= 1.4 Hz, 1H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-2-yl)pyrrolidin-3-y1]-2-oxoacetic
acid (1-98)
[0352] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-5-oxo-1-
(pyrimidin-2-yl)pyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-ylidene)propanenitrile
(1-67) in a
similar manner to method A, general procedure 6 (general scheme 3) as an
orange
gum (566 mg, 45% purity by 1H NMR, 73%) and used in the next step without
further
purification.
[0353] LC-MS (METCR1410): 82% (UV), Rt= 0.80 min, m/z (ES1+)= 326.0 [M+H].
[0354] 1H NMR (500 MHz, Chloroform-o) 63.06 (d, J= 8.0 Hz, 1H), 3.31 (dd, J=
5.0,
13.9 Hz, 1H), 3.42 ¨ 3.49 (m, 1H), 3.88 ¨ 3.98 (m, 2H), 7.06 ¨ 7.09 (m, 1H),
7.18 ¨ 7.23
(m, 3H), 7.23 ¨ 7.27 (m, 3H), 8.67 (d, J= 4.8 Hz, 2H)
Rac-2-[(3R,4R)-4-benzy1-1-(2-chloropyrimidin-4-y1)-5-oxopyrrolidin-3-y1]-2-
oxoacetic
acid (1-99)
[0355] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-1-(2-
chloropyrimidin-4-y1)-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propanenitrile
(1-68) in a similar manner to method A, general procedure 6 (general scheme 3)
as an
off-white powder (409 mg, 75% purity by 1H NMR, 98%) and used in the next step
without further purification.
[0356] LC-MS (METCR1410): 81% (UV), Rt= 0.96 min, m/z (ES14-)= 360.0/362.0
[M+H]4-
[0357] 1H NMR (500 MHz, DMSO-d6) 5 2.95 ¨ 3.01 (m, 1H), 3.07 (dd, J= 5.7, 13.8
Hz, 1H), 3.37 ¨ 3.42 (m, 1H), 3.80 (dd, J= 6.8, 9.2 Hz, 1H), 3.87 (dd, J= 6.5,
11.3 Hz,
1H), 4.00 (dd, J= 9.3, 11.3 Hz, 1H), 7.17 ¨ 7.29 (m, 5H), 8.27 (d, J= 5.8 Hz,
1H), 8.61
(d, J= 5.8 Hz, 1H)
Rac-2-[(3R,4R)-4-benzy1-1-(6-chloropyridazin-3-y1)-5-oxopyrrolidin-3-y1]-2-
oxoacetic
acid (1-100)
[0358] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-1-(6-
chloropyridazin-3-y1)-5-oxopyrrolidin-3-y1]-3-oxo-2-(110-thiolan-1-
ylidene)propanenitrile
(1-69) in a similar manner to method A, general procedure 6 (general scheme 3)
as a

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
62
pale yellow oil (358 mg, 75% purity by 1H NMR, 95%) and used in the next step
without
further purification.
[0359] LC-MS (METCR1410): 87% (UV), Rt= 0.93 min, m/z (ES14-)= 360.0/362.0
[M+H]4-
[0360] 1H NMR (500 MHz, Chloroform-a) 63.06 (dd, J= 7.3, 13.9 Hz, 1H), 3.22
(dd, J
= 5.2, 13.9 Hz, 1H), 3.45¨ 3.51 (m, 1H), 3.87¨ 3.94 (m, 1H), 4.05 (dd, J= 6.8,
11.7
Hz, 1H), 4.19 (dd, J= 9.4, 11.6 Hz, 1H), 7.12 ¨ 7.20 (m, 3H), 7.21 ¨7.25 (m,
2H), 7.52
(d, J= 9.4 Hz, 1H), 8.73 (d, J= 9.4 Hz, 1H)
Rac-2-oxo-2-[(3R,4S)-5-oxo-4-pheny1-1-(pyrimidin-5-yl)pyrrolidin-3-yl]acetic
acid (I-
101)
[0361] The title compound was synthesized from rac-3-oxo-3-[(3R,4S)-5-oxo-4-
pheny1-1-(pyrimidin-5-yl)pyrrolidin-3-y1]-2-(1A4-thiolan-1-
ylidene)propanenitrile (1-70) in
a similar manner to method A, general procedure 6 (general scheme 3) as a
yellow
viscous oil (311 mg, 36% purity, 70%) and used in the next step without
further
purification.
[0362] LC-MS (METCR1410): 36% (UV), Rt= 0.77 min, m/z (ES14-)= 312.0 [M+H]4-
Rac-2-[(3R,4R)-4-benzy1-1-(4-cyanopyrimidin-5-y1)-5-oxopyrrolidin-3-y1]-2-
oxoacetic
acid (1-102)
[0363] The title compound was synthesized from rac-5-[(3R,4R)-3-benzy1-442-
cyano-
2-(110-thiolan-1-ylidene)acety1]-2-oxopyrrolidin-1-yl]pyrimidine-4-
carbonitrile (1-71) in a
similar manner to method A, general procedure 6 (general scheme 3) as a pale
yellow
viscous oil (241 mg, 77% purity, 76%) and used in the next step without
further
purification.
[0364] LC-MS (METCR1410): 77% (UV), Rt= 0.88 min, m/z (ES14-)= 351.0 [M+H]4-
Rac-2-[(3R,4R)-4-benzy1-1-(4-methylpyrimidin-5-y1)-5-oxopyrrolidin-3-y1]-2-
oxoacetic
acid (1-103)
[0365] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-1-(4-
methylpyrimidin-5-y1)-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propanenitrile
(1-72) in a similar manner to method A, general procedure 6 (general scheme 3)
as a
pale yellow viscous oil (227 mg, 74% purity, 67%) and used in the next step
without
further purification.
[0366] LC-MS (METCR1410): 74% (UV), Rt= 0.79 min, m/z (ES14-)= 340.0 [M-FH]4-

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
63
Rac-2-[(3R,4R)-4-benzy1-146-(benzyloxy)pyridin-2-y1]-5-oxopyrrolidin-3-y1]-2-
oxoacetic
acid (1-104)
[0367] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-146-
(benzyloxy)pyridin-2-y1]-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propane-
nitrile (1-73) in a similar manner to method A, general procedure 6 (general
scheme 3)
as a yellow viscous oil (371 mg, 66% purity, 99%) and used in the next step
without
further purification.
[0368] LC-MS (METCR1410): 66% (UV), Rt= 1.19 min, m/z (ES1)= 431.0 [M+H]
Rac-2-[(3R,4R)-4-benzy1-1-(1-methy1-1H-pyrazol-4-y1)-5-oxopyrrolidin-3-y1]-2-
oxoacetic
acid (1-105)
[0369] The title compound was synthesized from rac-3-[(3R,4R)-4-benzy1-1-(1-
methyl-
1H-pyrazol-4-y1)-5-oxopyrrolidin-3-y1]-3-oxo-2-(1A4-thiolan-1-
ylidene)propanenitrile (I-
74) in a similar manner to method A, general procedure 6 (general scheme 3) as
a
yellow viscous oil (209 mg, 76% purity, 96%) and used in the next step without
further
purification.
[0370] LC-MS (METCR1410): 76% (UV), Rt= 0.83 min, m/z (ES1)= 328.0 [M+H]+
Method B: m-CPBA oxidation to ketoester
Rac-methyl 2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-yl]acetate (1-106)
[0371] To an ice-cooled solution of rac-3-oxo-3-[(3R,4S)-5-oxo-4-
phenylpyrrolidin-3-
y1]-2-(1A4-thiolan-1-ylidene)propanenitrile (1-24) (80% purity by 1H NMR, 450
mg, 1.21
mmol) in dry Me0H (3 mL) was added ,n-CPBA (70%, 598 mg, 2.45 mmol)
portionwise at 0 C and the mixture stirred at 0 C for 1 h. The reaction was
quenched
with 1M Na2S203(5 mL) and extracted with DCM (3 x 10 mL). The organic extracts
were washed with sat. NaHCO3 (2 x 10 mL) and concentrated in vacuo to afford
150
mg of rac-methyl 2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-yl]acetate as a
yellow
viscous oil (23% purity, 12%) which was used in the next step without further
purification.
[0372] LC-MS (METCR1410): 23% (UV), Rt= 0.71 min, m/z (ES1)= 248.1 [M+H]+
GENERAL PROCEDURE 7a (GENERAL SCHEME 3): Ketoamide formation
Method A: T3P coupling on ketoacid
Rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-N-(cyclopropylmethyl)-2-
oxoacetamide
(FP-1)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
64
[0373] To a solution of rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-2-
oxoacetic acid
(1-75) (70% purity by 1H NMR, 485 mg, 1.37 mmol) in DMF (3 mL) were added in
quick
succession T3P (50% in DMF, 2 mL, 3.43 mmol), DIPEA (718 pL, 4.12 mmol) and 1-
cyclopropylmethanamine (179 pL, 2.06 mmol) and the mixture stirred at RT for 1
h.
The solution was diluted with Et0Ac (50 mL), washed with brine (5 x 50 mL) and
the
organic phase was dried over Na2SO4and concentrated in vacuo. The residue was
purified by FCC on normal phase silica (25 g SNAP KP-SIL cartridge, 0-100%
Et0Ac
in heptane gradient) to afford 164 mg of rac-2-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-
N-(cyclopropylmethyl)-2-oxoacetamide as an off-white solid (96% purity, 34%).
[0374] LC-MS (MET-uHPLC-AB-102): 96% (UV), Rt= 2.45 min, m/z (ES14-)= 301.2
[0375] 1H NMR (500 MHz, Chloroform-a) 60.22 (q, J=4.7 Hz, 2H), 0.51 ¨0.59 (m,
2H), 0.87 ¨ 0.99 (m, 1H), 2.89 (dd, J=8.0, 13.7 Hz, 1H), 3.05 ¨ 3.13 (m, 3H),
3.19 ¨
3.29 (m, 2H), 3.32 ¨ 3.39 (m, 1H), 4.08 (ddd, J=6.9, 7.7, 9.1 Hz, 1H), 5.60 ¨
5.68 (m,
1H), 6.72 ¨ 6.82 (m, 1H), 7.15 ¨ 7.24 (m, 3H), 7.22 ¨ 7.29 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-/V-cyclopropyl-2-oxoacetamide
(FP-2)
[0376] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-75) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (22 mg, 100% purity,
11%) after
purification by FCC on normal phase silica (10 g SNAP KP-SIL cartridge, 50-
100%
Et0Ac in heptane gradient) followed by FCC on normal phase silica (10 g SNAP
KP-
SIL cartridge, 0-100% Et0Ac in heptane gradient).
[0377] LC-MS (MET-uPLC-AB-102): 100% (UV), Rt= 2.11 min, m/z (ESI+)= 287.1
[M+H]4-
[0378] 1H NMR (500 MHz, Chloroform-a) 6 0.49 ¨ 0.60 (m, 2H), 0.79 ¨ 0.89 (m,
2H),
2.65 ¨ 2.74 (m, 1H), 2.88 (dd, J= 8.1, 13.7 Hz, 1H), 3.03 ¨ 3.11 (m, 1H), 3.18
¨ 3.28
(m, 2H), 3.30 ¨ 3.38 (m, 1H), 4.08 (ddd, J= 7.0, 7.8, 9.0 Hz, 1H), 5.59 (s,
1H), 6.69 (s,
1H), 7.16 ¨ 7.23 (m, 3H), 7.22 ¨7.29 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-/V-ethy1-2-oxoacetamide (FP-3)
[0379] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-75) in a similar manner to method A,
general
procedure 7a (general scheme 3) as a colourless gum (63 mg, 96% purity, 29%)
after

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
purification by FCC on normal phase silica (25 g SNAP Ultra cartridge, 0-100%
Et0Ac
in heptane gradient).
[0380] LC-MS (METCR1603): 96% (UV), Rt= 3.20 min, m/z (ES14)= 275.2 [M+H]4-
[0381] 1H NMR (500 MHz, Chloroform-o) 6 1.16 (t, J =7 .3 Hz, 3H), 2.88 (dd, J
=8.1,
13.7 Hz, 1H), 3.08 (td, J = 4.7 , 7.9 Hz, 1H), 3.20 - 3.24 (m, 1H), 3.24 -
3.31 (m, 3H),
3.33- 3.38(m, 1H), 4.08 (ddd, J=6.9, 7.8,9.1 Hz, 1H), 5.68 (s, 1H), 6.66(s,
1H),
7.17- 7.23 (m, 3H), 7.23 - 7.27 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-/V-(2,2-difluoroethyl)-2-
oxoacetamide
(FP-4)
[0382] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-75) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (115 mg, 100% purity,
49%)
after purification by FCC on normal phase silica (25 g SNAP Ultra cartridge, 0-
100%
Et0Ac in heptane gradient).
[0383] LC-MS (METCR1603): 100% (UV), Rt= 3.25 min, m/z (ES1+)= 311.2 [M+H]
[0384] 1H NMR (500 MHz, Chloroform-0 62.85 (dd, J=8.4, 13.8 Hz, 1H), 3.10 (td,
J
=4.7, 8.2 Hz, 1H), 3.22 - 3.28 (m, 2H), 3.34 - 3.40 (m, 1H), 3.55 - 3.67 (m,
2H), 4.08
(ddd, J =7 .1, 8.1, 9.0 Hz, 1H), 5.62 (s, 1H), 5.81 (tt, J=3.9, 55.4 Hz, 1H),
6.82 -6.95
(m, 1H), 7.16 - 7.22 (m, 3H), 7.23 - 7.28 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-2-oxo-N-(propan-2-yl)acetamide
(FP-5)
[0385] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-yI]-2-oxoacetic acid (1-75) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (89 mg, 100% purity,
38%) after
purification by FCC on normal phase silica (25 g SNAP Ultra cartridge, 0-100%
Et0Ac
in heptane gradient).
[0386] LC-MS (MET-uHPLC-AB-102): 100% (UV), Rt= 3.46 min, m/z (ES1)= 289.2
[M+H]
[0387] 1H NMR (500 MHz, Chloroform-a) 6 1.16 (dd, J=0.9, 6.6 Hz, 6H), 2.88
(dd, J
=8.1, 13.7 Hz, 1H), 3.08 (td, J = 4.7 , 8.0 Hz, 1H), 3.20 - 3.27 (m, 2H), 3.31
-3.38 (m,
1H), 3.90 - 4.03 (m, 1H), 4.09 (ddd, J=6.9, 7.8, 9.0 Hz, 1H), 5.58(s, 1H),
6.40 - 6.59
(m, 1H), 7.15 - 7.23 (m, 3H), 7.21 -7.29 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-A-N-(2-cyanoethyl)-2-oxoacetamide
(FP-6)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
66
[0388] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-75) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (82 mg, 100% purity,
34%) after
purification by FCC on normal phase silica (25 g SNAP Ultra cartridge, 0-100%
Et0Ac
in heptane gradient).
[0389] LC-MS (MET-uHPLC-AB-102): 100% (UV), Rt= 1.83 min, m/z (ES14-)= 300.1
[M+H].
[0390] 1H NMR (500 MHz, Chloroform-d) 6 2.52 - 2.68 (m, 2H), 2.82 - 2.90 (m,
1H),
3.10 (td, J = 4.7 , 8.2 Hz, 1H), 3.21 -3.29 (m, 2H), 3.33 - 3.39 (m, 1H), 3.45
- 3.58 (m,
2H), 4.07 (ddd, J =7 .1, 8.0, 9.0 Hz, 1H), 5.66 (s, 1H), 7.04 -7.12 (m, 1H),
7.17 -7.23
(m, 3H), 7.23 - 7.30 (m, 2H).
Rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-N-(oxan-4-y1)-2-oxoacetamide (FP-
7)
[0391] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-75) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (76 mg, 100% purity,
28%) after
purification by FCC on normal phase silica (25 g SNAP Ultra cartridge, 0-100%
Et0Ac
in heptane gradient) followed by trituration in Et20.
[0392] LC-MS (MET-uHPLC-AB-102): 100% (UV), Rt= 2.02 min, m/z (ES1+)= 331.2
[M+H]4-
[0393] 1H NMR (500 MHz, Chloroform-d) 6 1.50 (dddd, J=2.2, 4.5, 9.2, 17.3 Hz,
2H),
1.80 - 1.87 (m, 2H), 2.88 (dd, J=8.1, 13.7 Hz, 1H), 3.08 (td, J = 4.7 , 8.0
Hz, 1H), 3.20
- 3.28 (m, 2H), 3.31 -3.37 (m, 1H), 3.47 (tdd, J =2.2, 7.5, 11.6 Hz, 2H), 3.82
- 3.92
(m, 1H), 3.93 - 4.01 (m, 2H), 4.09 (ddd, J = 6.9 , 7.8, 9.0 Hz, 1H), 5.61 (s,
1H), 6.59(d,
J =7 .9 Hz, 1H), 7.17 - 7.22 (m, 3H), 7.23 - 7.27 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-2-oxo-N-(propan-2-
yloxy)acetamide (FP-
[0394] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-75) in a similar manner to method A,
general
procedure 7a (general scheme 3) as a colourless glass (7 mg, 90% purity by 1H
NMR,
4%) after purification by FCC on normal phase silica (25 g SNAP Ultra
cartridge, 0-
100% Et0Ac in heptane gradient) followed by preparative LC (acidic pH, early
elution
method).
[0395] LC-MS (METCR1603): 97% (UV), Rt= 2.28 min, m/z (ES14-)= 305.2 [M+H]4-

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
67
[0396] 1H NMR (500 MHz, Chloroform-o) 6 1.20 ¨ 1.30 (m, 6H), 2.83 ¨2.92 (m,
1H),
3.04 ¨ 3.12 (m, 1H), 3.19 ¨ 3.28 (m, 2H), 3.34 (t, J= 9.4 Hz, 1H), 4.00 ¨ 4.08
(m, 1H),
4.14 (hept, J= 6.0 Hz, 1H), 5.96 ¨ 6.13 (m, 1H), 7.16 ¨ 7.23 (m, 3H), 7.23 ¨
7.30 (m,
2H), 9.02 (s, 1H)
Rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-/V-(cyclohexyloxy)-2-
oxoacetamide (FP-
[0397] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-75) in a similar manner to method A,
general
procedure 7a (general scheme 3) as a colourless glass (9 mg, 84% purity by 1H
NMR,
5%) after purification by FCC on normal phase silica (25 g SNAP Ultra
cartridge, 0-
100% Et0Ac in heptane gradient) followed by FCC on reversel phase silica (12 g
SNAP C18 Ultra cartridge, acidic pH, standard elution method).
[0398] LC-MS (METCR1603): 100% (UV), Rt= 2.60 min, m/z (ES14-)= 344.2 [M+H]4-
[0399] 1H NMR (500 MHz, Chloroform-a) 6 1.22 ¨ 1.40 (m, 3H), 1.41 ¨ 1.51 (m,
2H),
1.52 ¨ 1.59 (m, 1H), 1.67 ¨ 1.81 (m, 2H), 1.87 ¨ 1.96 (m, 2H), 2.70 (dd, J=
13.8, 9.3
Hz, 1H), 3.19 (dd, J= 13.8, 3.8 Hz, 1H), 3.25 ¨ 3.32 (m, 1H), 3.40 ¨ 3.53 (m,
2H), 3.87
(q, J= 8.9 Hz, 1H), 4.10 ¨ 4.19 (m, 1H), 6.74(s, 1H), 7.14 ¨ 7.25 (m, 5H),
9.03(s, 1H)
Rac-/V-(cyclopropylmethyl)-2-oxo-2-[(3R,45)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide
(FP-10)
[0400] The title compound was synthesized from rac-2-oxo-2-[(3R,45)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (17 mg, 98% purity, 4%)
after
purification by FCC on normal phase silica (25 g SNAP KP-SIL cartridge, 0-100%
Et0Ac in heptane gradient) followed by preparative LC (acidic pH, early
elution
method) and FCC on normal phase silica (10 g SNAP KP-SIL cartridge, 0-100%
Et0Ac in heptane gradient).
[0401] LC-MS (METCR1603): 98% (UV), Rt= 3.3 min, m/z (ESI)= 287.1 [M-FH]+
[0402] 1H NMR (500 MHz, Chloroform-o) 6 0.19 ¨ 0.26 (m, 2H), 0.51 ¨0.59 (m,
2H),
0.90 ¨ 1.02 (m, 1H), 3.08 ¨ 3.21 (m, 2H), 3.38 ¨ 3.46 (m, 1H), 3.94 ¨ 4.01 (m,
1H), 4.07
(d, J=8.0 Hz, 1H), 4.28 ¨ 4.37 (m, 1H), 6.40 (s, 1H), 7.05 (s, 1H), 7.25 ¨
7.33 (m, 3H),
7.31 ¨ 7.38 (m, 2H)
Rac-N-(2,2-difluoropropy1)-2-oxo-2-[(3R,45)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide
(FP-11) and

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
68
Rac-2-[(3R,4R)-4-cyclohexy1-5-oxopyrrolidin-3-y1]-N-(2,2-difluoropropy1)-2-
oxoacetamide (FP-12)
[0403] The title compounds were synthesized from crude rac-2-oxo-2-[(3R,4S)-5-
oxo-
4-phenylpyrrolidin-3-yl]acetic acid (1-76) containing rac-2-[(3R,4R)-4-
cyclohexy1-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid as a minor by-product in a similar manner
to
method A, general procedure 7a (general scheme 3) as off-white solids to give
38 mg
of rac-N-(2,2-difluoropropyI)-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide
(100% purity, 10%) and 16 mg of rac-2-[(3R,4R)-4-cyclohexy1-5-oxopyrrolidin-
311]-N-
(2,2-difluoropropyI)-2-oxoacetamide (97% purity, 4%).
Rac-N-(2,2-difluoropropy1)-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide
(FP-11)
[0404] LC-MS (METCR1603): 100% (UV), Rt= 3.14 min, m/z (ES1+)= 311.2 [M+H]
[0405] 1H NMR (500 MHz, Chloroform-0 6 1.54 - 1.66 (m, 3H), 3.45 (dd, J=7.1,
9.9
Hz, 1H), 3.67 (td, J =6.7 , 13.8 Hz, 2H), 3.93- 3.98 (m, 1H), 4.02 -4.07 (m,
1H), 4.28
-4.35 (m, 1H), 6.44 (s, 1H), 7.18 - 7.40 (m, 6H)
Rac-2-[(3R,4R)-4-cyclohexy1-5-oxopyrrolidin-3-A-N-(2,2-difluoropropy1)-2-
oxoacet-
amide (FP-12)
[0406] LC-MS (METCR1603): 97% (UV), Rt= 3.70 min, m/z (ES1)= 317.3 [M+H]
[0407] 1H NMR (500 MHz, Chloroform-a) 6 0.95- 1.07 (m, 1H), 1.06- 1.35 (m,
4H),
1.57- 1.79 (m, 8H), 1.88- 1.99 (m, 1H), 2.71 (dd, J=4.2, 6.2 Hz, 1H), 3.35
(ddd, J =
0.9, 5.4, 9.9 Hz, 1H), 3.62 - 3.77 (m, 3H), 4.08 - 4.17 (m, 1H), 5.77(s, 1H),
7.24 -7.30
(m, 1H)
Rac-N-(2-methylpropy1)-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide (FP-
[0408] The title compound was synthesized from rac-2-oxo-2-[(3R,4S)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as a tan powder (36 mg, 100% purity, 11%)
after
purification by preparative LC (acidic pH, standard elution method).
[0409] LC-MS (METCR1603): 100% (UV), Rt= 3.47 min, m/z (ES1+)= 289.2 [M+H]+
[0410] 1H NMR (500 MHz, Chloroform-a) 6 0.91 (d, J= 6.7 Hz, 6H), 1.74 - 1.85
(m,
1H), 3.07 - 3.17 (m, 2H), 3.41 (dd, J= 7.1, 9.7 Hz, 1H), 3.96 (t, J= 9.6 Hz,
1H), 4.05
(d, J= 7.9 Hz, 1H), 4.28 - 4.35 (m, 1H), 6.74(s, 1H), 6.94 - 7.07 (m, 1H),
7.24 -7.32
(m, 3H), 7.32 - 7.37 (m, 2H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
69
Rac-N-cyclopropy1-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-yl]acetamide (FP-
14)
[0411] The title compound was synthesized from rac-2-oxo-2-[(3R,4S)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white powder (25 mg, 95% purity, 7%)
after
purification by preparative LC (acidic pH, early elution method).
[0412] LC-MS (MET-uPLC-AB-102): 95% (UV), Rt= 1.70 min, m/z (ES14-)= 273.1
[M+Hr
[0413] 1H NMR (500 MHz, Chloroform-a) 6 0.55 ¨ 0.63 (m, 2H), 0.82 ¨0.90 (m,
2H),
2.72 ¨ 2.80 (m, 1H), 3.38 ¨ 3.48 (m, 1H), 3.99 (t, J= 9.5 Hz, 1H), 4.05 (d, J=
8.0 Hz,
1H), 4.28 ¨ 4.35 (m, 1H), 5.84 (s, 1H), 6.96 (s, 1H), 7.27 ¨ 7.32 (m, 3H),
7.31 ¨ 7.38
(m, 2H)
Rac-/V-ethy1-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-yl]acetamide (FP-15)
[0414] The title compound was synthesized from rac-2-oxo-2-[(3R,4S)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (10 mg, 90% purity by 1H
NMR,
3%) after purification by preparative LC (acidic pH, early elution method).
[0415] LC-MS (MET-uPLC-AB-102): 99% (UV), Rt= 1.67 min, m/z (ES1+)= 261.0
[M+H].
[0416] 1H NMR (500 MHz, Chloroform-a) 6 1.14 (t, J= 7.3 Hz, 3H), 3.20 ¨ 3.33
(m,
2H), 3.33 ¨ 3.41 (m, 1H), 3.92 (t, J= 9.7 Hz, 1H), 4.03 (d, J= 8.0 Hz, 1H),
4.21 ¨4.33
(m, 1H), 6.80 ¨ 6.99 (m, 2H), 7.21 ¨ 7.27 (m, 3H), 7.28 ¨ 7.37 (m, 2H)
Rac-/V-(3,3-difluorocyclobuty1)-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide (FP-16)
[0417] The title compound was synthesized from rac-2-oxo-2-[(3R,4S)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (20 mg, 96% purity by 1H
NMR,
4%) after purification by preparative LC (acidic pH, early elution method).
[0418] LC-MS (METCR1603): 100% (UV), Rt= 3.30 min, m/z (ES14-)= 323.5 [M+H]4-
[0419] 1H NMR (500 MHz, DMSO-d6) 6 2.69 ¨ 2.91 (m, 4H), 3.35 ¨ 3.39 (m, 1H),
3.66
¨ 3.73 (m, 2H), 4.01 ¨4.17 (m, 2H), 7.23 ¨7.27 (m, 3H), 7.28 ¨ 7.36 (m, 2H),
7.97 (s,
1H), 9.22 (d, J= 7.2 Hz, 1H)
Rac-N-tert-buty1-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-yl]acetamide (FP-
17)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
[0420] The title compound was synthesized from rac-2-oxo-2-[(3R,4S)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (94 mg, 96% purity by 1H
NMR,
27%) after purification by FCC on normal phase silica (10 g SNAP Ultra
cartridge, 0-
100% Et0Ac in heptane gradient).
[0421] LC-MS (METCR1603): 100% (UV), Rt= 3.62 min, m/z (ES14-)= 289.5 [M+H]4-
[0422] 1H NMR (500 MHz, Chloroform-o) 5 1.37 (s, 9H), 3.38 ¨ 3.46 (m, 1H),
3.97 (t, J
= 9.7 Hz, 1H), 4.05 (d, J= 8.0 Hz, 1H), 4.26 ¨4.35 (m, 1H), 6.40 (s, 1H), 6.79
(s, 1H),
7.26 ¨ 7.31 (m, 3H), 7.32 ¨ 7.39 (m, 2H)
Rac-2-oxo-2-[(3R,45)-5-oxo-4-phenylpyrrolidin-3-y1]-/V-propylacetamide (FP-18)

[0423] The title compound was synthesized from rac-2-oxo-2-[(3R,45)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (35 mg, 98% purity by 1H
NMR,
14%) after purification by FCC on normal phase silica (10 g SNAP Ultra
cartridge, 0-
100% Et0Ac in heptane gradient).
[0424] LC-MS (METCR1603): 100% (UV), Rt= 3.23 min, m/z (ES1+)= 275.3 [M+H]4-
[0425] 1H NMR (500 MHz, Chloroform-a) 60.93 (t, J= 7.4 Hz, 3H), 1.56 (q, J=
7.3
Hz, 2H), 3.19 ¨ 3.31 (m, 2H), 3.41 (dd, J= 7.1, 9.6 Hz, 1H), 3.97 (t, J= 9.7
Hz, 1H),
4.06 (d, J= 8.0 Hz, 1H), 4.29 ¨ 4.37 (m, 1H), 6.43 (s, 1H), 6.97 (s, 1H), 7.26
¨ 7.32 (m,
3H), 7.32 ¨ 7.38 (m, 2H)
Rac-/V-cyclobuty1-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-yl]acetamide (FP-
19)
[0426] The title compound was synthesized from rac-2-oxo-2-[(3R,45)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (8 mg, 100% purity, 3%)
after
purification by FCC on normal phase silica (10 g SNAP Ultra cartridge, 0-100%
Et0Ac
in heptane gradient) followed by trituration in MeCN.
[0427] LC-MS (METCR1603): 100% (UV), Rt= 3.40 min, m/z (ES14-)= 287.2 [M+H]4-
[0428] 1H NMR (500 MHz, Chloroform-0 5 1.69 ¨ 1.82 (m, 2H), 1.88 ¨ 2.02 (m,
2H),
2.29 ¨ 2.40 (m, 2H), 3.39 (dd, J= 7.2, 9.9 Hz, 1H), 3.95 (t, J= 9.6 Hz, 1H),
4.05 (d, J=
8.1 Hz, 1H), 4.25 ¨ 4.38 (m, 2H), 6.43 (s, 1H), 7.06 (d, J= 8.2 Hz, 1H), 7.26
¨ 7.30 (m,
3H), 7.31 ¨ 7.36 (m, 2H)
Rac-N-(1-methylcyclopropy1)-2-oxo-2-[(3R,45)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide
(FP-20)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
71
[0429] The title compound was synthesized from rac-2-oxo-2-[(3R,4S)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (21 mg, 100% purity,
10%) after
purification by trituration in MeCN.
[0430] LC-MS (METCR1603): 100% (UV), Rt= 3.35 min, miz (ES14-)= 287.2 [M+H]4-
[0431] 1H NMR (500 MHz, Chloroform-a) 6 0.66 ¨ 0.73 (m, 2H), 0.74 ¨ 0.80 (m,
2H),
1.37 (s, 3H), 3.42 (dd, J= 7.2, 9.9 Hz, 1H), 3.96 (t, J= 9.6 Hz, 1H), 4.03 (d,
J= 8.0 Hz,
1H), 4.23 ¨ 4.33 (m, 1H), 6.44 (s, 1H), 7.17(s, 1H), 7.26 ¨ 7.31 (m, 3H), 7.31
¨7.38
(m, 2H)
Rac-N-(cyclobutylmethyl)-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide
(FP-21)
[0432] The title compound was synthesized from rac-2-oxo-2-[(3R,4S)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (10 mg, 100% purity, 4%)
after
purification by FCC on normal phase silica (10 g SNAP Ultra cartridge, 0-100%
Et0Ac
in heptane gradient).
[0433] LC-MS (METCR1603): 100% (UV), Rt= 3.54 min, rniz (ES14-)= 301.2 [M+H]4-
[0434] 1H NMR (500 MHz, Chloroform-a) 6 1.63 ¨ 1.74 (m, 2H), 1.84¨ 1.97 (m,
2H),
2.02 ¨ 2.11 (m, 2H), 2.43 ¨ 2.56 (m, 1H), 3.26 ¨ 3.36 (m, 2H), 3.42 ¨ 3.47 (m,
1H), 3.98
(t, J= 9.5 Hz, 1H), 4.05 (d, J= 8.0 Hz, 1H), 4.29 ¨ 4.40 (m, 1H), 5.70 (s,
1H), 6.89 (s,
1H), 7.27 ¨ 7.31 (m, 3H), 7.31 ¨ 7.39 (m, 2H)
Rac-2-oxo-2-[(3R,45)-5-oxo-4-phenylpyrrolidin-3-y1]-N-(2,2,2-
trifluoroethyl)acetamide
(FP-22)
[0435] The title compound was synthesized from rac-2-oxo-2-[(3R,45)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (9 mg, 95% purity, 4%)
after
purification by trituration in Et20.
[0436] LC-MS (METCR1603): 95% (UV), Rt= 3.09 min, rniz (ES14-)= 315.2 [M+H]-
[0437] 1H NMR (500 MHz, Chloroform-d) 6 3.44 ¨ 3.49 (m, 1H), 3.86 ¨ 4.00 (m,
3H),
4.04 (d, J= 7.9 Hz, 1H), 4.27 ¨ 4.36 (m, 1H), 6.18 (s, 1H), 7.20 ¨ 7.26 (m,
1H), 7.27 ¨
7.32 (m, 3H), 7.32 ¨ 7.40 (m, 2H)
Rac-N-[(3,3-difluorocyclobutyl)methyl]-2-oxo-2-[(3R,45)-5-oxo-4-
phenylpyrrolidin-3-
yl]acetamide (FP-23)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
72
[0438] The title compound was synthesized from rac-2-oxo-2-[(3R,4S)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (27 mg, 98% purity, 11%)
after
purification by FCC on normal phase silica (10 g SNAP Ultra cartridge, 0-100%
Et0Ac
in heptane gradient).
[0439] LC-MS (METCR1603): 98% (UV), Rt= 3.41 min, m/z (ES14-)= 337.1 [M-FH]4-
[0440] 1H NMR (500 MHz, Chloroform-o) 6 2.19 ¨ 2.31 (m, 2H), 2.32 ¨ 2.41 (m,
1H),
2.62 ¨ 2.74 (m, 2H), 3.36 ¨ 3.49 (m, 3H), 3.96 (t, J= 9.8 Hz, 1H), 4.03 (d, J=
7.9 Hz,
1H), 4.29 ¨ 4.36 (m, 1H), 6.05 (s, 1H), 6.97 ¨ 7.12 (m, 1H), 7.26 ¨ 7.32 (m,
3H), 7.33 ¨
7.39 (m, 2H)
Rac-/V-(2-cyclopropylethyl)-2-oxo-2-[(3R,45)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide
(FP-24)
[0441] The title compound was synthesized from rac-2-oxo-2-[(3R,45)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (43 mg, 100% purity,
21%) after
purification by FCC on normal phase silica (10 g SNAP Ultra cartridge, 0-100%
Et0Ac
in heptane gradient).
[0442] LC-MS (METCR1603): 100% (UV), Rt= 3.47 min, m/z (ES14-)= 301.2 [M+H]4-
[0443] 1H NMR (500 MHz, Chloroform-a) 6 0.02 ¨0.12 (m, 2H), 0.41 ¨0.52 (m,
2H),
0.61 ¨0.72 (m, 1H), 1.40¨ 1.48 (m, 2H), 3.34 ¨ 3.43 (m, 3H), 3.95 (t, J= 9.6
Hz, 1H),
4.06 (d, J= 8.0 Hz, 1H), 4.28 ¨ 4.37 (m, 1H), 6.57 (s, 1H), 7.00 ¨ 7.13 (m,
1H), 7.26 ¨
7.31 (m, 3H), 7.32 ¨ 7.39 (m, 2H)
Rac-2-oxo-2-[(3R,45)-5-oxo-4-phenylpyrrolidin-3-A-N-(2,2,3,3,3-pentafluoro-
propyl)acetamide (FP-25)
[0444] The title compound was synthesized from rac-2-oxo-2-[(3R,45)-5-oxo-4-
phenylpyrrolidin-3-yl]acetic acid (1-76) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (13 mg, 95% purity, 6%)
after
purification by FCC on normal phase silica (10 g SNAP Ultra cartridge, 0-100%
Et0Ac
in heptane gradient).
[0445] LC-MS (METCR1603): 95% (UV), Rt= 3.57 min, m/z (ES1+)= 365.1 [M+H]+
[0446] 1H NMR (500 MHz, Chloroform-a) 63.46 (dd, J= 7.0, 10.0 Hz, 1H), 3.87 ¨
4.07 (m, 4H), 4.28 ¨ 4.36 (m, 1H), 6.27 (s, 1H), 7.17 ¨ 7.25 (m, 1H), 7.27 ¨
7.32 (m,
3H), 7.32 ¨ 7.39 (m, 2H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
73
Rac-N-(2,2-difluoropropy1)-2-[(3R,4S)-4-(4-fluoropheny1)-5-oxopyrrolidin-3-y1]-
2-
oxoacetamide (FP-26)
[0447] The title compound was synthesized from rac-2-[(3R,4S)-4-(4-
fluoropheny1)-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-77) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (37 mg, 100% purity,
15%) after
purification by FCC on normal phase silica (10 g SNAP Ultra cartridge, 0-100%
Et0Ac
in heptane gradient).
[0448] LC-MS (METCR1603): 100% (UV), Rt= 3.20 min, m/z (ES14-)= 329.2 [M+H]4-
[0449] 1H NMR (500 MHz, Chloroform-d) 6 1.61 (t, J = 18.4 Hz, 3H), 3.42 ¨ 3.48
(m,
1H), 3.61 ¨ 3.74 (m, 2H), 3.94 (t, J = 9.6 Hz, 1H), 4.02 (d, J = 8.3 Hz, 1H),
4.23 ¨4.33
(m, 1H), 6.30 (s, 1H), 7.01 ¨7.07 (m, 2H), 7.17 ¨ 7.24 (m, 1H), 7.24 ¨ 7.29
(m, 2H)
Rac-2-[(3R,45)-4-(4-fluoropheny1)-5-oxopyrrolidin-3-y1]-2-oxo-N-(propan-2-
yl)acetamide (FP-27)
[0450] The title compound was synthesized from rac-2-[(3R,45)-4-(4-
fluoropheny1)-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-77) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (61 mg, 100% purity,
30%) after
purification by trituration in Et20.
[0451] LC-MS (METCR1603): 100% (UV), Rt= 3.17 min, m/z (ES14-)= 293.2 [M+Hy.
[0452] 1H NMR (500 MHz, Chloroform-a) 6 1.12 ¨ 1.26 (m, 6H), 3.41 (dd, J= 7.4,
9.9
Hz, 1H), 3.94 (t, J= 9.6 Hz, 1H), 3.97 ¨ 4.08 (m, 2H), 4.21 ¨ 4.32 (m, 1H),
6.61 (s, 1H),
6.76 (d, J= 7.5 Hz, 1H), 6.99 ¨ 7.08 (m, 2H), 7.23 ¨ 7.33 (m, 2H)
Rac-N-(cyclopropylmethyl)-2-[(3R,45)-4-(4-fluorophenyl)-5-oxopyrrolidin-3-y1]-
2-
oxoacetamide (FP-28)
[0453] The title compound was synthesized from rac-2-[(3R,45)-4-(4-
fluoropheny1)-5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-77) in a similar manner to method A,
general
procedure 7a (general scheme 3) as an off-white solid (10 mg, 100% purity, 4%)
after
purification by FCC on normal phase silica (10 g SNAP Ultra cartridge, 0-100%
Et0Ac
in heptane gradient) followed by trituation in Et20.
[0454] LC-MS (METCR1603): 100% (UV), Rt= 3.37 min, m/z (ES1+)= 305.2 [M+H]4-
[0455] 1H NMR (500 MHz, Chloroform-o) 6 0.21 ¨ 0.31 (m, 2H), 0.52 ¨ 0.61 (m,
2H),
0.94¨ 1.03 (m, 1H), 3.12 ¨ 3.22 (m, 2H), 3.46 (dd, J= 7.4, 9.9 Hz, 1H), 3.99
(t, J= 9.6
Hz, 1H), 4.07 (d, J= 8.3 Hz, 1H), 4.27 ¨4.35 (m, 1H), 6.13 (s, 1H), 6.98 ¨7.13
(m,
3H), 7.28 ¨ 7.32 (m, 2H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
74
Rac-N-cyclopropy1-2-[(3R,4R)-4-[(4-fluorophenyl)methyl]-5-oxopyrrolidin-3-y1]-
2-
oxoacetamide (FP-29)
[0456] The title compound was synthesized from rac-2-[(3R,4R)-4-[(4-
fluoropheny1)-
methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-78) in a similar manner to
method A,
general procedure 7a (general scheme 3) as an off-white solid (66 mg, 100%
purity,
32%) after purification by FCC on normal phase silica (10 g SNAP Ultra
cartridge, 0-
100% Et0Ac in heptane gradient).
[0457] LC-MS (METCR1603): 100% (UV), Rt= 3.25 min, m/z (ES1+)= 305.2 [M+H]
[0458] 1H NMR (500 MHz, Chloroform-a) 5 0.52 ¨ 0.61 (m, 2H), 0.81 ¨ 0.90 (m,
2H),
2.68 ¨ 2.77 (m, 1H), 2.89 (dd, J= 7.7, 13.8 Hz, 1H), 3.02 (td, J= 4.8, 7.8 Hz,
1H), 3.19
(dd, J= 4.7, 13.8 Hz, 1H), 3.27 (dd, J= 7.0, 9.6 Hz, 1H), 3.35 (t, J= 9.4 Hz,
1H), 4.02
¨4.09 (m, 1H), 5.65 (s, 1H), 6.75 (s, 1H), 6.90 ¨ 6.98 (m, 2H), 7.15 ¨ 7.22
(m, 2H)
Rac-N-ethy1-2-[(3R,4R)-4-[(4-fluorophenyl)methyl]-5-oxopyrrolidin-3-y1]-2-
oxoacetamide (FP-30)
[0459] The title compound was synthesized from rac-2-[(3R,4R)-4-[(4-
fluorophenyl)methy1]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-78) in a
similar manner to
method A, general procedure 7a (general scheme 3) as an off-white solid (98
mg,
100% purity, 49%) after purification by FCC on normal phase silica (10 g SNAP
Ultra
cartridge, 0-100% Et0Ac in heptane gradient).
[0460] LC-MS (METCR1603): 100% (UV), Rt= 3.19 min, m/z (ES1+)= 293.2 [M+H]4-
[0461] 1H NMR (500 MHz, Chloroform-a) 5 1.17 (t, J= 7.3 Hz, 3H), 2.88 (dd, J=
7.8,
13.8 Hz, 1H), 3.03 (td, J= 4.8, 7.9 Hz, 1H), 3.19 (dd, J= 4.7, 13.9 Hz, 1H),
3.25 ¨ 3.33
(m, 3H), 3.34 ¨ 3.39 (m, 1H), 4.03 ¨4.10 (m, 1H), 5.61 (s, 1H), 6.70 (s, 1H),
6.90 ¨
6.98 (m, 2H), 7.14 ¨7.22 (m, 2H)
Rac-N-(cyclopropylmethyl)-2-[(3R,4R)-4-[(4-fluorophenyl)methy1]-5-
oxopyrrolidin-3-y1]-
2-oxoacetamide (FP-31)
[0462] The title compound was synthesized from rac-2-[(3R,4R)-4-[(4-
fluorophenyl)methy1]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-78) in a
similar manner to
method A, general procedure 7a (general scheme 3) as an off-white solid (107
mg,
100% purity, 50%) after purification by FCC on normal phase silica (10 g SNAP
Ultra
cartridge, 0-85% Et0Ac in heptane gradient).
[0463] LC-MS (METCR1603): 100% (UV), Rt= 3.58 min, m/z (ES1+)= 319.2 [M-FH]4-

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
[0464] 1H NMR (500 MHz, Chloroform-o) 6 0.18 ¨0.28 (m, 2H), 0.51 ¨0.62 (m,
2H),
0.90 ¨ 0.99 (m, 1H), 2.89 (dd, J= 7.8, 13.8 Hz, 1H), 3.04 (td, J= 4.8, 7.9 Hz,
1H), 3.10
(dd, J= 6.0, 7.1 Hz, 2H), 3.19 (dd, J= 4.8, 13.9 Hz, 1H), 3.28 (dd, J= 7.0,
9.6 Hz, 1H),
3.34 ¨ 3.40 (m, 1H), 4.07 (ddd, J= 7.1, 7.9, 9.0 Hz, 1H), 5.60 (s, 1H), 6.76 ¨
6.87 (m,
1H), 6.91 ¨6.99 (m, 2H), 7.14 ¨ 7.22 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-1-[(oxan-4-yl)methyl]-5-oxopyrrolidin-3-y1]-/V-
cyclopropy1-2-
oxoacetamide (FP-32)
[0465] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-
[(oxan-4-
yl)methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-79) in a similar manner
to method A,
general procedure 7a (general scheme 3) as a pale yellow gum (135 mg, 100%
purity,
50%) after purification by FCC on normal phase silica (10 g SNAP Ultra
cartridge, 0-
100% Et0Ac in heptane gradient).
[0466] LC-MS (METCR1603): 100% (UV), Rt= 3.58 min, miz (ES14-)= 385.2 [M+H]4-
[0467] 1H NMR (500 MHz, Chloroform-a) 6 0.51 ¨ 0.60 (m, 2H), 0.81 ¨ 0.89 (m,
2H),
1.21 ¨ 1.32 (m, 2H), 1.37¨ 1.46 (m, 2H), 1.72¨ 1.84 (m, 1H), 2.69 ¨ 2.75 (m,
1H), 2.98
(dd, J= 7.1, 13.5 Hz, 1H), 3.04 ¨ 3.12 (m, 3H), 3.15 ¨ 3.22 (m, 2H), 3.26 (dd,
J= 6.2,
9.8 Hz, 1H), 3.31 (td, J= 2.1, 11.7 Hz, 2H), 3.90 ¨ 3.98 (m, 3H), 6.74 (s,
1H), 7.16 ¨
7.26 (m, 5H)
Rac-2-[(3R,4R)-4-benzy1-1-[(oxan-4-yl)methyl]-5-oxopyrrolidin-3-y1]-Methyl-2-
oxoacetamide (FP-33)
[0468] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-
[(oxan-4-
yl)methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-79) in a similar manner
to method A,
general procedure 7a (general scheme 3) as an off-white solid (137 mg, 100%
purity,
56%) after purification by FCC on normal phase silica (25 g SNAP Ultra
cartridge, 0-
100% Et0Ac in heptane gradient).
[0469] LC-MS (METCR1603): 100% (UV), Rt= 3.55 min, rrilz (ES1+)= 373.2 [M+H]4-
[0470] 1H NMR (500 MHz, Chloroform-a) 6 1.17 (t, J= 7.3 Hz, 3H), 1.21 ¨1.33
(m,
2H), 1.37 ¨ 1.47 (m, 2H), 1.72 ¨ 1.84 (m, 1H), 2.99 (dd, J= 7.1, 13.5 Hz, 1H),
3.04 ¨
3.14 (m, 3H), 3.16¨ 3.22 (m, 2H), 3.23¨ 3.36 (m, 5H), 3.89¨ 3.99 (m, 3H), 6.64
¨6.76
(m, 1H), 7.16 ¨ 7.26 (m, 5H)
Rac-2-[(3R,4R)-4-benzy1-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-5-
oxopyrrolidin-3-
y1]-/V-cyclopropy1-2-oxoacetamide (FP-34)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
76
[0471] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-[(3-
methyl-1,2,4-oxadiazol-5-yl)methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-
80) in a
similar manner to method A, general procedure 7a (general scheme 3) as an
orange
solid (74 mg, 99% purity, 64%) after purification by FCC on normal phase
silica (25 g
SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient).
[0472] LC-MS (METCR1603): 99% (UV), Rt= 2.57 min, m/z (ES14-)= 383.2 [M+H]4-
[0473] 1H NMR (500 MHz, Chloroform-o) 6 0.51 ¨ 0.58 (m, 2H), 0.80 ¨ 0.88 (m,
2H),
2.38 (s, 3H), 2.67 ¨ 2.73 (m, 1H), 2.94 (dd, 1=7.7, 13.7 Hz, 1H), 3.15 ¨ 3.21
(m, 1H),
3.26 (dd, 1=4.9, 13.7 Hz, 1H), 3.37 (dd, J= 6.7, 9.5 Hz, 1H), 3.43 (t, 1=9.3
Hz, 1H),
4.00 (dt, J= 7.0, 9.0 Hz, 1H), 4.60 ¨ 4.71 (m, 2H), 6.70(s, 1H), 7.15 ¨ 7.26
(m, 5H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-[(pyrimidin-2-yl)methyl]pyrrolidin-3-y11-N-
cyclopropyl-
2-oxoacetamide (FP-35)
[0474] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-oxo-1-
[(pyrimidin-2-yl)methyl]pyrrolidin-3-y1]-2-oxoacetic acid (1-81) in a similar
manner to
method A, general procedure 7a (general scheme 3) as a pale orange gum (63 mg,
99% purity, 28%) after purification by FCC on normal phase silica (25 g SNAP
Ultra
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-5% Me0H in Et0Ac
gradient).
[0475] LC-MS (METCR1603): 99% (UV), Rt= 3.28 min, m/z (ES1)= 373.2 [M+H]4-
[0476] 1H NMR (500 MHz, Chloroform-0 6 0.47 ¨ 0.57 (m, 2H), 0.77 ¨ 0.86 (m,
2H),
2.64 ¨ 2.71 (m, 1H), 2.85 ¨ 2.92 (m, 1H), 3.24 ¨ 3.35 (m, 2H), 3.38 (dd, J=
7.2, 9.5 Hz,
1H), 3.59(t, J= 9.4 Hz, 1H), 3.99 ¨ 4.08 (m, 1H), 4.72 (s, 2H), 6.64 (s, 1H),
7.14 ¨7.26
(m, 6H), 8.67 (d, J= 4.9 Hz, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-[(pyrimidin-2-yl)methyl]pyrrolidin-3-y1]-N-
ethy1-2-
oxoacetamide (FP-36)
[0477] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-oxo-1-
[(pyrimidin-2-yl)methyl]pyrrolidin-3-y1]-2-oxoacetic acid (1-81) in a similar
manner to
method A, general procedure 7a (general scheme 3) as a pale orange gum (78 mg,
100% purity, 45%) after purification by FCC on normal phase silica (25 g SNAP
Ultra
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-10% Me0H in Et0Ac
gradient).
[0478] LC-MS (METCR1603): 100% (UV), Rt= 3.25 min, m/z (ES1+)= 367.2 [M-FH].#

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
77
[0479] 1H NMR (500 MHz, Chloroform-o) 6 1.14 (t, J= 7.3 Hz, 3H), 2.85 ¨2.94
(m,
1H), 3.22 ¨ 3.34 (m, 4H), 3.39 (dd, J= 7.2, 9.5 Hz, 1H), 3.61 (t, J= 9.4 Hz,
1H), 4.00 ¨
4.08 (m, 1H), 4.72 (s, 2H), 6.55 ¨ 6.68 (m, 1H), 7.15 ¨ 7.25 (m, 6H), 8.67 (d,
J= 4.9
Hz, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-[(pyrimidin-4-yl)methyl]pyrrolidin-3-y1]-N-
cyclopropyl-
2-oxoacetamide (1-37)
[0480] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-oxo-1-
[(pyrimidin-4-yl)methyl]pyrrolidin-3-y1]-2-oxoacetic acid (1-82) in a similar
manner to
method A, general procedure 7a (general scheme 3) as an orange gum (38 mg,
100%
purity, 34%) after purification by FCC on normal phase silica (25 g SNAP Ultra
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-20% Me0H in Et0Ac
gradient).
[0481] LC-MS (METCR1603): 100% (UV), Rt= 2.24 min, m/z (ESI+)= 379.1 [M+H]+
[0482] 1H NMR (500 MHz, Chloroform-a) 6 0.52 ¨ 0.60 (m, 2H), 0.81 ¨ 0.90 (m,
2H),
2.68 ¨ 2.75 (m, 1H), 3.05 (dd, J= 6.9, 13.5 Hz, 1H), 3.14 ¨ 3.19 (m, 1H), 3.21
¨3.27
(m, 2H), 3.33 (dd, J= 6.2, 9.9 Hz, 1H), 4.03 (dt, J= 6.4, 9.1 Hz, 1H), 4.45
¨4.55 (m,
2H), 6.76 (s, 1H), 7.01 ¨ 7.05 (m, 1H), 7.20 ¨ 7.28 (m, 5H), 8.64 (d, J= 5.2
Hz, 1H),
9.11 (d, J= 1.1 Hz, 1H)
Rac-2-[(3R,4R)-4-cyclohexy1-1-methyl-5-oxopyrrolidin-3-y1]-N-cyclopropy1-2-
oxoacet-
amide (FP-38)
[0483] The title compound was synthesized from rac-2-[(3R,4R)-4-cyclohexy1-1-
methyl-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-83) in a similar manner to
method A,
general procedure 7a (general scheme 3) as a pale yellow glass (181 mg, 99%
purity,
36%) after purification by FCC on normal phase silica (25 g SNAP KP-SIL
cartridge,
50-100% Et0Ac in heptane gradient).
[0484] LC-MS (MET-uPLC-AB-102): 99% (UV), Rt= 2.52 min, m/z (ESI+)= 293.1
[M+H14-
[0485] 1H NMR (500 MHz, Chloroform-o) 6 0.57 ¨ 0.64 (m, 2H), 0.85 ¨ 0.90 (m,
2H),
0.94¨ 1.04 (m, 1H), 1.08¨ 1.32 (m, 4H), 1.48¨ 1.55 (m, 1H), 1.62 ¨ 1.68 (m,
2H), 1.68
¨ 1.76 (m, 2H), 1.90¨ 2.00 (m, 1H), 2.71 ¨2.75 (m, 1H), 2.76 ¨ 2.82 (m, 1H),
2.83 (s,
3H), 3.28 (dd, J= 5.2, 10.2 Hz, 1H), 3.64 (t, J= 9.8 Hz, 1H), 3.98 (dt, J=
5.5, 9.5 Hz,
1H), 7.00 (s, 1H).

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
78
Rac-2-[(3R,4R)-4-benzy1-1-(2-methoxyethyl)-5-oxopyrrolidin-3-y1]-N-cyclopropy1-
2-
oxoacetamide (FP-39)
[0486] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-(2-
methoxyethyl)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-84) in a similar
manner to
method A, general procedure 7a (general scheme 3) as an orange gum (84 mg,
100%
purity, 54%) after purification by FCC on normal phase silica (25 g SNAP Ultra
cartridge, 0-100% Et0Ac in heptane gradient) followed by preparative LC
(acidic pH,
standard elution method).
[0487] LC-MS (METCR1603): 100% (UV), Rt= 3.57 min, m/z (ES1+)= 345.3 [M+H]4-
[0488] 1H NMR (500 MHz, Chloroform-a) 6 0.50 ¨ 0.58 (m, 2H), 0.79 ¨ 0.88 (m,
2H),
2.66 ¨ 2.74 (m, 1H), 2.89 (dd, J= 7.9, 13.7 Hz, 1H), 3.06 ¨ 3.12 (m, 1H), 3.24
(dd, J=
4.7, 13.7 Hz, 1H), 3.28 (s, 3H), 3.29 ¨ 3.34 (m, 1H), 3.34 ¨ 3.49 (m, 5H),
3.92 ¨ 3.99
(m, 1H), 6.69 (s, 1H), 7.16 ¨ 7.21 (m, 3H), 7.22 ¨ 7.26 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-1-(carbamoylmethyl)-5-oxopyrrolidin-3-y1]-N-(2-
methylpropy1)-
2-oxoacetamide (FP-40)
[0489] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-
(carbamoylmethyl)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-85) in a similar
manner to
method A, general procedure 7a (general scheme 3) as a pale orange solid (5
mg,
95% purity, 4%) after purification by FCC on normal phase silica (25 g SNAP
Ultra
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-10% Me0H in Et0Ac
gradient) then by two FCC on reverse phase silica (12 g SNAP C18 Ultra
cartridge,
basic pH, standard elution method).
[0490] LC-MS (METCR1603): 95% (UV), Rt= 2.39 min, m/z (ES14-)= 360.3 [M+H]4-
[0491] 1H NMR (500 MHz, Chloroform-o) 60.93 (d, J= 6.7 Hz, 6H), 1.76 ¨ 1.86
(m,
1H), 3.02 ¨ 3.13 (m, 5H), 3.16 ¨ 3.22 (m, 1H), 3.39 (dd, J= 4.7, 9.9 Hz, 1H),
3.66 (d, J
= 16.5 Hz, 1H), 3.96 ¨ 4.02 (m, 1H), 4.06 (d, J= 16.5 Hz, 1H), 5.36(s, 1H),
6.10 (s,
1H), 6.82 ¨ 6.95 (m, 1H), 7.21 ¨ 7.30 (m, 5H)
Rac-2-[(3R,4R)-4-benzy1-1-[(5-methy1-1,2-oxazol-3-yl)methyl]-5-oxopyrrolidin-3-
yll-N-
cyclopropy1-2-oxoacetamide (FP-41)
[0492] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-[(5-
methyl-1,2-oxazol-3-yl)methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-86)
in a similar
manner to method A, general procedure 7a (general scheme 3) as an off-white
solid
(82 mg, 100% purity, 28%) after purification by FCC on normal phase silica (10
g

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
79
SNAP Ultra cartridge, 0-70% Et0Ac in heptane gradient) followed by preparative
LC
(acidic pH, standard elution method).
[0493] LC-MS (METCR1603): 100% (UV), Rt= 3.78 min, m/z (ES14-)= 382.2 [M+H]f
[0494] 1H NMR (500 MHz, Chloroform-o) 5 0.48 - 0.58 (m, 2H), 0.77 - 0.89 (m,
2H),
2.36 - 2.41 (m, 3H), 2.65 - 2.75 (m, 1H), 2.95 (dd, J= 7.5, 13.6 Hz, 1H), 3.11
(td, J=
4.7, 7.4 Hz, 1H), 3.17 - 3.27 (m, 3H), 3.97 (q, J= 7.7 Hz, 1H), 4.38 - 4.48
(m, 2H),
5.78 - 5.82 (m, 1H), 6.69(s, 1H), 7.17 - 7.21 (m, 3H), 7.21 - 7.25 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-1-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-5-
oxopyrrolidin-3-
y1]-Akcyclopropy1-2-oxoacetamide (FP-42)
[0495] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-[(1-
methyl-1H-1,2,4-triazol-5-yl)methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-
87) in a
similar manner to method A, general procedure 7a (general scheme 3) as a
yellow
gum (49 mg, 100% purity, 30%) after purification by FCC on normal phase silica
(10 g
SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient followed by 0-5% Me0H
in
Et0Ac gradient).
[0496] LC-MS (METCR1603): 100% (UV), Rt= 3.14 min, m/z (ESI+)= 382.2 [M-FH]4-
[0497] 1H NMR (500 MHz, Chloroform-o) 5 0.51 - 0.57 (m, 2H), 0.79 - 0.88 (m,
2H),
2.66 - 2.75 (m, 1H), 2.94 - 3.00 (m, 1H), 3.06 - 3.12 (m, 1H), 3.17 - 3.26 (m,
3H), 3.88
(s, 3H), 3.92 - 4.02 (m, 1H), 4.50 - 4.64 (m, 2H), 6.71 (s, 1H), 7.13 - 7.17
(m, 2H),
7.17 - 7.24 (m, 3H), 7.77 (s, 1H)
Rac-2-[(3R,4R)-4-benzy1-1-[(methylcarbamoyl)methyl]-5-oxopyrrolidin-3-y1]-N-(2-
methylpropyI)-2-oxoacetamide (FP-43)
[0498] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-
[(methylcarbamoyl)methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-88) in a
similar
manner to method A, general procedure 7a (general scheme 3) as an off-white
gum
(69 mg, 100% purity, 65%) after purification by FCC on normal phase silica (10
g
SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient).
[0499] LC-MS (METCR1603): 100% (UV), Rt= 3.55 min, m/z (ES14-)= 374.6 [M+H]4-
[0500] 1H NMR (500 MHz, Chloroform-0 60.93 (d, J= 6.7 Hz, 6H), 1.77 - 1.87 (m,
1H), 2.76 (d, J= 4.8 Hz, 3H), 2.98 - 3.07 (m, 2H), 3.09 - 3.15 (m, 3H), 3.18
(dd, J=
5.0, 13.6 Hz, 1H), 3.35 (dd, J= 4.8, 10.0 Hz, 1H), 3.69 (d, J= 16.3 Hz, 1H),
3.95 -
4.03 (m, 2H), 6.01 -6.13 (m, 1H), 6.83 - 6.95 (m, 1H), 7.22 - 7.31 (m, 5H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
Rac-2-[(3R,4R)-3-benzy1-4-{[(2-methylpropyl)carbamoyl]carbony1}-2-
oxopyrrolidin-1-y1]-
NN-dimethylacetamide (FP-44)
[0501] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-
[(dimethylcarbamoyl)methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-89) in a
similar
manner to method A, general procedure 7a (general scheme 3) as a yellow gum
(69
mg, 97% purity, 72%) after purification by FCC on normal phase silica (25 g
SNAP
Ultra cartridge, 0-100% Et0Ac in heptane gradient followed by 0-5% Me0H in
Et0Ac
gradient).
[0502] LC-MS (METCR1603): 97% (UV), Rt= 3.69 min, rrilz (ES14-)= 388.6 [M+H]4-
[0503] 1H NMR (500 MHz, Chloroform-a) 60.89 (dd, J= 1.3, 6.7 Hz, 6H), 1.71
¨1.81
(m, 1H), 2.82 ¨ 2.90 (m, 1H), 2.93 (s, 3H), 2.99 (s, 3H), 3.04 (t, J= 6.6 Hz,
2H), 3.20 ¨
3.29 (m, 2H), 3.43 (dd, J= 6.8, 9.6 Hz, 1H), 3.55 (t, J= 9.5 Hz, 1H), 3.92 (d,
J= 16.1
Hz, 1H), 3.94 ¨4.01 (m, 1H), 4.21 (d, J= 16.1 Hz, 1H), 6.70 ¨ 6.77 (m, 1H),
7.14 ¨
7.20 (m, 3H), 7.21 ¨ 7.26 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1]-N-ethy1-2-
oxoacetamide (FP-45)
[0504] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-[(4-
carbamoylphenyl)methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-90) in a
similar
manner to method A, general procedure 7a (general scheme 3) as an off-white
solid
(61 mg, 93% purity by 1H NMR, 42%) after purification by FCC on normal phase
silica
(25 g SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient).
[0505] LC-MS (METCR1603): 100% (UV), Rt= 3.29 min, rrilz (ES14-)= 420.2 [M+H]4-
[0506] 1H NMR (500 MHz, Chloroform-a) 5 0.47 ¨ 0.60 (m, 2H), 0.78 ¨ 0.89 (m,
2H),
2.66 ¨ 2.73 (m, 1H), 3.02 (dd, J= 7.1, 13.5 Hz, 1H), 3.06 ¨ 3.17 (m, 3H), 3.24
(dd, J=
4.7, 13.5 Hz, 1H), 3.89 ¨ 3.98 (m, 1H), 4.39 ¨4.52 (m, 2H), 5.57 (s, 1H), 6.03
(s, 1H),
6.68 ¨ 6.78 (m, 1H), 7.16 ¨ 7.20 (m, 2H), 7.20 ¨ 7.27 (m, 5H), 7.69 ¨ 7.77 (m,
2H)
Rac-2-[(3R,4R)-4-benzy1-1-[(3-methy1-1,2-oxazol-5-yl)methyl]-5-oxopyrrolidin-3-
y1]-N-
cyclopropy1-2-oxoacetamide (FP-46)
[0507] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-[(3-
methyl-1,2-oxazol-5-yl)methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-91)
in a similar
manner to method A, general procedure 7a (general scheme 3) as a yellow gum
(162
mg, 100% purity, 62%) after purification by FCC on normal phase silica (10 g
SNAP
Ultra cartridge, 0-70% Et0Ac in heptane gradient).

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
81
[0508] LC-MS (METCR1603): 100% (UV), Rt= 3.69 min, m/z (ES14-)= 388.6 [M+H]
[0509] 1H NMR (500 MHz, Chloroform-a) 6 0.50 ¨ 0.60 (m, 2H), 0.78 ¨ 0.89 (m,
2H),
2.27 (s, 3H), 2.68 ¨ 2.74 (m, 1H), 2.97 (dd, J= 7.2, 13.6 Hz, 1H), 3.10 (td,
J= 4.8, 7.2
Hz, 1H), 3.22 (dd, J= 4.0, 9.6 Hz, 1H), 3.23 ¨ 3.27 (m, 1H), 3.29 (dd, J= 6.3,
9.8 Hz,
1H), 3.93 ¨ 4.00 (m, 1H), 4.44 ¨ 4.52 (m, 2H), 5.89 (s, 1H), 6.73 (s, 1H),
7.16 ¨ 7.25
(m, 5H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]pyrrolidin-3-
y1]-N-(2-
methylpropy1)-2-oxoacetamide (FP-47)
[0510] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-oxo-
142-
(2-oxopyrrolidin-1-ypethyllpyrrolidin-3-y1]-2-oxoacetic acid (1-92) in a
similar manner to
method A, general procedure 7a (general scheme 3) as a yellow gum (115 mg,
100%
purity, 75%) after purification by FCC on normal phase silica (25 g SNAP Ultra
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-10% Me0H in Et0Ac
gradient).
[0511] LC-MS (METCR1603): 100% (UV), Rt= 3.72 min, m/z (ES14-)= 414.2 [M+H]4-
[0512] 1H NMR (500 MHz, Chloroform-d) 60.91 (d, J= 6.7 Hz, 6H), 1.74 ¨ 1.84
(m,
1H), 1.93 ¨ 2.05 (m, 2H), 2.23 ¨ 2.36 (m, 2H), 2.84 ¨ 2.91 (m, 1H), 3.08 (t,
J= 6.6 Hz,
2H), 3.09 ¨ 3.20 (m, 4H), 3.29 ¨ 3.36 (m, 2H), 3.38 (dd, J= 5.7, 9.8 Hz, 1H),
3.49 ¨
3.55 (m, 1H), 3.55 ¨ 3.62 (m, 1H), 3.62 ¨ 3.70 (m, 1H), 3.84 ¨ 3.91 (m, 1H),
6.90 ¨ 6.97
(m, 1H), 7.15 ¨ 7.20 (m, 3H), 7.21 ¨7.26 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-[2-(2-oxopyrrolidin-1-ypethyl]pyrrolidin-3-y1}-
N-
cyclopropy1-2-oxoacetamide (FP-48)
[0513] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-oxo-
142-
(2-oxopyrrolidin-1-yl)ethyllpyrrolidin-3-y1]-2-oxoacetic acid (1-92) in a
similar manner to
method A, general procedure 7a (general scheme 3) as a yellow gum (54 mg, 100%
purity, 37%) after purification by FCC on normal phase silica (10 g SNAP Ultra
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-10% Me0H in Et0Ac
gradient).
[0514] LC-MS (METCR1603): 100% (UV), Rt= 3.23 min, m/z (ES14-)= 398.2 [M-FH]4-
[0515] 1H NMR (500 MHz, Chloroform-o) 6 0.51 ¨ 0.62 (m, 2H), 0.76 ¨ 0.87 (m,
2H),
1.90 ¨ 2.06 (m, 2H), 2.23 ¨ 2.35 (m, 2H), 2.68 ¨ 2.75 (m, 1H), 2.82 ¨ 2.91 (m,
1H), 3.06
¨3.19 (m, 4H), 3.28 ¨ 3.35 (m, 2H), 3.38 (dd, J= 5.7, 9.9 Hz, 1H), 3.49 ¨ 3.55
(m, 1H),

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
82
3.56 - 3.63 (m, 1H), 3.64 - 3.71 (m, 1H), 3.83- 3.89 (m, 1H), 6.90 (b.s, 1H),
7.15 -
7.21 (m, 3H), 7.22 - 7.26 (m, 2H)
Rac-2-[(3R,4R)-4-benzy1-1-(2,2-difluoroethyl)-5-oxopyrrolidin-3-A-N-
cyclopropy1-2-
oxoacetamide (FP-49)
[0516] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-(2,2-
difluoroethyl)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-93) in a similar
manner to
method A, general procedure 7a (general scheme 3) as an off-white solid (39
mg,
100% purity, 18%) after purification by FCC on normal phase silica (10 g SNAP
Ultra
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-20% Me0H in Et0Ac
gradient).
[0517] LC-MS (METCR1603): 100% (UV), Rt= 3.60 min, m/z (ES14-)= 351.2 [M+H]-
[0518] 1H NMR (500 MHz, Chloroform-a) 6 0.48 - 0.61 (m, 2H), 0.82 - 0.89 (m,
2H),
2.67 - 2.75 (m, 1H), 2.95 (dd, J= 7.4, 13.6 Hz, 1H), 3.07 - 3.15 (m, 1H), 3.23
(dd, J=
4.8, 13.6 Hz, 1H), 3.28 - 3.37 (m, 2H), 3.51 - 3.67 (m, 2H), 3.96 - 4.03 (m,
1H), 5.78
(II, J= 4.2, 55.6 Hz, 1H), 6.72 (s, 1H), 7.16 - 7.23 (m, 3H), 7.24 - 7.28 (m,
2H)
Rac-2-[(3R,4R)-4-benzy1-1-(2,2-difluoroethyl)-5-oxopyrrolidin-3-y1]-N-ethy1-2-
oxoacetamide (FP-50)
[0519] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-(2,2-
difluoroethyl)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-93) in a similar
manner to
method A, general procedure 7a (general scheme 3) as an off-white solid (21
mg,
100% purity, 22%) after purification by FCC on normal phase silica (10 g SNAP
Ultra
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-20% Me0H in Et0Ac
gradient).
[0520] LC-MS (METCR1603): 100% (UV), Rt= 3.55 min, m/z (ES14-)= 339.2 [M+H]-
[0521] 1H NMR (500 MHz, Chloroform-a) 6 1.19 (t, J= 7.3 Hz, 3H), 2.97 (dd, J=
7.4,
13.6 Hz, 1H), 3.11 -3.17 (m, 1H), 3.24 (dd, J= 4.8, 13.6 Hz, 1H), 3.29 - 3.40
(m, 4H),
3.53 - 3.68 (m, 2H), 3.97 - 4.06 (m, 1H), 5.80(11, J= 4.2, 55.6 Hz, 1H), 6.74
(s, 1H),
7.18 - 7.25 (m, 3H), 7.25 - 7.30 (m, 2H)
Rac-N-cyclopropy1-2-[(3R,4R)-4-[(4-fluorophenyl)methy1]-1-[(1-methyl-1H-1,2,4-
triazol-
3-yl)methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetamide (FP-51)
[0522] The title compound was synthesized from rac-2-[(3R,4R)-4-[(4-
fluorophenyl)methy1]-1-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-5-
oxopyrrolidin-3-y1]-2-
oxoacetic acid (1-94) in a similar manner to method A, general procedure 7a
(general

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
83
scheme 3) as a yellow viscous oil (12 mg, 100% purity, 13%) after purification
by FCC
on normal phase silica (10 g SNAP Ultra cartridge, 0-100% Et0Ac in heptane
gradient
followed by 0-15% Me0H in Et0Ac gradient).
[0523] LC-MS (METCR1603): 100% (UV), Rt= 3.19 min, m/z (ES14-)= 400.1 [M+H]4-
[0524] 1H NMR (500 MHz, Chloroform-o) 6 0.50 - 0.57 (m, 2H), 0.78 - 0.89 (m,
2H),
2.66 - 2.73 (m, 1H), 2.88 (dd, J= 8.0, 13.9 Hz, 1H), 3.12 (td, J= 4.8, 7.9 Hz,
1H), 3.23
(dd, J= 4.8, 13.9 Hz, 1H), 3.30 (dd, J= 7.0, 9.8 Hz, 1H), 3.43 (t, J= 9.5 Hz,
1H), 3.87
(s, 3H), 3.91 -3.99 (m, 1H), 4.46 (d, J= 15.4 Hz, 1H), 4.61 (d, J= 15.4 Hz,
1H), 6.67 -
6.75 (m, 1H), 6.85 - 6.92 (m, 2H), 7.11 -7.17 (m, 2H), 7.93 (s, 1H)
Rac-/V-cyclopropy1-2-[(3R,4R)-4-[(4-fluorophenyl)methy1]-1-[(1-methy1-1H-1,2,4-
triazol-
5-yl)methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetamide (FP-52)
[0525] The title compound was synthesized from rac-2-[(3R,4R)-4-[(4-
fluorophenyl)methy1]-1-[(1-methy1-1H-1,2,4-triazol-5-yl)methyl]-5-
oxopyrrolidin-3-y1]-2-
oxoacetic acid (1-95) in a similar manner to method A, general procedure 7a
(general
scheme 3) as a pale yellow viscous oil (17 mg, 100% purity, 10%) after
purification by
FCC on normal phase silica (10 g SNAP Ultra cartridge, 0-100% Et0Ac in heptane
gradient followed by 0-20% Me0H in Et0Ac gradient).
[0526] LC-MS (METCR1603): 100% (UV), Rt= 3.26 min, m/z (ES14-)= 400.2 [M-FH]+
[0527] 1H NMR (500 MHz, Chloroform-a) 6 0.52 - 0.58 (m, 2H), 0.82 - 0.86 (m,
2H),
2.67 - 2.75 (m, 1H), 2.93 (dd, J= 7.1, 13.7 Hz, 1H), 3.02 - 3.06 (m, 1H), 3.16
(dd, J=
4.7, 13.7 Hz, 1H), 3.28 (d, J= 7.7 Hz, 2H), 3.89 (s, 3H), 3.95 (q, J= 7.6 Hz,
1H), 4.55
(d, J= 15.3 Hz, 1H), 4.60 (d, J= 15.3 Hz, 1H), 6.78 (s, 1H), 6.86 - 6.92 (m,
2H), 7.09 -
7.14 (m, 2H), 7.78 (s, 1H)
Rac-N-(2,2-difluoropropy1)-2-1(3R,4R)-4-[(4-fluorophenyl)methyl]-1-[(1-methy1-
1H-1,2,4-
triazol-5-yl)methyl]-5-oxopyrrolidin-3-y1]-2-oxoacetamide (FP-53)
[0528] The title compound was synthesized from rac-2-[(3R,4R)-4-[(4-
fluorophenyl)methy1]-1-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-5-
oxopyrrolidin-3-y1]-2-
oxoacetic acid (1-95) in a similar manner to method A, general procedure 7a
(general
scheme 3) as a pale yellow solid (29 mg, 100% purity, 20%) after purification
by FCC
on normal phase silica (10 g SNAP Ultra cartridge, 0-100% Et0Ac in heptane
gradient
followed by 0-40% Me0H in Et0Ac gradient).
[0529] LC-MS (METCR1603): 100% (UV), Rt= 3.49 min, m/z (ES14-)= 438.1 [M+H]

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
84
[0530] 1H NMR (500 MHz, Chloroform-a) 5 1.60 (t, J= 18.4 Hz, 3H), 2.94 (dd, J=
7.1,
13.7 Hz, 1H), 3.05 ¨ 3.10 (m, 1H), 3.15 (dd, J= 4.7, 13.7 Hz, 1H), 3.28 ¨ 3.39
(m, 2H),
3.56 ¨ 3.69 (m, 2H), 3.87 ¨ 3.99 (m, 4H), 4.49 ¨ 4.67 (m, 2H), 6.86 ¨ 6.94 (m,
2H), 7.00
¨7.08 (m, 1H), 7.09 ¨ 7.15 (m, 2H), 7.80 (s, 1H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1]-N-cyclopropy1-
2-
oxoacetamide (FP-54)
[0531] The title compound was synthesized from Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-
(pyrimidin-5-yl)pyrrolidin-3-y1]-2-oxoacetic acid (1-96) in a similar manner
to method A,
general procedure 7a (general scheme 3) as an off-white solid (21 mg, 100%
purity,
25%) after purification by FCC on normal phase silica (10 g SNAP KP-SIL
cartridge, 0-
100% Et0Ac in heptane gradient) followed by trituration in heptane.
[0532] LC-MS (METCR1603): 100% (UV), Rt= 3.43 min, m/z (ESI+)= 365.1 [M+H].
[0533] 1H NMR (500 MHz, DMSO-d6) 5 0.53 ¨ 0.60 (m, 2H), 0.62 ¨ 0.68 (m, 2H),
2.68
¨2.77 (m, 1H), 2.97 (dd, J= 7.5, 13.7 Hz, 1H), 3.10 (dd, J= 5.2, 13.7 Hz, 1H),
3.25
(td, J= 5.3, 7.4 Hz, 1H), 3.79 (dd, J= 6.6, 10.0 Hz, 1H), 3.87 (t, J= 9.6 Hz,
1H), 4.02
(dt, J= 6.9, 9.1 Hz, 1H), 7.16 ¨ 7.29 (m, 5H), 8.66 (d, J= 5.1 Hz, 1H), 8.95
(s, 1H),
9.07 (s, 2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-01-N-ethy1-2-oxo-
acetamide (FP-55)
[0534] The title compound was synthesized from Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-
(pyrimidin-5-yl)pyrrolidin-3-y1]-2-oxoacetic acid (1-96) in a similar manner
to method A,
general procedure 7a (general scheme 3) as a yellow solid (25 mg, 97% purity,
29%)
after purification by FCC on normal phase silica (10 g SNAP Ultra cartridge, 0-
100%
Et0Ac in heptane gradient).
[0535] LC-MS (METCR1603): 97% (UV), Rt= 3.38 min, m/z (ES14-)= 353.2 [M+H]+
[0536] 1H NMR (500 MHz, Chloroform-a) 5 1.20 (t, J= 7.3 Hz, 3H), 3.06 ¨ 3.14
(m,
1H), 3.27 ¨ 3.36 (m, 4H), 3.62 (t, J= 9.3 Hz, 1H), 3.72 (dd, J= 6.3, 9.6 Hz,
1H), 4.10 ¨
4.18 (m, 1H), 6.65 ¨ 6.79 (m, 1H), 7.18 ¨ 7.30 (m, 5H), 9.01 (s, 1H), 9.02 (s,
2H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1]-N-(2,2-
difluoropropy1)-
2-oxoacetamide (FP-56)
[0537] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-oxo-1-
(pyrimidin-5-yl)pyrrolidin-3-y1]-2-oxoacetic acid (1-96) in a similar manner
to method A,
general procedure 7a (general scheme 3) as a yellow gum (94 mg, 100% purity,
58%)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
after purification by FCC on normal phase silica (25 g SNAP Ultra cartridge, 0-
100%
Et0Ac in heptane gradient).
[0538] LC-MS (METCR1603): 100% (UV), Rt= 3.67 min, m/z (ES14-)= 403.2 [M+H]4-
[0539] 1H NMR (500 MHz, Chloroform-a) 6 1.64 (t, J= 18.4 Hz, 3H), 3.06 - 3.12
(m,
1H), 3.28 - 3.36 (m, 2H), 3.55 - 3.65 (m, 2H), 3.65 - 3.71 (m, 1H), 3.73 (dd,
J= 6.4,
9.6 Hz, 1H), 4.10 -4.16 (m, 1H), 6.96 - 7.04 (m, 1H), 7.18 - 7.22 (m, 2H),
7.22 - 7.28
(m, 3H), 9.01 (s, 3H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrazin-2-yl)pyrrolidin-3-y11-N-cyclopropy1-2-
oxoacetamide (FP-57)
[0540] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-oxo-1-
(pyrazin-2-yl)pyrrolidin-3-y1]-2-oxoacetic acid (1-97) in a similar manner to
method A,
general procedure 7a (general scheme 3) as an off-white solid (62 mg, 100%
purity,
39%) after purification by FCC on normal phase silica (10 g SNAP Ultra
cartridge, 0-
50% Et0Ac in heptane gradient) followed by preparative LC (acidic pH, standard
elution method).
[0541] LC-MS (METCR1603): 100% (UV), Rt= 3.84 min, m/z (ES14-)= 365.2 [M+H].
[0542] 1H NMR (500 MHz, DMSO-d6) 6 0.55 - 0.59 (m, 2H), 0.63 - 0.68 (m, 2H),
2.70
-2.76 (m, 1H), 3.01 (dd, J= 7.2, 13.7 Hz, 1H), 3.11 (dd, J= 5.4, 13.7 Hz, 1H),
3.33 -
3.36 (m, 1H), 3.78 - 3.85 (m, 1H), 3.92 - 3.98 (m, 2H), 7.17 - 7.21 (m, 1H),
7.21 -7.27
(m, 4H), 8.39 (d, J= 2.6 Hz, 1H), 8.43 (dd, J= 1.6, 2.6 Hz, 1H), 8.66 (d, J=
5.1 Hz,
1H), 9.55 (d, J= 1.5 Hz, 1H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-2-yl)pyrrolidin-3-01-N-cyclopropy1-
2-
oxoacetamide (FP-58)
[0543] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-oxo-1-
(pyrimidin-2-yl)pyrrolidin-3-y1]-2-oxoacetic acid (1-98) in a similar manner
to method A,
general procedure 7a (general scheme 3) as a yellow solid (48 mg, 98% purity,
33%)
after purification by FCC on reverse phase silica (12 g SNAP C18 Ultra
cartridge,
acidic pH, standard elution method).
[0544] LC-MS (METCR1603): 98% (UV), Rt= 3.39 min, m/z (ES14-)= 365.1 [M+H]+
[0545] 1H NMR (500 MHz, Chloroform-d) 6 0.51 - 0.58 (m, 2H), 0.81 - 0.86 (m,
2H),
2.67 - 2.73 (m, 1H), 2.93 - 2.99 (m, 1H), 3.34 - 3.44 (m, 2H), 3.81 - 3.89 (m,
1H), 4.07
-4.15 (m, 2H), 6.65 (b.s, 1H), 7.05 (t, J=4.8 Hz, 1H), 7.15 - 7.28 (m, 5H),
8.67(d, J
=4.8 Hz, 2H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
86
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-2-yl)pyrrolidin-3-y1]-N-ethy1-2-oxo-
acetamide (FP-59)
[0546] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-5-oxo-1-
(pyrimidin-2-yl)pyrrolidin-3-y1]-2-oxoacetic acid (1-98) in a similar manner
to method A,
general procedure 7a (general scheme 3) as a yellow solid (65 mg, 94% purity,
45%)
after purification by FCC on reverse phase silica (30 g SNAP C18 Ultra
cartridge,
acidic pH, standard elution method).
[0547] LC-MS (METCR1603): 94% (UV), Rt= 3.38 min, m/z (ES14-)= 353.2 [M+H]
[0548] 1H NMR (500 MHz, Chloroform-0 6 1.16 (t, J=7.3 Hz, 3H), 2.97 (dd,
J=8.4,
13.7 Hz, 1H), 3.23 ¨ 3.32 (m, 2H), 3.36 (dd, J=4.8, 13.7 Hz, 1H), 3.39 ¨ 3.45
(m, 1H),
3.82 ¨ 3.89 (m, 1H), 4.07 ¨ 4.16 (m, 2H), 6.54 ¨ 6.69 (m, 1H), 7.05 (t, J =4.8
Hz, 1H),
7.15 ¨ 7.20 (m, 1H), 7.20 ¨ 7.25 (m, 4H), 8.67 (d, J =4.8 Hz, 2H)
Rac-2-[(3R,4R)-4-benzy1-1-(2-chloropyrimidin-4-y1)-5-oxopyrrolidin-3-y11-N-
cyclopropyl-
2-oxoacetamide (FP-60)
[0549] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-(2-
chloropyrimidin-4-y1)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-99) in a
similar manner to
method A, general procedure 7a (general scheme 3) as a pale yellow solid (99
mg,
95% purity by 1H NMR, 47%) after purification by FCC on normal phase silica
(10 g
SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient).
[0550] LC-MS (METCR1603): 92% (UV), Rt= 4.36 min, m/z (ES14-)= 399.1/401.1
[M+H]
[0551] 1H NMR (500 MHz, Chloroform-a) 6 0.51 ¨ 0.62 (m, 2H), 0.83 ¨ 0.88 (m,
2H),
2.67 ¨ 2.77 (m, 1H), 2.96 (dd, J= 8.1, 13.9 Hz, 1H), 3.30 (dd, J= 5.0, 13.8
Hz, 1H),
3.36 ¨ 3.44 (m, 1H), 3.78 ¨ 3.85 (m, 1H), 4.07 ¨ 4.15 (m, 2H), 6.68 (s, 1H),
7.14 ¨ 7.19
(m, 2H), 7.19 ¨ 7.23 (m, 1H), 7.23 ¨ 7.26 (m, 2H), 8.34 (d, J= 5.8 Hz, 1H),
8.48 (d, J=
5.8 Hz, 1H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-4-yl)pyrrolidin-3-y1]-N-cyclopropy1-
2-
oxoacetamide (FP-61)
[0552] To a solution of rac-2-[(3R,4R)-4-benzy1-1-(2-chloropyrimidin-4-y1)-5-
oxopyrrolidin-3-01-N-cyclopropy1-2-oxoacetamide (FP-60) (60 mg, 0.15 mmol) in
Et0H
(5 mL) was added 50% Pd/C (31 mg, 0.15 mmol) and the suspension stirred at RT
under an atmosphere of hydrogen for 2 h. Further 50% Pd/C (31 mg, 0.15 mmol)
was
added and the mixture stirred at RT under an atmosphere of hydrogen for 2 h.
The

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
87
reaction was filtered through a plug of Celite and the resultant cake washed
with Et0H.
The filtrates were combined and concentrated in vacuo. The residue was
purified by
FCC on normal phase silica (10 g SNAP Ultra cartridge, 0-100% Et0Ac in heptane
gradient) to afford 10 mg of rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-4-
yl)pyrrolidin-
3-y1]-N-cyclopropy1-2-oxoacetamide as a pale yellow viscous oil (100% purity,
18%).
[0553] LC-MS (METCR1603): 100% (UV), Rt= 3.77 min, m/z (ESI+)= 365.1 [M-FH]-
[0554] 1H NMR (500 MHz, Chloroform-a) 6 0.52 ¨ 0.59 (m, 2H), 0.83 ¨ 0.87 (m,
2H),
2.68 ¨ 2.75 (m, 1H), 2.96 (dd, J= 8.2, 13.8 Hz, 1H), 3.31 (dd, J= 4.9, 13.8
Hz, 1H),
3.38 ¨ 3.44 (m, 1H), 3.80 ¨ 3.86 (m, 1H), 4.07 ¨ 4.14 (m, 2H), 6.69 (s, 1H),
7.16 ¨ 7.22
(m, 3H), 7.22 ¨ 7.26 (m, 2H), 8.40 (dd, J= 0.9, 5.8 Hz, 1H), 8.55 ¨ 8.69 (m,
1H), 8.91
(s, 1H)
Rac-2-[(3R,4R)-4-benzy1-1-(6-chloropyridazin-3-y1)-5-oxopyrrolidin-3-y1]-N-
cyclopropyl-
2-oxoacetamide (FP-62)
[0555] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-(6-
chloropyridazin-3-y1)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-100) in a
similar manner
to method A, general procedure 7a (general scheme 3) as a pale yellow solid
(69 mg,
100% purity, 46%) after purification by FCC on normal phase silica (10 g SNAP
Ultra
cartridge, 0-100% Et0Ac in heptane gradient).
[0556] LC-MS (METCR1603): 100% (UV), Rt= 4.21 min, m/z (ES14-)= 399.0/401.0
[M+Hy
[0557] 1H NMR (500 MHz, Chloroform-a) 6 0.54 ¨ 0.62 (m, 2H), 0.84 ¨ 0.91 (m,
2H),
2.71 ¨2.78 (m, 1H), 3.02 (dd, J= 8.0, 13.7 Hz, 1H), 3.34 (dd, J= 4.9, 13.7 Hz,
1H),
3.38 ¨ 3.45 (m, 1H), 3.98 ¨ 4.06 (m, 1H), 4.14 ¨ 4.22 (m, 2H), 6.73 (s, 1H),
7.19 ¨ 7.24
(m, 3H), 7.25 ¨ 7.28 (m, 2H), 7.52 (d, J= 9.4 Hz, 1H), 8.73 (d, J= 9.4 Hz, 1H)
Rac-N-cyclopropy1-2-oxo-2-[(3R,45)-5-oxo-4-phenyl-1-(pyrimidin-5-yl)pyrrolidin-
3-
yl]acetamide (FP-63)
[0558] The title compound was synthesized from Rac-2-oxo-2-[(3R,45)-5-oxo-4-
pheny1-1-(pyrimidin-5-yl)pyrrolidin-3-yllacetic acid (1-101) in a similar
manner to method
A, general procedure 7a (general scheme 3) as an off-white solid (3 mg, 90%
purity by
1H NMR, 5%) after purification by FCC on normal phase silica (10 g SNAP KP-SIL
cartridge, 0-100% Et0Ac in heptane gradient) followed by preparative LC (basic
pH,
early elution method).
[0559] LC-MS (METCR1603): 96% (UV), Rt= 3.10 min, m/z (ESI+)= 351.2 [M+H]

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
88
[0560] 1H NMR (500 MHz, DMSO-d6) 5 0.54 ¨ 0.61 (m, 2H), 0.62 ¨ 0.67 (m, 2H),
2.70
¨2.78 (m, 1H), 4.05 (dd, J= 6.5, 9.8 Hz, 1H), 4.17 (d, J= 7.7 Hz, 1H), 4.29 ¨
4.35 (m,
1H), 4.42 (t, J= 9.4 Hz, 1H), 7.30 ¨ 7.39 (m, 5H), 8.81 (d, J= 5.0 Hz, 1H),
8.99 (s, 1H),
9.15 (s, 2H)
Rac-N-(cyclopropylmethyl)-2-oxo-2-[(3R,4S)-5-oxo-4-pheny1-1-(pyrimidin-5-y1)
pyrrolidin-3-yl]acetamide (FP-64)
[0561] The title compound was synthesized from rac-2-oxo-2-[(3R,4S)-5-oxo-4-
pheny1-1-(pyrimidin-5-yl)pyrrolidin-3-yl]acetic acid (1-101) in a similar
manner to method
A, general procedure 7a (general scheme 3) as an off-white solid (3 mg, 95%
purity by
1H NMR, 5%) after purification by FCC on normal phase silica (10 g SNAP Ultra
cartridge, 0-100% Et0Ac in heptane gradient) followed by preparative LC (basic
pH,
early elution method).
[0562] LC-MS (METCR1603): 92% (UV), Rt= 3.48 min, m/z (ES14-)= 365.2 [M+H]4-
[0563] 1H NMR (500 MHz, DMSO-d6) 5 0.16 ¨ 0.21 (m, 2H), 0.37 ¨ 0.41 (m, 2H),
0.90
¨ 1.00(m, 1H), 2.96 ¨ 3.02 (m, 2H), 4.06 (dd, J= 6.5, 9.6 Hz, 1H), 4.18(d, J=
7.8 Hz,
1H), 4.30 ¨ 4.37 (m, 1H), 4.42 (t, J= 9.4 Hz, 1H), 7.28 ¨ 7.33 (m, 1H), 7.34 ¨
7.38 (m,
4H), 8.82 ¨ 8.89 (m, 1H), 8.99 (s, 1H), 9.15 (s, 2H)
Rac-2-[(3R,4R)-4-benzy1-1-(4-cyanopyrimidin-5-y1)-5-oxopyrrolidin-3-y1]-
Akcyclopropyl-
2-oxoacetamide (FP-65)
[0564] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-(4-
cyanopyrimidin-5-y1)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-102) in a
similar manner
to method A, general procedure 7a (general scheme 3) as an off-white solid (41
mg,
97% purity by 1H NMR, 39%) after purification by FCC on normal phase silica
(10 g
SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient).
[0565] LC-MS (METCR1603): 100% (UV), Rt= 3.85 min, m/z (ES14-)= 390.2 [M-FH]4-
[0566] 1H NMR (500 MHz, Chloroform-a) 5 0.56 ¨ 0.63 (m, 2H), 0.84 ¨ 0.91 (m,
2H),
2.72 ¨ 2.79 (m, 1H), 3.13 ¨ 3.20 (m, 1H), 3.28 ¨ 3.37 (m, 2H), 3.66 ¨ 3.72 (m,
1H), 3.92
(dd, J= 5.8, 9.5 Hz, 1H), 4.15 ¨4.22 (m, 1H), 6.81 (s, 1H), 7.24 ¨7.29 (m,
3H), 7.29 ¨
7.33 (m, 2H), 8.89 (s, 1H), 9.17 (s, 1H)
Rac-2-[(3R,4R)-4-benzy1-1-(4-cyanopyrimidin-5-y1)-5-oxopyrrolidin-3-y11-N-(2,2-
difluoropropyI)-2-oxoacetamide (FP-66)
[0567] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-(4-
cyanopyrimidin-5-y1)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-102) in a
similar manner

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
89
to method A, general procedure 7a (general scheme 3) as an off-white solid (61
mg,
99% purity by 1H NMR, 54%) after purification by FCC on normal phase silica
(10 g
SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient).
[0568] LC-MS (METCR1603): 100% (UV), Rt= 4.07 min, rniz (ES14-)= 428.1 [M+H]-
[0569] 1H NMR (500 MHz, Chloroform-o) 6 1.63 (t, J= 18.4 Hz, 3H), 3.15 (dd, J=
7.0,
13.7 Hz, 1H), 3.31 (dd, J= 5.0, 13.7 Hz, 1H), 3.35 ¨ 3.40 (m, 1H), 3.58 ¨ 3.76
(m, 3H),
3.93 (dd, J= 5.9, 9.5 Hz, 1H), 4.15 ¨4.21 (m, 1H), 7.02 ¨ 7.12 (m, 1H), 7.23 ¨
7.28 (m,
3H), 7.29 ¨ 7.33 (m, 2H), 8.91 (s, 1H), 9.18 (s, 1H)
Rac-2-[(3R,4R)-4-benzy1-1-(4-methylpyrimidin-5-y1)-5-oxopyrrolidin-3-01-N-
cyclopropyl-
2-oxoacetamide (FP-67)
[0570] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-(4-
methylpyrimidin-5-y1)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-103) in a
similar manner
to method A, general procedure 7a (general scheme 3) as an off-white solid (21
mg,
96% purity, 22%) after purification by FCC on normal phase silica (10 g SNAP
Ultra
cartridge, 0-100% Et0Ac in heptane gradient followed by 0-20% Me0H in Et0Ac
gradient).
[0571] LC-MS (METCR1603): 96% (UV), Rt= 3.36 min, rniz (ES1+)= 379.1 [M+H]-
[0572] 1H NMR (500 MHz, Chloroform-a) 6 0.56 ¨ 0.65 (m, 2H), 0.85 ¨ 0.92 (m,
2H),
2.37 (s, 3H), 2.74 ¨ 2.80 (m, 1H), 3.18 ¨ 3.25 (m, 2H), 3.25 ¨ 3.31 (m, 1H),
3.31 ¨3.36
(m, 1H), 3.60 (dd, J= 5.1, 9.7 Hz, 1H), 4.17 ¨ 4.23 (m, 1H), 6.86 (s, 1H),
7.27 ¨ 7.36
(m, 5H), 8.25 (s, 1H), 9.00 (s, 1H)
Rac-2-[(3R,4R)-4-benzy1-1-(4-methylpyrimidin-5-y1)-5-oxopyrrolidin-3-y1]-N-
(2,2-
difluoropropyI)-2-oxoacetamide (FP-68)
[0573] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-(4-
methylpyrimidin-5-y1)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-103) in a
similar manner
to method A, general procedure 7a (general scheme 3) as a pale yellow viscous
oil (12
mg, 100% purity, 12%) after purification by FCC on normal phase silica (10 g
SNAP
Ultra cartridge, 0-100% Et0Ac in heptane gradient followed by 0-20% Me0H in
EtOac
gradient).
[0574] LC-MS (METCR1603): 100% (UV), Rt= 3.58 min, rniz (ES14-)= 417.1 [M+H]4-
[0575] 1H NMR (500 MHz, Chloroform-a) 6 1.64 (t, J= 18.4 Hz, 3H), 2.38 (s,
3H),
3.15 ¨ 3.30 (m, 3H), 3.32 ¨ 3.40 (m, 1H), 3.58 ¨ 3.77 (m, 3H), 4.15 ¨ 4.26 (m,
1H), 7.07
¨7.16 (m, 1H), 7.31 (h, J= 6.5, 7.2 Hz, 5H), 8.28 (s, 1H), 9.01 (s, 1H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
Rac-2-[(3R,4R)-4-benzy1-1-[6-(benzyloxy)pyridin-2-y1]-5-oxopyrrolidin-3-y1]-/V-
cyclopropy1-2-oxoacetamide (FP-69)
[0576] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-146-
(benzyloxy)pyridin-2-y1]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-104) in a
similar
manner to method A, general procedure 7a (general scheme 3) as a pale yellow
viscous oil (59 mg, 99% purity by 1H NMR, 40%) after purification by FCC on
normal
phase silica (10 g SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient).
[0577] LC-MS (METCR1603): 100% (UV), Rt= 5.32 min, m/z (ESI)= 470.2 [M+H]4-
[0578] 1H NMR (500 MHz, Chloroform-o) 6 0.52 ¨ 0.59 (m, 2H), 0.81 ¨ 0.88 (m,
2H),
2.66 ¨ 2.75 (m, 1H), 2.91 (dd, J= 8.6, 13.6 Hz, 1H), 3.29 ¨ 3.36 (m, 1H), 3.36
¨ 3.42
(m, 1H), 3.79 (dd, J= 7.1, 10.9 Hz, 1H), 4.05 ¨ 4.11 (m, 1H), 4.13 ¨ 4.19 (m,
1H), 5.23
¨5.30 (m, 2H), 6.56 (d, J= 8.0 Hz, 1H), 6.67 (d, 1H), 7.16 ¨ 7.21 (m, 3H),
7.21 ¨7.26
(m, 2H), 7.26 ¨ 7.31 (m, 1H), 7.32 ¨ 7.37 (m, 2H), 7.37 ¨ 7.42 (m, 2H), 7.61
(t, J= 8.0
Hz, 1H), 7.96 (d, J= 7.9 Hz, 1H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(6-oxo-1,6-dihydropyridin-2-yl)pyrrolidin-3-
y11-N-
cyclopropy1-2-oxoacetamide (FP-70),
rac-2-[(3R,4R)-4-benzy1-1-(4-chloro-6-oxo-1,6-dihydropyridin-2-y1)-5-
oxopyrrolidin-3-
yll-N-cyclopropy1-2-oxoacetamide (FP-71), and
rac-2-[(3R,4R)-4-benzy1-1-[6-(benzyloxy)-4-chloropyridin-2-y1]-5-oxopyrrolidin-
3-y1]-N-
cyclopropy1-2-oxoacetamide (FP-72)
[0579] To a solution of rac-2-[(3R,4R)-4-benzy1-1-[6-(benzyloxy)pyridin-2-y1]-
5-
oxopyrrolidin-3-yll-N-cyclopropy1-2-oxoacetamide (FP-69) (71% purity, 125 mg,
0.189
mmol) in Et0Ac (10 mL) was added 50% Pd/C (40 mg, 0.189 mmol) and the
suspension stirred at RT under an atmosphere of hydrogen for 20 min. The
reaction
mixture was filtered through a plug of Celite and the resultant cake washed
with Et0Ac
(30 mL). The filtrate was concentrated in vacuo and the crude material
purified by FCC
on normal phase silica (10 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane
gradient followed by 0-20% Me0H in Et0Ac/Me0H gradient) to give 41 mg of rac-2-
[(3R,4R)-4-benzy1-5-oxo-1-(6-oxo-1,6-dihydropyridin-2-yl)pyrrolidin-3-y11-N-
cyclopropyl-
2-oxoacetamide as an off-white solid (98% purity by 1H NMR, 56%), 8 mg of rac-
2-
[(3R,4R)-4-benzy1-1-(4-chloro-6-oxo-1,6-dihydropyridin-2-y1)-5-oxopyrrolidin-3-
y11-N-
cyclopropy1-2-oxoacetamide as an off-white solid (100% purity, 10%) and 12 mg
of rac-

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
91
2-[(3R,4R)-4-benzy1-1-[6-(benzyloxy)-4-chloropyridin-2-y1]-5-oxopyrrolidin-3-
y1FN-
cyclopropyl-2-oxoacetamide as an off-white solid (100% purity, 13%).
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(6-oxo-1,6-dihydropyridin-2-yl)pyrrolidin-3-
y1]-N-
cyclopropy1-2-oxoacetamide (FP-70)
[0580] LC-MS (METCR1603): 100% (UV), Rt= 3.06 min, m/z (ESII= 380.0 [M+H]
[0581] 1H NMR (500 MHz, Chloroform-o) 6 0.57 - 0.67 (m, 2H), 0.83 - 0.90 (m,
2H),
2.73 - 2.80 (m, 1H), 3.08 (dd, J= 6.9, 13.8 Hz, 1H), 3.24 (dd, J= 5.1, 13.8
Hz, 1H),
3.35- 3.41 (m, 1H), 3.52 - 3.59 (m, 1H), 3.63 (dd, J= 6.2, 10.2 Hz, 1H), 3.98 -
4.07
(m, 1H), 5.69(d, J= 7.4 Hz, 1H), 6.32 (d, J= 9.0 Hz, 1H), 7.15 -7.21 (m, 3H),
7.21 -
7.29 (m, 3H), 7.32 - 7.40 (m, 1H), 11.48 (s, 1H)
Rac-2-[(3R,4R)-4-benzy1-1-(4-chloro-6-oxo-1,6-dihydropyridin-2-y1)-5-
oxopyrrolidin-3-
y1FN-cyclopropy1-2-oxoacetamide (FP-71)
[0582] LC-MS (METCR1603): 100% (UV), Rt= 2.58 min, m/z (ESI+)= 414.2 [M+H]
[0583] 1H NMR (500 MHz, DMSO-d6) 6 0.52 - 0.61 (m, 2H), 0.62 - 0.69 (m, 2H),
2.70
- 2.77 (m, 1H), 2.99 (dd, J= 7.1, 13.7 Hz, 1H), 3.06 (dd, J= 5.3, 13.7 Hz,
1H), 3.24 -
3.27 (m, 1H), 3.79 (dd, J= 6.0, 10.4 Hz, 1H), 3.82 - 3.88 (m, 1H), 3.89 - 3.96
(m, 1H),
7.16 - 7.28 (m, 5H), 7.49 - 7.98 (m, 2H), 8.68(d, J= 5.2 Hz, 1H), 11.64 (s,
1H)
Rac-2-[(3R,4R)-4-benzy1-146-(benzyloxy)-4-chloropyridin-2-y1]-5-oxopyrrolidin-
3-y11-N-
cyclopropy1-2-oxoacetamide (FP-72)
[0584] LC-MS (METCR1603): 100% (UV), Rt= 5.44 min, m/z (ES11= 504.2 [M+H]
[0585] 1H NMR (500 MHz, Chloroform-0 6 0.51 - 0.61 (m, 2H), 0.83 - 0.89 (m,
2H),
2.69 - 2.77 (m, 1H), 2.92 (dd, J= 8.3, 13.7 Hz, 1H), 3.31 (dd, J= 4.8, 13.7
Hz, 1H),
3.35 - 3.41 (m, 1H), 3.71 - 3.78 (m, 1H), 4.03 - 4.10 (m, 2H), 5.31 - 5.37 (m,
2H), 6.60
-6.74 (m, 1H), 7.15 - 7.21 (m, 3H), 7.21 -7.26 (m, 2H), 7.27 - 7.31 (m, 1H),
7.32 -
7.37 (m, 2H), 7.37 - 7.42 (m, 2H), 7.65 (d, J= 8.4 Hz, 1H), 7.95 (d, J= 8.4
Hz, 1H)
Rac-2-[(3R,4R)-4-benzy1-146-(benzyloxy)pyridin-2-y1]-5-oxopyrrolidin-3-y1]-N-
(2,2-
difluoropropy1)-2-oxoacetamide (FP-73)
[0586] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-[6-
(benzyloxy)pyridin-2-y1]-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-104) in a
similar
manner to method A, general procedure 7a (general scheme 3) as a colourless
viscous oil (5 mg, 100% purity, 2%) after purification by FCC on normal phase
silica
(25 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient) followed by
preparative LC (basic pH, early elution method).

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
92
[0587] LC-MS (METCR1603): 100% (UV), Rt= 5.44 min, m/z (ES14-)= 508.2 [M+H]
[0588] 1H NMR (500 MHz, Chloroform-o) 6 1.61 (t, J= 18.4 Hz, 3H), 2.91 (dd, J=
8.7,
13.7 Hz, 1H), 3.34 (dd, J= 4.8, 13.8 Hz, 1H), 3.39- 3.45 (m, 1H), 3.54 - 3.70
(m, 2H),
3.81 (dd, J=7.4, 11.1 Hz, 1H), 4.03 - 4.10 (m, 1H), 4.16 (dd, J=9.3, 11.1 Hz,
1H),
5.26 (s, 2H), 6.56 (d, J= 8.0 Hz, 1H), 6.85 - 6.95 (m, 1H), 7.15 - 7.21 (m,
3H), 7.22 -
7.26 (m, 2H), 7.27 - 7.31 (m, 1H), 7.31 - 7.36 (m, 2H), 7.36 - 7.40 (m, 2H),
7.62 (t, J=
8.0 Hz, 1H), 7.96 (d, J= 7.9 Hz, 1H)
Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(6-oxo-1,6-dihydropyridin-2-yl)pyrrolidin-3-
y1]-N-(2,2-
difluoropropyI)-2-oxoacetamide (FP-74)
[0589] To a solution of rac-2-[(3R,4R)-4-benzy1-1-[6-(benzyloxy)pyridin-2-y1]-
5-
oxopyrrolidin-3-y1FN-(2,2-difluoropropy1)-2-oxoacetamide (FP-73) (62% purity,
43 mg,
0.053 mmol) in Et0Ac (5 mL) was added 50% Pd/C (11 mg, 0.053 mmol) and the
suspension stirred at RT under an atmosphere of hydrogen for 20 min. The
reaction
mixture was filtered through a plug of Celite and the filtrate concentrated in
vacuo. The
crude material was purified by FCC on normal phase silica (10 g SNAP KP-SIL
cartridge, 0-100% Et0Ac in heptane gradient) to give 2 mg of rac-2-[(3R,4R)-4-
benzyl-
5-oxo-1-(6-oxo-1,6-dihydropyridin-2-yl)pyrrolidin-3-y1]-N-(2,2-difluoropropy1)-
2-
oxoacetamide as a pale yellow viscous oil (94% purity, 9%).
[0590] LC-MS (METCR1603): 94% (UV), Rt= 3.35 min, m/z (ES14-)= 418.1 [M+H]4-
[0591] 1H NMR (500 MHz, Chloroform-0 6 1.64 (t, J= 18.4 Hz, 3H), 3.06 (dd, J=
7.2,
13.9 Hz, 1H), 3.26 (dd, J= 5.1, 13.9 Hz, 1H), 3.36 - 3.44 (m, 1H), 3.56 - 3.74
(m, 4H),
3.98 - 4.07 (m, 1H), 5.68 (d, J=7.1 Hz, 1H), 6.33 (dd, J= 0.6, 9.1 Hz,
1H),7.01 -7.11
(m, 1H), 7.15 - 7.19 (m, 2H), 7.26 (s, 3H), 7.35 (dd, J= 7.5, 9.1 Hz, 1H),
11.29 (s, 1H)
Rac-2-[(3R,4R)-4-benzy1-1-(1-methyl-1H-pyrazol-4-y1)-5-oxopyrrolidin-3-y1]-N-
cyclopropy1-2-oxoacetamide (FP-75)
[0592] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-(1-
methyl-
1H-pyrazol-4-y1)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-105) in a similar
manner to
method A, general procedure 7a (general scheme 3) as a pale yellow solid (40
mg,
100% purity, 46%) after purification by FCC on normal phase silica (10 g SNAP
Ultra
cartridge, 0-100% Et0Ac in heptane gradient).
[0593] LC-MS (METCR1603): 100% (UV), Rt= 3.48 min, m/z (ESI+)= 367.2 [M+H]f
[0594] 1H NMR (500 MHz, Chloroform-a) 6 0.53 - 0.61 (m, 2H), 0.83 - 0.88 (m,
2H),
2.69 - 2.77 (m, 1H), 2.98 - 3.05 (m, 1H), 3.22 - 3.30 (m, 2H), 3.57 (d, J= 7.9
Hz, 2H),

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
93
3.89 (s, 3H), 4.07 (q, J= 7.7 Hz, 1H), 6.75 (s, 1H), 7.16 ¨7.21 (m, 3H), 7.21
¨7.25 (m,
2H), 7.37 (s, 1H), 7.95 (s, 1H)
Rac-2-[(3R,4R)-4-benzy1-1-(1-methyl-1H-pyrazol-4-y1)-5-oxopyrrolidin-3-y1]-N-
(2,2-
difluoropropy1)-2-oxoacetamide (FP-76)
[0595] The title compound was synthesized from rac-2-[(3R,4R)-4-benzy1-1-(1-
methyl-
1H-pyrazol-4-y1)-5-oxopyrrolidin-3-y1]-2-oxoacetic acid (1-105) in a similar
manner to
method A, general procedure 7a (general scheme 3) as a yellow oil (19 mg, 97%
purity, 20%) after purification by FCC on normal phase silica (10 g SNAP Ultra
cartridge, 0-100% Et0Ac in heptane gradient).
[0596] LC-MS (METCR1603): 97% (UV), Rt= 3.75 min, m/z (ESI)= 405.0 [M+H]4-
[0597] 1H NMR (500 MHz, Chloroform-a) 5 1.62 (t, J= 18.4 Hz, 3H), 2.97 ¨ 3.05
(m,
1H), 3.24 ¨ 3.31 (m, 2H), 3.55 ¨ 3.72 (m, 4H), 3.87 ¨ 3.91 (m, 3H), 4.03 ¨4.10
(m, 1H),
6.92 ¨ 7.03 (m, 1H), 7.15 ¨ 7.21 (m, 3H), 7.21 ¨7.26 (m, 2H), 7.36 ¨ 7.38 (m,
1H), 7.96
(s, 1H)
Method B: HATU coupling on ketoacid
Rac-2-[(3R,4R)-4-[(4-fluorophenyl)methy1]-5-oxopyrrolidin-3-y1]-2-oxo-N-
(propan-2-
yloxy)acetamide (FP-77)
[0598] To an ice-cooled solution of rac-2-[(3R,4R)-4-[(4-fluorophenyl)methy1]-
5-
oxopyrrolidin-3-y1]-2-oxoacetic acid (1-78) (60% purity estimated by 1H NMR,
300 mg,
0.68 mmol) and DIPEA (296 pL, 1.70 mmol) in dry 1/1 DCM/DMF (6 mL) was added
at
0 C HATU (284 mg, 0.75 mmol) in one portion. The mixture was stirred at 0 C
for 15
min then 2-(aminooxy)propane hydrochloride (1:1) (76 mg, 0.68 mmol) was added.
After 15 min at 0 C, the reaction was allowed to warm up and stirred at RT for
3 h. The
mixture was cooled to 0 C then DIPEA (148 pL, 0.85 mmol) and HATU (142 mg,
0.38
mmol) were added. The mixture was stirred at 0 C for 15 min then 2-(aminooxy)-
propane hydrochloride (1:1) (38 mg, 0.34 mmol) was added. After 15 min at 0 C,
the
reaction was allowed to warm up and stirred at RT for 2 h. The solution was
quenched
with water (5 mL) and extracted with DCM (3 x 5 mL). The 2 layers were
separated on
a hydrophobic frit and the combined organic extracts were concentrated in
vacuo. The
crude material was purified by FCC on normal phase silica (25 g SNAP Ultra, 0-
100%
Et0Ac in heptane gradient followed by 0-20% Me0H in Et0Ac gradient) then by
FCC
on reverse phase silica (12 g SNAP Ultra C18, acidic pH, normal elution
method) to

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
94
afford 10 mg of rac-2-[(3R,4R)-4-[(4-fluorophenyl)methy1]-5-oxopyrrolidin-3-
y1]-2-oxo-N-
(propan-2-yloxy)acetamide_as a colourless oil (85% purity by 1H NMR, 4%).
[0599] LC-MS (METCR1603): 95% (UV), Rt= 2.37 min, m/z (ES14-)= 323.2 [M+H].
[0600] 1H NMR (500 MHz, Chloroform-o) 6 1.27 (s, 6H), 2.85 ¨ 2.97 (m, 1H),
2.98 ¨
3.09 (m, 1H), 3.11 ¨3.24 (m, 1H), 3.29 (dd, J= 9.5, 7.2 Hz, 1H), 3.32 ¨ 3.39
(m, 1H),
3.97 ¨ 4.09 (m, 1H), 4.09 ¨ 4.21 (m, 1H), 5.55 (s, 1H), 6.91 ¨7.01 (m, 2H),
7.13 ¨ 7.23
(m, 2H), 8.93 (s, 1H)
Method C: Displacement on methyl ketoester
Rac-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-y1]-N-(propan-2-yl)acetamide
(FP-78)
[0601] To a solution of rac-methyl 2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
yl]acetate (1-106) (23% purity, 100 mg, 0.08 mmol) in Me0H (3 mL) was added
isopropylamine (48 mg, 0.81 mmol) and the reaction heated at reflux for 1 h
then
cooled to RT and concentrated in vacuo. The residue was dissolved in MeCN (1
mL)
and purified by preparative LC (acidic pH, standard elution method) to afford
4 mg of
rac-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-y1]-A/-(propan-2-ypacetamide
as an
off-white solid (93% purity, 8%).
[0602] LC-MS (METCR1603): 93% (UV), Rt= 3.13 min, m/z (ES14-)= 275.3 [M-FH]-
[0603] 1H NMR (500 MHz, Chloroform-a) 6 1.17 ¨ 1.22 (m, 6H), 3.38 ¨ 3.46 (m,
1H),
3.94 ¨ 4.08 (m, 3H), 4.27 ¨ 4.35 (m, 1H), 6.40 (s, 1H), 6.76 (d, J=7.6 Hz,
1H), 7.24 ¨
7.38 (m, 5H)
Rac-N-cyclopenty1-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-yl]acetamide (FP-
79)
[0604] The title compound was synthesized from rac-methyl 2-oxo-2-[(3R,4S)-5-
oxo-
4-phenylpyrrolidin-3-yl]acetate (1-106) in a similar manner to method C,
general
procedure 7a (general scheme 3) as an off-white powder (22 mg, 100% purity,
18%)
after purification by preparative LC (acidic pH, standard elution method).
[0605] LC-MS (METCR1603): 100% (UV), Rt= 3.60 min, m/z (ES14-)= 301.2 [M+H]4-
[0606] 1H NMR (500 MHz, Chloroform-a) 6 1.38 ¨ 1.48 (m, 2H), 1.57¨ 1.75 (m,
4H),
1.94 ¨ 2.07 (m, 2H), 3.37 ¨ 3.43 (m, 1H), 3.93 ¨ 3.99 (m, 1H), 4.05 (d, J =8.0
Hz, 1H),
4.09 ¨ 4.18 (m, 1H), 4.25 ¨ 4.34 (m, 1H), 6.79 (s, 1H), 6.88 (d, J= 7.7 Hz,
1H), 7.25 ¨
7.31 (m, 3H), 7.31 ¨ 7.37 (m, 2H)
GENERAL PROCEDURE 7b (GENERAL SCHEME 3): Ketoamide formation
Rac-N-(2-methylpropy1)-2-oxo-2-[(3R,4R)-5-oxo-4-[(pyridin-2-
yl)methyl]pyrrolidin-3-
yllacetamide (FP-80)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
[0607] To an ice-cooled stirred solution of rac-3-oxo-3-[(3R,4R)-5-oxo-4-
[(pyridin-2-
yl)methyl]pyrrolidin-3-y1]-2-(1A4-thiolan-1-ylidene)propanenitrile (1-36) (76%
purity by 1H
NMR, 660 mg, 1.52 mmol) in Me0H (5 mL) was added m-CPBA (70%, 750 mg, 3.04
mmol) in one portion and the mixture stirred at 0 00 for 1 h under nitrogen.
Isobutylamine (1 mL, 10.06 mmol) was added and the suspension stirred at RT
for 3.5
h. The mixture was concentrated in vacuo and the residue purified by ion-
exchange
flash chromatography (10 g 'solute Si II cartridge, 0-20% Me0H in Et0Ac
gradient
then 0-10% 7N methanolic ammonia in Et0Ac gradient) followed by preparative LC
(basic pH, early elution method) to afford 128 mg of rac-N-(2-methylpropy1)-2-
oxo-2-
[(3R,4R)-5-oxo-4-[(pyridin-2-yl)methyl]pyrrolidin-3-yllacetamide as an off-
white powder
(97% purity, 27%).
[0608] LC-MS (METCR1603): 97% (UV), Rt= 3.04 min, m/z (ESI+)= 302.2 [M+H].
[0609] 1H NMR (500 MHz, Chloroform-o) 60.95 (d, J= 6.7 Hz, 6H), 1.76 ¨ 1.88
(m,
1H), 3.03 (dd, J= 9.6, 15.1 Hz, 1H), 3.07 ¨ 3.17 (m, 2H), 3.27 (td, J= 3.8,
9.1 Hz, 1H),
3.32 (dd, J= 8.1, 9.2 Hz, 1H), 3.43 (dd, J= 3.8, 15.1 Hz, 1H), 3.57 ¨ 3.64 (m,
1H), 4.38
¨ 4.45 (m, 1H), 5.72 (s, 1H), 6.93 ¨ 7.01 (m, 1H), 7.04 ¨ 7.09 (m, 1H),
7.19(d, J= 7.8
Hz, 1H), 7.56 (td, J= 1.8, 7.7 Hz, 1H), 8.30 ¨ 8.35 (m, 1H)
GENERAL PROCEDURE 8 (GENERAL SCHEME 3): Chiral purification
2-[(3R,4R)-4-Benzy1-5-oxo-pyrrolidin-3-y1]-N-(cyclopropylmethyl)-2-oxo-
acetamide (FP-
81), and
2-[(3S,4S)-4-Benzy1-5-oxo-pyrrolidin-3-y1]-/V-(cyclopropylmethyl)-2-oxo-
acetamide (FP-
82) ((R,R) and (S,R) assignments arbitrary)
[0610] Rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-N-(cyclopropylmethyl)-2-
oxoacetamide (FP-1) (100 mg, 0.33 mmol) was purified by chiral separation on
Berger
SFC Prep [Column: Pirkle Covalent (R,R) Whelk-01 Kromasil (21.1 mm x 250 mm, 5
pm) at 40 C; Isocratic eluent: 8:2 002:IPA; Flow rate: 50 mL/min; Detector
wavelength: 210 nm; Dilution solvent: MeCN; Injection volume: 250 pL]. The
samples
were dissolved in MeCN/DCM/water, transferred to vials, the solvent removed
under a
stream of air and the residues dried in vacuo at 40 C to afford 31 mg of 2-
[(3R,4R)-4-
benzy1-5-oxo-pyrrolidin-3-y1]-N-(cyclopropylmethyl)-2-oxo-acetamide as an off-
white
solid (96% purity, 94% ee, 30%) and 29 mg of 2-[(35,45)-4-benzy1-5-oxo-
pyrrolidin-3-
y1]-N-(cyclopropylmethyl)-2-oxo-acetamide as an off-white solid (97% purity,
>99% ee,
29%).

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
96
2-[(3R,4R)-4-Benzy1-5-oxo-pyrrolidin-3-y1]-AA(cyclopropylmethyl)-2-oxo-
acetamide (FP-
81)
[0611] LC-MS (MET-uHPLC-AB-102): 98% (UV), Rt= 2.50 min, m/z (ES14-)= 301.4
[M+H]4-
[0612] LC-MS (CAM-1): 96% (UV), Rt= 2.66 min, 94% ee, m/z (ESI)= 301.0 [M+H]
[0613] 1H NMR (500 MHz, Chloroform-a) 6 0.18 - 0.24 (m, 2H), 0.51 -0.58 (m,
2H),
0.88 - 0.98 (m, 1H), 2.89 (dd, J =8.0, 13.7 Hz, 1H), 3.05 -3.12 (m, 3H), 3.19-
3.29
(m, 2H), 3.35 (t, J = 9.4 Hz, 1H), 4.04 -4.12 (m, 1H), 5.62 (s, 1H), 6.71 -
6.83 (m, 1H),
7.17 - 7.23 (m, 3H), 7.23 - 7.28 (m, 2H)
2-[(3S,4S)-4-Benzy1-5-oxo-pyrrolidin-3-y1]-N-(cyclopropylmethyl)-2-oxo-
acetamide (FP-
82)
[0614] LC-MS (MET-uHPLC-AB-102): 99% (UV), Rt= 2.49 min, m/z (ESI+)= 301.4
[M+H]4-
[0615] LC-MS (CAM-1): 97% (UV), Rt= 1.89 min, >99% ee, m/z (ES14-)= 301.0
[M+H]-
[0616] 1H NMR (500 MHz, Chloroform-o) 6 0.18 - 0.25 (m, 2H), 0.51 -0.59 (m,
2H),
0.87 - 0.99 (m, 1H), 2.89 (dd, J =8.0, 13.7 Hz, 1H), 3.05 - 3.13 (m, 3H), 3.19
- 3.29
(m, 2H), 3.35 (t, J = 9.4 Hz, 1H), 4.04 -4.13 (m, 1H), 5.58 (s, 1H), 6.70 -
6.81 (m, 1H),
7.15 - 7.24 (m, 4H), 7.22 - 7.30 (m, 2H)
2-[(3R,4R)-4-Benzy1-5-oxopyrrolidin-3-y1]-A/-(2,2-difluoroethyl)-2-
oxoacetamide (FP-
83), and
2-[(3S,4S)-4-Benzy1-5-oxopyrrolidin-3-y1]-/V-(2,2-difluoroethyl)-2-
oxoacetamide (FP-84)
((R,R) and (S,S) assignments arbitrary)
[0617] Rac-2-[(3R,4R)-4-benzy1-5-oxopyrrolidin-3-y1]-N-(2,2-difluoroethyl)-2-
oxoacetamide (FP-4) (105 mg, 0.34 mmol) was purified by chiral separation on
Berger
SFC Prep [Column: Pirkle Covalent (R,R) Whelk-01 Kromasil (21.1 mm x 250 mm, 5
pm) at 40 C; Isocratic eluent: 85:15 CO2:IPA; Flow rate: 50 mL/min; Detector
wavelength: 220 nm; Dilution solvent: IPA; Injection volume: 100 pL]. The two
compounds obtained were purified by FCC on normal phase silica (10 g SNAP
Ultra
cartridge, 0-100% Et0Ac in heptane gradient) to afford 22 mg of 2-[(3R,4R)-4-
benzyl-
5-oxopyrrolidin-3-y1]-N-(2,2-difluoroethyl)-2-oxoacetamide as an off-white
solid (99%
purity, 99% ee, 21%) and 28 mg of 2-[(35,45)-4-benzy1-5-oxopyrrolidin-3-A-N-
(2,2-
difluoroethyl)-2-oxoacetamide as an off-white solid (98% purity, 96% ee, 26%).
2-[(3R,4R)-4-Benzy1-5-oxopyrrolidin-3-y1]-N-(2,2-difluoroethyl)-2-oxoacetamide
(FP-83)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
97
[0618] LC-MS (METCR1603): 100% (UV), Rt= 2.79 min, m/z (ES14-)= 311.5 [M+H]
[0619] LC-MS (CAM-2): 99% (UV), Rt= 9.66 min, 99% ee
[0620] 1H NMR (500 MHz, Chloroform-a) 62.85 (dd, J= 8.4, 13.8 Hz, 1H), 3.10
(td, J
= 4.7, 8.2 Hz, 1H), 3.21 -3.29 (m, 2H), 3.34 - 3.41 (m, 1H), 3.61 (ttd, J=
3.9, 6.5, 14.8
Hz, 2H), 4.08 (ddd, J= 7.1, 8.1, 9.0 Hz, 1H), 5.62 (s, 1H), 5.81 (tt, J= 3.9,
55.4 Hz,
1H), 6.84 - 6.94 (m, 1H), 7.16 - 7.23 (m, 3H), 7.23 - 7.27 (m, 2H)
2-[(3S,4S)-4-Benzy1-5-oxopyrrolidin-3-y1]-N-(2,2-difluoroethyl)-2-oxoacetamide
(FP-84)
[0621] LC-MS (METCR1603): 100% (UV), Rt= 2.79 min, m/z (ES14-)= 311.5 [M+H]-
[0622] LC-MS (CAM-2): 98% (UV), Rt= 5.96 min, 96% ee
[0623] 1H NMR (500 MHz, Chloroform-a) 62.85 (dd, J= 8.4, 13.8 Hz, 1H), 3.10
(td, J
= 4.7, 8.2 Hz, 1H), 3.21 -3.29 (m, 2H), 3.33 - 3.41 (m, 1H), 3.61 (ttd, J=
3.9, 6.5, 14.8
Hz, 2H), 4.08 (ddd, J= 7.1, 8.1, 9.0 Hz, 1H), 5.61 (s, 1H), 5.81 (tt, J= 3.9,
55.4 Hz,
1H), 6.82 - 6.95 (m, 1H), 7.16 - 7.22 (m, 3H), 7.23 - 7.27 (m, 2H)
N-(Cyclopropylmethyl)-2-oxo-2-[(3S,4R)-5-oxo-4-phenylpyrrolidin-3-yl]acetamide
(FP-
85) and
N-(Cyclopropylmethyl)-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-yl]acetamide
(FP-
86) ((R,S) and (S,R) assignments arbitrary)
[0624] Rac-N-(cyclopropylmethyl)-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide (FP-10) (90 mg, 0.31 mmol) was purified by chiral separation on
Gilson
LC [Column: Chiralpak AS (20 mm x 250 mm, 10 pm) at RT; Isocratic eluent:
MeCN;
Flow rate: 8 mL/min; Detector wavelength: 215 nm; Dilution solvent: MeCN;
Injection
volume: 100-1000 pL]. The samples were dissolved in MeCN, transferred to
vials, the
solvent removed under a stream of air and the residues dried in vacuo at 40 C
to
afford 27 mg of N-(cyclopropylmethyl)-2-oxo-2-[(3S,4R)-5-oxo-4-
phenylpyrrolidin-3-
yl]acetamide as an off-white gum (89% purity by 1H NMR, 100% ee, 27%) and 26
mg
of N-(cyclopropylmethyl)-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide as
an off-white solid (91% purity by 1H NMR, 96% ee, 26%).
N-(Cyclopropylmethyl)-2-oxo-2-[(3S,4R)-5-oxo-4-phenylpyrrolidin-3-yl]acetamide
(FP-
85)
[0625] LC-MS (METCR1603): 100% (UV), Rt= 3.28 min, m/z (ESI-)= 287.3 [M+H]4-
[0626] LC-MS (CAM-2): 99% (UV), Rt= 4.55 min, 100% ee
[0627] 1H NMR (500 MHz, Chloroform-0 5 0.15 - 0.19 (m, 2H), 0.47 - 0.52 (m,
2H),
0.87 - 0.98 (m, 1H), 3.05 - 3.11 (m, 2H), 3.31 -3.37 (m, 1H), 3.90 (t, J =9.8
Hz, 1H),

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
98
4.02 (d, J =7 .9 Hz, 1H), 4.22 -4.31 (m, 1H), 7.02 - 7.11 (m, 1H), 7.22 - 7.27
(m, 3H),
7.27 - 7.33 (m, 2H), 7.39 (s, 1H)
N-(Cyclopropylmethyl)-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-yl]acetamide
(FP-
[0628] LC-MS (METCR1603): 100% (UV), Rt= 3.24 min, m/z (ESI)= 287.2 [M+H]+
[0629] LC-MS (CAM-2): 95% (UV), Rt= 7.92 min, 96% ee
[0630] 1H NMR (500 MHz, Chloroform-0 6 0.15 - 0.21 (m, 2H), 0.48 - 0.52 (m,
2H),
0.86 - 0.96 (m, 1H), 3.04 - 3.11 (m, 2H), 3.32 - 3.37 (m, 1H), 3.90 (t, J =9.8
Hz, 1H),
4.03 (d, J =7.9 Hz, 1H), 4.22 -4.30 (m, 1H), 7.03- 7.10 (m, 1H), 7.22 - 7.27
(m, 3H),
7.27 - 7.33 (m, 2H), 7.36 (s, 1H)
N-(2,2-Difluoropropy1)-2-oxo-2-[(3S,4R)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide (FP-
87) and
N-(2,2-DifluoropropyI)-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide (FP-
88) ((R,S) and (S,R) assignments arbitrary)
[0631] Rac-N-(2,2-difluoropropyI)-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide (FP-11) (90 mg, 0.31 mmol) was purified by chiral separation on
Waters
Investigator SFC [Column: Chiralcel OD-H (10 mm x 250 mm, 5 pm) at 40 C;
Isocratic
eluent: 7.5:2.5 CO2:MeCN; Flow rate: 15 mUmin; Detector wavelength: 215/254
nm;
Dilution solvent: MeCN; Injection volume: 250 pL]. The samples were dissolved
in
Et0Ac, transferred to vials, the solvent removed under a stream of air and the
residues
dried in vacuo at 40 C to afford 33 mg of N-(2,2-difluoropropyI)-2-oxo-2-
[(3S,4R)-5-
oxo-4-phenylpyrrolidin-3-yl]acetamide as an off-white solid (88% purity by 1H
NMR,
97% ee, 27%) and 23 mg of N-(2,2-difluoropropyI)-2-oxo-2-[(3R,4S)-5-oxo-4-
phenylpyrrolidin-3-yl]acetamide as an off-white solid (92% purity by 1H NMR,
100% ee,
20%).
N-(2,2-DifluoropropyI)-2-oxo-2-[(3S,4R)-5-oxo-4-phenylpyrrolidin-3-
yl]acetamide (FP-
[0632] LC-MS (MET-uHPLC-AB-102): 100% (UV), Rt= 1.99 min, m/z (ESII= 311.2
[M+H]
[0633] LC-MS (CAM-3): 99% (UV), Rt= 4.08 min, 97% cc, m/z (ES1)= 311.0 [M+H]+
[0634] 1H NMR (500 MHz, Chloroform-0 6 1.60 (t, J= 18.4 Hz, 3H), 3.40 - 3.45
(m,
1H), 3.59 - 3.71 (m, 2H), 3.94 (t, J= 9.7 Hz, 1H), 4.04 (d, J= 7.9 Hz, 1H),
4.26 -4.34
(m, 1H), 7.02 - 7.07 (m, 1H), 7.24 - 7.31 (m, 4H), 7.32 - 7.38 (m, 2H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
99
N-(2,2-Difluoropropy1)-2-oxo-2-[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-
yfiacetamide (FP-
[0635] LC-MS (MET-uHPLC-AB-102): 99% (UV), Rt= 1.99 min, m/z (ES1)= 311.2
[M+H]+
[0636] LC-MS (CAM-3): 100% (UV), Rt= 5.55 min, 100% ee, m/z (ESI)= 311.0
[M+H]+
[0637] 1H NMR (500 MHz, Chloroform-0 6 1.61 (t, J= 18.4 Hz, 3H), 3.41 -3.49
(m,
1H), 3.62 - 3.71 (m, 2H), 3.96 (t, J= 9.6 Hz, 1H), 4.05 (d, J= 8.0 Hz, 1H),
4.27 -4.37
(m, 1H), 6.48 (s, 1H), 7.19 - 7.25 (m, 1H), 7.27 - 7.31 (m, 3H), 7.31 -7.38
(m, 2H)
2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1j-N-cyclopropy1-2-
oxoacetamide (FP-89) and 2-[(3S,4S)-4-benzy1-5-oxo-1-(pyrimidin-5-
yl)pyrrolidin-3-y1]-
N-cyclopropy1-2-oxoacetamide (FP-90) ((R,R) and (S,S) assignments arbitrary)
[0638] Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1j-N-
cyclopropy1-
2-oxoacetamide (FP-54) (91% purity by 1H NMR, 148 mg, 0.37 mmol) was purified
by
chiral separation on Gilson LC [Column: Cellulose-4 (21.2 mm x 250 mm, 5 pm)
at RT;
lsocratic eluent: MeCN; Flow rate: 18 mL/min; Detector wavelength; 215 nm;
Dilution
solvent: MeCN, injection volume:100-1000 pL] to afford 74 mg of 2-[(3R,4R)-4-
benzy1-
5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-ylj-N-cyclopropy1-2-oxoacetamide as an
off-white
solid (98% purity, 100% ee, 55%) and a second product which was further
purified by
FCC on normal phase silica (10 g SNAP Ultra cartridge, 0-100% Et0Ac in heptane
gradient) to give 38 mg of 2-[(35,45)-4-benzy1-5-oxo-1-(pyrimidin-5-
yl)pyrrolidin-3-y1j-
N-cyclopropy1-2-oxoacetamide as an off-white solid (97% purity, 94% ee, 29%).
2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1j-Mcyclopropyl-2-
oxoacetamide (FP-89)
[0639] LC-MS (METCR1603): 98% (UV), Rt= 3.42 min, m/z (ES1)= 365.1 [M+1-1]+
[0640] LC-MS (CAM-4): 100% (UV), Rt= 7.42 min, 100% ee
[0641] 1H NMR (500 MHz, Chloroform-0 6 0.53 - 0.65 (m, 2H), 0.83 - 0.92 (m,
2H),
2.70 - 2.78 (m, 1H), 3.06 - 3.14 (m, 1H), 3.27 - 3.35 (m, 2H), 3.61 (t, J= 9.3
Hz, 1H),
3.72 (dd, J= 6.3, 9.6 Hz, 1H), 4.10 - 4.17 (m, 1H), 6.76 (b.s, 1H), 7.19 -
7.28 (m, 5H),
9.01 (s, 1H), 9.01 (s, 2H)
2-[(35,45)-4-benzy1-5-oxo-1-(pyrimidin-5-Apyrrolidin-3-A-N-cyclopropy1-2-
oxoacetamide (FP-90)
[0642] LC-MS (METCR1603): 100% (UV), Rt= 3.44 min, m/z (ES1)= 365.2 [M+H]+

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
100
[0643] LC-MS (CAM-4): 97% (UV), Rt= 10.27 min, 94% ee
[0644] 1H NMR (500 MHz, Chloroform-a) 5 0.51 - 0.66 (m, 2H), 0.80 - 0.93 (m,
2H),
2.70 - 2.78 (m, 1H), 3.05 - 3.14 (m, 1H), 3.27 - 3.35 (m, 2H), 3.61 (t, J= 9.3
Hz, 1H),
3.72 (dd, J= 6.3, 9.6 Hz, 1H), 4.13 (dt, J= 6.6, 9.0 Hz, 1H), 6.76 (b.s, 1H),
7.19 - 7.28
(m, 5H), 9.01 (s, 1H), 9.01 (s, 2H)
2-[(3R,4R)-3-benzy1-4-{[(2-methylpropyl)carbamoyl]carbony11-2-oxopyrrolidin-1-
y1}-N,N-
dimethylacetamide (FP-91) and 2-[(3S,4S)-3-benzy1-4-{[(2-
methylpropyl)carbamoy1]-
carbony1}-2-oxopyrrolidin-1-y1]-N,N-dimethylacetamide (FP-92) ((R,R) and (S,S)
assignments arbitrary)
[0645] Rac-2-[(3R,4R)-3-benzy1-4-{[(2-methylpropyl)carbamoyl]carbony11-2-
oxopyrrolidin-1-A-N,N-dimethylacetamide (FP-44) (97% purity, 58.2 mg, 0.15
mmol)
was purified by chiral separation on Gilson LC [Column: Cellulose-4 (21.2 mm x
250
mm, 5 pm) at RT; Isocratic eluent: MeCN; Flow rate: 9 mL/min; Detector
wavelength;
215 nm; Dilution solvent: MeCN; injection volume:100-1000 pL] to afford 17 mg
of 2-
[(3R,4R)-3-benzy1-4-{[(2-methylpropyl)carbamoyl]carbony1}-2-oxopyrrolidin-1-
y1]-/ViV-
dimethylacetamide as a pale pink solid (100% purity, 100% ee, 30%) and 23 mg
of 2-
[(3S,4S)-3-benzy1-4-{[(2-methylpropyl)carbamoyl]carbonyl}-2-oxopyrrolidin-1-
y1]-/V,/V-
dimethylacetamide as a pale pink glass (97% purity, 94% ee, 39%).
2-[(3S,4S)-3-benzy1-4-{[(2-methylpropyl)carbamoyl]carbony1}-2-oxopyrrolidin-1-
y1]-N,/V-
dimethylacetamide (FP-91)
[0646] LC-MS (METCR1603): 100% (UV), Rt= 3.68 min, m/z (ES1+)= 388.1 [M-FH]-
[0647] LC-MS (CAM-5): 100% (UV), Rt= 21.98 min, 100% ee
[0648] 1H NMR (500 MHz, Chloroform-a) 5 0.87 - 0.92 (m, 6H), 1.71 -1.81 (m,
1H),
2.83 - 2.90 (m, 1H), 2.93 (s, 3H), 2.99 (s, 3H), 3.05 (t, J= 6.6 Hz, 2H), 3.21
- 3.29 (m,
2H), 3.43 (dd, J= 6.8, 9.6 Hz, 1H), 3.55 (t, J= 9.5 Hz, 1H), 3.92 (d, J= 16.1
Hz, 1H),
3.94 - 4.01 (m, 1H),4.21 (d, J= 16.1 Hz, 1H), 6.73 (t, J= 6.6 Hz, 1H), 7.14 -
7.21 (m,
3H), 7.21 - 7.26 (m, 2H)
2-[(3R,4R)-3-benzy1-4-{[(2-methylpropyl)carbamoyl]carbony1}-2-oxopyrrolidin-1-
y1]-/V,N-
dimethylacetamide (FP-92)
[0649] LC-MS (METCR1603): 100% (UV), Rt= 3.68 min, m/z (ES1+)= 388.1 [M+H]4-
[0650] LC-MS (CAM-5): 97% (UV), Rt= 25.34 min, 94% ee
[0651] 1H NMR (500 MHz, Chloroform-a) 5 0.87 - 0.91 (m, 6H), 1.71 - 1.80 (m,
1H),
2.83 - 2.90 (m, 1H), 2.93 (s, 3H), 2.99 (s, 3H), 3.04 (t, J= 6.6 Hz, 2H), 3.21
- 3.28 (m,

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
101
2H), 3.43 (dd, J= 6.8, 9.6 Hz, 1H), 3.55 (t, J= 9.5 Hz, 1H), 3.92 (d, J= 16.1
Hz, 1H),
3.94 ¨ 4.00 (m, 1H), 4.20 (d, J= 16.1 Hz, 1H), 6.70 ¨ 6.78 (m, 1H), 7.14 ¨
7.20 (m,
3H), 7.21 ¨ 7.25 (m, 2H)
2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrazin-2-yl)pyrrolidin-3-y11-N-cyclopropy1-2-oxo-
acetamide (FP-93), and
2-[(3S,4R)-4-benzy1-5-oxo-1-(pyrazin-2-yl)pyrrolidin-3-y1]-/Vcyclopropyl-2-
oxoacetamide (FP-94) ((R,R) and (S,S) assignments arbitrary)
[0652] Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrazin-2-yl)pyrrolidin-3-y1]-N-
cyclopropy1-2-
oxoacetamide (FP-57) (50.0 mg, 0.137 mmol) was purified by chiral separation
on
Gilson LC [Column: Amylose-2 (21.2 mm x 250 mm, 5 pm) at RT; Isocratic eluent:
MeCN; Flow rate: 18 mL/min; Detector wavelength; 215 nm; Dilution solvent:
MeCN;
injection volume:100-1000 pL] to afford 22 mg of 2-[(3R,4R)-4-benzy1-5-oxo-1-
(pyrazin-
2-yl)pyrrolidin-3-y1]-N-cyclopropy1-2-oxoacetamide as a yellow sticky solid
(93% purity,
100% ee, 41%) and 20 mg of 2-[(3S,4R)-4-benzy1-5-oxo-1-(pyrazin-2-
yl)pyrrolidin-3-y11-
N-cyclopropy1-2-oxoacetamide as a yellow sticky solid (100% purity, 100% ee,
40%).
2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrazin-2-yl)pyrrolidin-3-y1]-N-cyclopropy1-2-
oxoacetamide (FP-93)
[0653] LC-MS (METCR1603): 100% (UV), Rt= 3.84 min, m/z (ESI+)= 365.2 [M-FH]+
[0654] LC-MS (CAM-6): 93% (UV), Rt= 4.39 min, 100% ee
[0655] 1H NMR (500 MHz, Chloroform-a) 5 0.52 ¨ 0.60 (m, 2H), 0.81 ¨ 0.91 (m,
2H),
2.69 ¨ 2.75 (m, 1H), 3.00 (dd, J= 8.1, 13.8 Hz, 1H), 3.34 (dd, J= 4.9, 13.7
Hz, 1H),
3.41 (td, J= 4.9, 8.0 Hz, 1H), 3.83 (dd, J= 7.1, 11.3 Hz, 1H), 4.05 (dd, J=
9.2, 11.2
Hz, 1H), 4.09 ¨ 4.18 (m, 1H), 6.69 (s, 1H), 7.17 ¨7.22 (m, 3H), 7.22 ¨7.25 (m,
2H),
8.27 (dd, J= 1.6, 2.6 Hz, 1H), 8.32 (d, J= 2.6 Hz, 1H), 9.74 (d, J= 1.5 Hz,
1H)
2-[(3S,4S)-4-benzy1-5-oxo-1-(pyrazin-2-yl)pyrrolidin-3-y1]-N-cyclopropy1-2-
oxoacetamide (FP-94)
[0656] LC-MS (METCR1603): 100% (UV), Rt= 3.82 min, m/z (ESI+)= 365.2 [M+H].
[0657] LC-MS (CAM-6): 100% (UV), Rt= 7.84 min, 100% ee
[0658] 1H NMR (500 MHz, Chloroform-a) 5 0.50 ¨ 0.62 (m, 2H), 0.78 ¨ 0.92 (m,
2H),
2.68 ¨ 2.75 (m, 1H), 3.00 (dd, J= 8.1, 13.8 Hz, 1H), 3.34 (dd, J= 4.9, 13.8
Hz, 1H),
3.38¨ 3.44 (m, 1H), 3.83 (dd, J= 7.1, 11.3 Hz, 1H), 4.05 (dd, J= 9.2, 11.2 Hz,
1H),
4.10 ¨ 4.17 (m, 1H), 6.69 (s, 1H), 7.17 ¨ 7.22 (m, 3H), 7.22 ¨ 7.26 (m, 2H),
8.27 (dd, J
= 1.6, 2.5 Hz, 1H), 8.32 (d, J= 2.6 Hz, 1H), 9.74 (d, J= 1.4 Hz, 1H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
102
2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1FN-(2,2-
difluoropropy1)-2-
oxoacetamide (FP-95), and
2-[(3S,4S)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1]-N-(2,2-
difluoropropy1)-2-
oxoacetamide (FP-96) ((R,R) and (S,S) assignments arbitrary)
[0659] Rac-2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1]-N-(2,2-
difluoropropy1)-2-oxoacetamide (FP-56) (83 mg, 0.21 mmol) was purified by
chiral
separation on Gilson LC [Column: Cellulose-4 (21.2 mm x 250 mm, 5 pm) at RT;
Isocratic eluent: MeCN; Flow rate: 10 mL/min; Detector wavelength; 215 nm;
Dilution
solvent: MeCN; injection volume:100-1000 pL] to afford 18 mg of 2-[(3R,4R)-4-
benzy1-
5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-ylj-N-(2,2-difluoropropy1)-2-oxoacetamide
as a
yellow sticky solid (98% purity, 100% ee, 21%) and 16 mg of 2-[(3S,4S)-4-
benzy1-5-
oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1]-N-(2,2-difluoropropy1)-2-oxoacetamide
as a yellow
sticky solid (92% purity, 84% ee, 18%).
2-[(3R,4R)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-y1j-N-(2,2-
difluoropropy1)-2-
oxoacetamide (FP-95)
[0660] LC-MS (METCR1603): 98% (UV), Rt= 1.53 min, m/z (ESII= 403.1 [M+H]+
[0661] LC-MS (CAM-5): 100% (UV), Rt= 10.16 min, 100% ee
[0662] 1H NMR (500 MHz, Chloroform-0 6 1.63 (t, J= 18.4 Hz, 3H), 3.04 -3.13
(m,
1H), 3.27 - 3.36 (m, 2H), 3.56 - 3.71 (m, 3H), 3.73 (dd, J= 6.4, 9.6 Hz, 1H),
4.13 (dt, J
= 6.5, 8.9 Hz, 1H), 7.03 (t, J= 5.9 Hz, 1H), 7.17 - 7.28 (m, 5H), 9.01 (s, 3H)
2-[(3S,4S)-4-benzy1-5-oxo-1-(pyrimidin-5-yl)pyrrolidin-3-ylj-N-(2,2-
difluoropropy1)-2-
oxoacetamide D3801 (FP-96)
[0663] LC-MS (METCR1603): 100% (UV), Rt= 1.54 min, m/z (ESI+)= 403.1 [M+H]
[0664] LC-MS (CAM-5): 92% (UV), Rt= 12.54 min, 84% ee
[0665] 1H NMR (500 MHz, Chloroform-o) 6 1.63 (t, J= 18.4 Hz, 3H), 3.03 -3.13
(m,
1H), 3.26 - 3.37 (m, 2H), 3.59 - 3.77 (m, 4H), 4.13 (dt, J= 6.6, 8.9 Hz, 1H),
7.03 (t, J=
6.0 Hz, 1H), 7.17 - 7.29 (m, 5H), 8.99 - 9.03 (m, 3H)
2-[(3S,4S)-4-benzy1-1-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-5-oxopyrrolidin-
3-y1]-N-
cyclopropy1-2-oxoacetamide (FP-97), and
2-[(3R,4R)-4-benzy1-1-[(1-methy1-1H-1,2,4-triazol-5-y1)methyl]-5-oxopyrrolidin-
3-y1]-N-
cyclopropy1-2-oxoacetamide (FP-98) ((R,R) and (S,S) assignments arbitrary)
[0666] Rac-2-[(3R,4R)-4-benzy1-1-[(1-methyl-1H-1,2,4-triazol-5-y1)methyl]-5-
oxopyrrolidin-3-y1]-N-cyclopropy1-2-oxoacetamide (FP-42) (98% purity, 63 mg,
0.16

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
103
mmol) was purified by chiral separation on Gilson LC [Column: Cellulose-4
(21.2 mm x
250 mm, 5 pm) at RT; Isocratic eluent: MeCN; Flow rate: 10 mL/min; Detector
wavelength; 215 nm; Dilution solvent: MeCN, injection volume:100-1000 pL] to
afford
mg of 2-[(3S,4S)-4-benzy1-1-[(1-methyl-1H-1,2,4-triazol-5-Amethyl]-5-
oxopyrrolidin-
3-ylj-N-cyclopropy1-2-oxoacetamide as a pale yellow viscous oil (95% purity by
1H
NMR, 100% ee, 15%) and 9 mg of 2-[(3R,4R)-4-benzy1-1-[(1-methyl-1H-1,2,4-
triazol-5-
yl)methyl]-5-oxopyrrolidin-311j-N-cyclopropy1-2-oxoacetamide as a pale yellow
viscous
oil (95% purity by 1H NMR, 96% ee, 14%).
2-[(3S,4S)-4-benzy1-1-[(1-methyl-1H-1 ,2,4-triazol-5-yl)methyl]-5-
oxopyrrolidin-3-ylj-N-
cyclopropy1-2-oxoacetamide (FP-97)
[0667] LC-MS (METCR1603): 100% (UV), Rt= 3.16 min, m/z (ESI)= 382.2 [M+H]+
[0668] LC-MS (CAM-5): 97% (UV), Rt= 15.83 min, 100% ee
[0669] 1H NMR (500 MHz, Chloroform-0 6 0.50 - 0.57 (m, 2H), 0.80 - 0.86 (m,
2H),
2.66 - 2.73 (m, 1H), 2.96 (dd, J= 7.1, 13.6 Hz, 1H), 3.05 - 3.10 (m, 1H), 3.15
- 3.26
(m, 3H), 3.87 (s, 3H), 3.93 - 3.98 (m, 1H), 4.53 (d, J= 15.2 Hz, 1H), 4.59 (d,
J= 15.2
Hz, 1H), 6.74 (s, 1H), 7.12 - 7.16 (m, 2H), 7.16 - 7.21 (m, 3H), 7.76 (s, 1H)
2-[(3R,4R)-4-benzy1-1-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-5-oxopyrrolidin-
3-ylj-N-
cyclopropy1-2-oxoacetamide (FP-98)
[0670] LC-MS (METCR1603): 100% (UV), Rt= 3.17 min, m/z (ESI)= 382.2 [M+H]
[0671] LC-MS (CAM-5): 94% (UV), Rt= 21.13 min, 96% ee
[0672] 1H NMR (500 MHz, Chloroform-0 6 0.51 - 0.56 (m, 2H), 0.80 - 0.86 (m,
2H),
2.66 - 2.73 (m, 1H), 2.96 (dd, J= 7.1, 13.6 Hz, 1H), 3.04 - 3.10 (m, 1H), 3.16
- 3.26
(m, 3H), 3.87 (s, 3H), 3.93 - 3.98 (m, 1H), 4.53 (d, J= 15.2 Hz, 1H), 4.59 (d,
J= 15.3
Hz, 1H), 6.74 (s, 1H), 7.12 - 7.16 (m, 2H), 7.16 - 7.23 (m, 3H), 7.76 (s, 1H)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
104
GENERAL SCHEME 4:
N R2
ci I I 0 '1HrHa
0
-..dudion A Deprotectlon I R0)....nr..'R Reducdve amlnaton
it
R3 0 General procedure 1 R3 0 General procedure 2a
o R3
AND EN/U.1710MR
Ft= Me, Et
IReduclon
General procedure 3
.-1 72 72
I. recb/I 0
0
R.....r
N-Substitubon, N.---- . Reduction
0 R3 General procedure 2b E-T- General procedure 3
0 R3 OH R3
R= Me, Et
AND ENARTIOMER AND ENAR710MER
Oxidation
Reducton General procedure 4
General procedure 3
R2= H
IleCiN72
Ozdaton 8, Passerini
H 0 reaction
General procedure 6
0 /1.3
AND ENANTIOMER
IRasserini reaction
General procedure 5
72 72
..... ...lirCz 0 Ri 0 .1 __
RI 0 4 N . Deprolection &
''N)11110.
H 7:- Oxidalon H a
0 F.13 General procedure? OAc W3
AND ENANTIOMER AND ENANTIONER
GENERAL PROCEDURE 1 (GENERAL SCHEME 4): Reduction & Deprotection
1,4-Diethyl 2-(aminomethyl)-3-phenylbutanedioate hydrochloride (1-107)
[0673] To a solution of 1,4-diethyl 2-cyano-3-phenylbutanedioate (1-6) (20 g,
67.56
mmol) in Et0H (600 mL) cooled at 0 00 was added Boc20 (36.9 g, 168.9 mmol) and
NiC12.6H20 (24.1 g, 101.34 mmol) followed by NaBF14 (25.6 g, 675.6 mmol)
portionwise over 2 min. The reaction was stirred at RT for 1 h, cooled to 10
0C and
ethylene diamine (50 mL) added. The mixture was stirred at 10 00 for 1 h, sat.
NaHCO3 (200 mL) added and the mixture stirred at RT for 10 min. The suspension
was diluted with Et0Ac (200 mL) and ethylene diamine (100 mL), stirred at RT
until a
purple solution was obtained. Brine (200 mL) was added and the phases
separated.
The aqueous layer was extracted with Et0Ac (3 x 300 mL) and the combined
organic
extracts were washed with brine (2 x 200 mL), dried over MgSO4 and
concentrated in

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
105
vacuo. The orange oil was dissolved in 4N HCI in 1,4-dioxane (100 mL, 400
mmol) and
stirred at RT for 18 h. The resulting precipitate was filtered off to afford
7.66 g of 1,4-
diethyl 2-(aminomethyl)-3-phenylbutanedioate hydrochloride as an off-white
solid
(100% purity, 36%) which was used in the next step without further
purification.
[0674] LC-MS (METCR0990): 100% (UV), Rt= 1.59 min, m/z (ESI)= 280.2 [M+H]4-
GENERAL PROCEDURE 2a (GENERAL SCHEME 4): Reductive amination
Rac-ethyl (3R,4R)-1-benzy1-5-oxo-4-phenylpyrrolidine-3-carboxylate (1-108)
[0675] A suspension of 1,4-diethyl 2-(aminomethyl)-3-phenylbutanedioate
hydrochloride (1-6) (500 mg, 1.58 mmol) and benzaldehyde (168 mg, 1.58 mmol)
in
1,2-DCE (10 mL) was stirred for 5 min then STAB (671 mg, 3.18 mmol) was added
in
one portion and the mixture stirred at RT for 18 h. Sat. NaHCO3 (20 mL) and
DCM (20
mL) were added and the phases separated. The aqueous phase was extracted with
DCM (3 x 15 mL) and the combined organic phases washed with brine (30 mL),
dried
over MgSO4 and concentrated in vacuo. The residue was purified by FCC on
normal
phase silica (25 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient) to
afford 153 mg of rac-ethyl (3R,4R)-1-benzy1-5-oxo-4-phenylpyrrolidine-3-
carboxylate
as an off-white solid (92% purity, 27%).
[0676] LC-MS (METCR1410): 92% (UV), Rt= 1.13 min, m/z (ES14-)= 324.0 [M+H]+
[0677] 1H NMR (500 MHz, Chloroform-o) 6 0.81 (t, J= 7.2 Hz, 3H), 3.36 ¨ 3.44
(m,
1H), 3.53 ¨ 3.59 (m, 1H), 3.59 ¨ 3.67 (m, 1H), 3.67 ¨ 3.73 (m, 1H), 3.75 ¨
3.82 (m, 1H),
4.05 (d, J= 10.2 Hz, 1H), 4.49 (d, J= 14.6 Hz, 1H), 4.68 (d, J= 14.6 Hz, 1H),
7.07 ¨
7.13 (m, 2H), 7.19 ¨ 7.28 (m, 3H), 7.28 ¨ 7.43 (m, 5H)
GENERAL PROCEDURE 2b (GENERAL SCHEME 4): N-Substitution on ester
Method A: N-Alkylation using NaH in DMF
Rac-ethyl (3R,4S)-1-[(5-methy1-1,2-oxazol-3-yl)methyl]-5-oxo-4-
phenylpyrrolidine-3-
carboxylate (1-109)
[0678] To a solution of ethyl 5-oxo-4-phenylpyrrolidine-3-carboxylate (1-17)
(500 mg,
2.14 mmol) in DMF (4 mL) cooled at 0 0C was added NaH (60% in mineral oil, 103
mg,
2.57 mmol) portionwise. 3-(Bromomethyl)-5-methyl-1,2-oxazole (215 mg, 2.36
mmol)
was added and the mixture stirred at 0 0C for 30 min then at RT for 30 min.
The
reaction was quenched with Me0H (5 mL), diluted with 1M HCI (5 mL) and the
aqueous layer extracted with DCM (3 x 20 mL). The combined organic extracts
were
concentrated in vacuo and the residue purified by preparative LC (acidic pH,
early

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
106
elution method) to afford 401 mg of rac-ethyl (3R,4S)-1-[(5-methy1-1,2-oxazol-
3-
y1)methyl]-5-oxo-4-phenylpyrrolidine-3-carboxylate as a colourless viscous oil
(99%
purity, 56%).
[0679] LC-MS (METCR1410): 99% (UV), Rt= 1.08 min, rn/z (ESI+)= 329.0 [M+H]-
[0680] 1H NMR (500 MHz, Chloroform-o) 6 1.21 (t, J= 7.1 Hz, 3H), 2.42 (d, J=
0.8
Hz, 3H), 3.24 - 3.31 (m, 1H), 3.55 (dd, J= 7.7, 9.9 Hz, 1H), 3.70 (dd, J= 9.0,
9.8 Hz,
1H), 4.02 (d, J= 8.7 Hz, 1H), 4.11 -4.19 (m, 2H), 4.55 (d, J= 15.1 Hz, 1H),
4.60 (d, J
= 15.1 Hz, 1H), 5.98 (d, J= 0.8 Hz, 1H), 7.21 -7.26 (m, 2H), 7.26 - 7.32 (m,
1H), 7.32
- 7.38 (m, 2H)
Method B: N-Alkylation using NaH in THF followed by hydrolysis and methyl
ester
formation
Rac-ethyl (3R,4S)-1-[(4-methoxyphenyl)methy1]-5-oxo-4-phenylpyrrolidine-3-
carboxylate (1-110)
[0681] To a solution of ethyl 5-oxo-4-phenylpyrrolidine-3-carboxylate (1-17)
(1 g, 4.29
mmol) in THF (30 mL) cooled at 0 00 was added NaH (60% in mineral oil, 343 mg,
8.57 mmol) portionwise and the suspension stirred at 000 for 30 min. 1-
(chloromethyl)-
4-methoxybenzene (786 4, 4.716 mmol) was added dropwise at 0 00 over 10 min
and
the mixture stirred at RT for 1 h. The reaction was quenched with water (10
mL) then
2M NaOH (20 mL) was added and the mixture heated at 50 00 for 2 h. THF was
removed in vacuo and the suspension acidified to pH -3 with 2M HCI then
extracted
with DCM (3 x 20 mL). The combined organic extracts were washed with brine (30
mL), dried over MgSO4, filtered and concentrated in vacuo. The resulting solid
was
dissolved in Me0H (20 mL) and conc. H2SO4 (100 4) added. The solution was
heated
at 60 00 for 1 h then concentrated in vacuo. The residue was purified by FCC
on
normal phase silica (25 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane
gradient)
to afford 350 mg of rac-ethyl (3R,45)-1-[(4-methoxyphenyl)methy1]-5-oxo-4-
phenylpyrrolidine-3-carboxylate as a yellow viscous oil (98% purity, 24%).
[0682] LC-MS (METCR1410): 98% (UV), Rt= 1.11 min, m/z (ES14-)= 340.1 [M-FH]-
[0683] 1H NMR (500 MHz, Chloroform-a) 6 3.22 - 3.31 (m, 1H), 3.43 - 3.50 (m,
1H),
3.54 - 3.58 (m, 1H), 3.70 (s, 3H), 3.84 (s, 3H), 4.07 (d, J= 8.7 Hz, 1H), 4.44
(d, J=
14.5 Hz, 1H), 4.59 (d, J= 14.5 Hz, 1H), 6.89 - 6.93 (m, 2H), 7.20 - 7.33 (m,
5H), 7.33
- 7.41 (m, 2H)
GENERAL PROCEDURE 3 (GENERAL SCHEME 4): Reduction

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
107
Rac-(3R,4S)-1-benzy1-4-(hydroxymethyl)-3-phenylpyrrolidin-2-one (1-111)
[0684] To a solution of rac-ethyl (3R,4R)-1-benzy1-5-oxo-4-phenylpyrrolidine-3-
carboxylate (1-108) (140 mg, 0.43 mmol) in Et0H (10 mL) was added NaBH4 (33
mg,
0.87 mmol) and the mixture stirred at RT for 18 h. The reaction was quenched
with
water (10 mL) and extracted with Et0Ac (3 x 20 mL). The combined organic
extracts
were washed with brine (20 mL), dried over MgSO4, filtered and concentrated in
vacuo
to afford 118 mg of rac-(3R,4S)-1-benzy1-4-(hydroxymethyl)-3-phenylpyrrolidin-
2-one
as a viscous colourless oil (89% purity, 86%).
[0685] LC-MS (METCR1410): 89% (UV), Rt= 1.02 min, m/z (ES14-)= 282.5 [M+H]4-
[0686] 1H NMR (500 MHz, Chloroform-a) 5 2.39 ¨ 2.55 (m, 2H), 3.17 (dd, J= 7.1,
9.9
Hz, 1H), 3.39 (dd, J= 8.2, 9.9 Hz, 1H), 3.51 (dd, J= 4.0, 9.5 Hz, 2H), 3.60
(dd, J= 4.7,
10.7 Hz, 1H), 4.42 (d, J= 14.6 Hz, 1H), 4.61 (d, J= 14.6 Hz, 1H), 7.16 ¨ 7.20
(m, 2H),
7.21 ¨ 7.39 (m, 8H)
Rac-(3R,4S)-4-(hydroxymethyl)-1-[(5-methy1-1,2-oxazol-3-y1)methyl]-3-
phenylpyrrolidin-2-one (1-112)
[0687] The title compound was synthesized from rac-ethyl (3R,4S)-1-[(5-methy1-
1,2-
oxazol-3-y1)methyl]-5-oxo-4-phenylpyrrolidine-3-carboxylate (1-109) in a
similar manner
to general procedure 3 (general scheme 4) as a viscous colourless oil (197 mg,
97%
purity, 57%) after purification by preparative LC (acidic pH, early elution
method).
[0688] LC-MS (METCR1410): 97% (UV), Rt= 0.91 min, m/z (ES14-)= 287.1 [M+H]
[0689] 1H NMR (500 MHz, Chloroform-a) 5 2.42 (d, J= 0.8 Hz, 3H), 2.47 ¨ 2.57
(m,
1H), 2.92 (s, 1H), 3.31 (dd, J= 7.0, 9.7 Hz, 1H), 3.51 ¨3.58 (m, 3H), 3.63
(dd, J= 4.4,
10.9 Hz, 1H), 4.50 ¨ 4.59 (m, 2H), 5.98 (d, J= 0.7 Hz, 1H), 7.13 ¨ 7.23 (m,
2H), 7.23 ¨
7.28 (m, 1H), 7.29 ¨ 7.37 (m, 2H)
Rac-(3R,4S)-4-(hydroxymethyl)-1-[(4-methoxyphenyl)methy1]-3-phenylpyrrolidin-2-
one
(1-113)
[0690] The title compound was synthesized from rac-ethyl (3R,4S)-1-[(4-
methoxyphenyl)methy1]-5-oxo-4-phenylpyrrolidine-3-carboxylate (1-110) in a
similar
manner to general procedure 3 (general scheme 4) as a viscous colourless oil
(320
mg, 98% purity by 1H NMR, 98%) after work-up and used in the next step without
further purification.
[0691] LC-MS (METCR1410): 83% (UV), Rt= 1.01 min, m/z (ES14-)= 312.1 [M+H]

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
108
[0692] 1H NMR (500 MHz, Chloroform-a) 62.06 (s, 1H), 2.49 -2.60 (m, 1H), 3.21
(dd,
J= 9.9, 7.1 Hz, 1H), 3.47 (dd, J= 9.8, 8.3 Hz, 1H), 3.56 (d, J= 8.3 Hz, 1H),
3.63 (dd, J
= 10.7, 6.8 Hz, 1H), 3.73 (dd, J= 10.8, 4.7 Hz, 1H), 3.87 (s, 3H), 4.44 (d, J=
14.4 Hz,
1H), 4.60 (d, J= 14.4 Hz, 1H), 6.94 (d, J= 8.6 Hz, 2H), 7.22 - 7.34 (m, 5H),
7.35 -
7.44 (m, 2H)
Rac-(3R,4S)-4-(hydroxymethyl)-3-phenylpyrrolidin-2-one (1-114)
[0693] The title compound was synthesized from ethyl 5-oxo-4-phenylpyrrolidine-
3-
carboxylate (1-17) in a similar manner to general procedure 3 (general scheme
4) as an
off-white solid (1.27 g, 95% purity, 92%) after work-up and used in the next
step
without further purification.
[0694] LC-MS (METCR1410): 95% (UV), Rt= 0.67 min, m/z (ES14-)= 192.3 [M+H].#
[0695] 1H NMR (500 MHz, Methanol-d4) 5 2.57 - 2.66 (m, 1H), 3.28 - 3.36 (m,
2H),
3.49 (d, J= 8.7 Hz, 1H), 3.54 - 3.61 (m, 2H), 3.65 (dd, J= 4.7, 11.1 Hz, 1H),
7.22 -
7.29 (m, 3H), 7.31 - 7.37 (m, 2H)
GENERAL PROCEDURE 4 (GENERAL SCHEME 4): Oxidation
Rac-(3R,4S)-1-[(4-methoxyphenyl)methyI]-5-oxo-4-phenylpyrrolidine-3-
carbaldehyde
(1-115)
[0696] To a solution of rac-(3R,4S)-4-(hydroxymethyl)-1-[(4-
methoxyphenyl)methy1]-3-
phenylpyrrolidin-2-one (1-113) (280 mg, 0.90 mmol) in DCM (20 mL) was added
DMP
(458 mg, 1.08 mmol) and the suspension stirred at RT for 3 h. Further DMP (458
mg,
1.08 mmol) was added and the mixture stirred at RT for 18 h. The suspension
was
then concentrated in vacuo, diluted with Et0Ac (20 mL) and washed with sat.
NaHCO3
(10 mL) and 1M Na2S03 (10 mL). The aqueous phase was extracted with Et0Ac (3 x
mL) and the combined organic extracts washed with brine (20 mL), dried over
MgSO4 and concentrated in vacuo to afford 290 mg of rac-(3R,4S)-1-[(4-methoxy-
phenyl)methy1]-5-oxo-4-phenylpyrrolidine-3-carbaldehyde as an off-white
crystalline
solid (95% purity by 1H NMR, 99%).
[0697] 1H NMR (500 MHz, Chloroform-a) 5 3.22 - 3.31 (m, 1H), 3.50 (dd, J= 8.7,
10.2 Hz, 1H), 3.57 (dd, J= 6.3, 10.3 Hz, 1H), 3.81 (s, 3H), 3.99 (d, J= 7.4
Hz, 1H),
4.40 (d, J= 14.5 Hz, 1H), 4.57 (d, J= 14.5 Hz, 1H), 6.86 - 6.92 (m, 2H), 7.19 -
7.22
(m, 2H), 7.22 - 7.25 (m, 2H), 7.27 - 7.32 (m, 1H), 7.32 - 7.39 (m, 2H), 9.73
(d, J= 1.0
Hz, 1H)
GENERAL PROCEDURE 5 (GENERAL SCHEME 4): Passerini reaction

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
109
Rac-(cyclopropylcarbamoy1)[(3R,4S)-1-[(4-methoxyphenyl)methyl]-5-oxo-4-
phenylpyrrolidin-3-yl]methyl acetate (1-116)
[0698] To a solution of rac-(3R,4S)-1-[(4-methoxyphenyl)methy1]-5-oxo-4-
phenylpyrrolidine-3-carbaldehyde (1-115) (92 mg, 0.30 mmol) in DCM (5 mL) was
added cyclopropylisocyanide (18 mg, 0.26 mmol) and the reaction stirred at RT
for 5
min. Glacial acetic acid (23 4, 0.52 mmol) was added and the mixture stirred
at RT for
1 h. Sat. NaHCO3 (10 mL) was added and the aqueous phase extracted with DCM (3
x
mL). The combined organic extracts were washed with sat. NaHCO3 (10 mL) and
brine (20 mL), dried over MgSO4 and concentrated in vacuo. The residue was
purified
by FCC on normal phase silica (25 g SNAP KP-SIL cartridge, 0-100% Et0Ac in
heptane gradient) to afford 86 mg of rac-(cyclopropylcarbamoy1)[(3R,4S)-1-[(4-
methoxyphenyl)methyl]-5-oxo-4-phenylpyrrolidin-3-yl]methyl acetate as as
colourless
viscous oil (92% purity, 69%).
[0699] LC-MS (METCR1410): 92% (UV), Rt= 1.06 min, m/z (ES14-)= 437.2 [M+H].
[0700] 1H NMR (500 MHz, Chloroform-a) 6 0.27 - 0.39 (m, 2H), 0.65 - 0.73 (m,
2H),
2.11 (s, 3H), 2.49 - 2.53 (m, 1H), 2.88 - 2.95 (m, 1H), 3.20 (dd, J= 7.0, 10.4
Hz, 1H),
3.31 -3.36 (m, 1H), 3.49 - 3.53 (m, 1H), 3.83 (s, 3H), 4.33 (dd, J= 10.4, 14.4
Hz, 1H),
4.61 (d, J= 14.5 Hz, 1H), 5.10 (d, J= 4.2 Hz, 1H), 6.35 (s, 1H), 6.87 - 6.93
(m, 2H),
7.13 -7.18 (m, 2H), 7.19 - 7.24 (m, 2H), 7.24 - 7.30 (m, 1H), 7.30 - 7.37 (m,
2H)
GENERAL PROCEDURE 6 (GENERAL SCHEME 4): Oxidation & Passerini reaction
Rac-R3R,45)-1-benzy1-5-oxo-4-phenylpyrrolidin-3-ylycyclopropylcarbamoyl)methyl

acetate (1-117)
[0701] To a solution of rac-(3R,45)-1-benzy1-4-(hydroxymethyl)-3-
phenylpyrrolidin-2-
one (1-111) (99 mg, 0.352 mmol) in DCM (10 mL) was added DMP (224 mg, 0.53
mmol) and the suspension stirred at RT for 2 h. Cyclopropylisocyanide (28 mg,
0.42
mmol) was then added and the reaction stirred at RT for 1 h. The mixture was
filtered
and the filtrate washed successively with sat. NaHCO3 (2 x 10 mL), 1M Na2S203
(10
mL) and brine (10 mL) then dried over MgSO4, filtered and concentrated in
vacuo. The
residue was purified by FCC on normal phase silica (25 g SNAP KP-SIL
cartridge, 0-
100% Et0Ac in heptane gradient followed by 0-50% Me0H in Et0Ac gradient) to
afford 126 mg of rac-R3R,45)-1-benzy1-5-oxo-4-phenylpyrrolidin-3-
ylycyclopropyl-
carbamoyl)methyl acetate as an off-white solid (43% purity, 38%).
[0702] LC-MS (METCR1410): 43% (UV), Rt= 1.06 min, m/z (ES14-)= 407.1 [M+H]4-

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
110
Rac-(cyclopropylcarbamoy1)[(3R,4S)-1-[(5-methyl-1,2-oxazol-3-y1)methyl]-5-oxo-
4-
phenylpyrrolidin-3-yl]methyl acetate (1-118)
[0703] The title compound was synthesized from rac-(3R,4S)-4-(hydroxymethyl)-1-
[(5-
methyl-1,2-oxazol-3-yl)methyl]-3-phenylpyrrolidin-2-one (1-112) in a similar
manner to
general procedure 6 (general scheme 4) as a viscous colourless oil (127 mg,
61%
purity, 47%) after purification by FCC on normal phase silica (25 g SNAP KP-
SIL
cartridge, 0-100% Et0Ac in heptane gradient).
[0704] LC-MS (METCR1410): 61% (UV), Rt= 0.97 min, m/z (ES14-)= 412.1 [M-FH]4-
[0705] 1H NMR (500 MHz, Chloroform-o) 6 0.30 - 0.44 (m, 2H), 0.68 - 0.77 (m,
2H),
1.94 - 2.13 (m, 3H), 2.41 -2.43 (m, 3H), 2.53 - 2.63 (m, 1H), 2.97 - 3.12 (m,
1H), 3.33
- 3.55 (m, 2H), 3.59 - 3.71 (m, 1H), 4.41 - 4.67 (m, 2H), 5.14 - 5.25 (m, 1H),
5.93 -
5.98 (m, 1H), 6.14 - 6.25 (m, 1H), 7.12 - 7.19 (m, 2H), 7.23 - 7.29 (m, 1H),
7.31 -7.36
(m, 2H)
Rac-R3R,45)-1-[(5-methy1-1,2-oxazol-3-yl)methyl]-5-oxo-4-phenylpyrrolidin-3-
yl][(propan-2-yl)carbamoyl]methyl acetate (1-119)
[0706] The title compound was synthesized from rac-(3R,45)-4-(hydroxymethyl)-1-
[(5-
methy1-1,2-oxazol-3-Amethyl]-3-phenylpyrrolidin-2-one (1-112) in a similar
manner to
general procedure 6 (general scheme 4) as a viscous colourless oil (31 mg, 87%
purity, 41%) after purification by FCC on normal phase silica (10 g SNAP Ultra
cartridge, 0-100% Et0Ac in heptane gradient).
[0707] LC-MS (METCR1410): 87% (UV), Rt= 1.01 min, m/z (ES14-)= 414.2 [M+H].
[0708] 1H NMR (500 MHz, Chloroform-o) 6 1.04 - 1.10 (m, 6H), 1.94 - 2.13 (m,
3H),
2.38 - 2.42 (m, 3H), 2.96 - 3.12 (m, 1H), 3.34 - 3.53 (m, 2H), 3.57 - 3.72 (m,
1H), 3.88
-4.00 (m, 1H), 4.41 -4.66 (m, 2H), 5.14 -5.24 (m, 1H), 5.87 (dd, J= 7.8, 33.9
Hz,
1H), 5.93 - 5.97 (m, 1H), 7.12 - 7.19 (m, 2H), 7.27 - 7.36 (m, 3H)
Rac-(butylcarbamoyI)[(3R,4S)-5-oxo-4-phenylpyrrolidin-3-yl]methyl acetate (1-
120)
[0709] The title compound was synthesized from rac-(3R,45)-4-(hydroxymethyl)-3-
phenylpyrrolidin-2-one (1-114) in a similar manner to general procedure 6
(general
scheme 4) as an off-white solid (297 mg, 100% purity, 43%) after purification
by FCC
on normal phase silica (25 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane
gradient followed by 0-50% Me0H in Et0Ac gradient).
[0710] LC-MS (METCR1410): 100% (UV), Rt= 1.45 min, m/z (ES14-)= 333.2 [M+H]

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
111
[0711] 1H NMR (500 MHz, Chloroform-a) 6 0.83 ¨ 0.92 (m, 3H), 1.20 ¨ 1.31 (m,
2H),
1.32¨ 1.44 (m, 2H), 1.93 ¨ 2.18 (m, 3H), 3.02 ¨ 3.24 (m, 3H), 3.27 ¨ 3.61 (m,
3H), 5.13
¨5.38 (m, 1H), 6.09 ¨ 6.22 (m, 1H), 6.98 ¨ 7.07 (m, 1H), 7.15 ¨ 7.21 (m, 2H),
7.22 ¨
7.29 (m, 1H), 7.30 ¨ 7.36 (m, 2H)
GENERAL PROCEDURE 7 (GENERAL SCHEME 4): Deprotection & Oxidation
Rac-2-[(3R,4S)-1-benzy1-5-oxo-4-phenylpyrrolidin-3-y1]-N-cyclopropy1-2-
oxoacetamide
(FP-99)
[0712] To a solution of rac-R3R,4S)-1-benzy1-5-oxo-4-phenylpyrrolidin-3-
ylycyclo-
propylcarbamoyl)methyl acetate (I-117)(43% purity, 126 mg, 0.13 mmol) in Me0H
(2
mL) was added K2CO3 (50 mg, 0.362 mmol) and the mixture stirred at RT for 30
min.
The suspension was filtered and the filtrate concentrated in vacuo. The
residue was
dissolved in DCM (5 mL) and DMP (224 mg, 0.53 mmol) added. The suspension was
stirred at RT for 5 h then sat. NaHCO3 (10 mL) was added and the phases
separated.
The aqueous layer was extracted with DCM (3 x 20 mL) and the combined organic
phases washed sequentially with sat. NaHCO3 (20 mL), 1M Na2S203 (20 mL) and
brine (30 mL) then dried over MgSO4, filtered and concentrated in vacuo. The
residue
was purified by FCC on normal phase silica (25 g SNAP KP-SIL cartridge, 0-100%
Et0Ac in heptane gradient) followed by preparative LC (basic pH, early elute
method)
to afford 10 mg of rac-2-[(3R,45)-1-benzy1-5-oxo-4-phenylpyrrolidin-3-y1]-N-
cyclopropy1-2-oxoacetamide as a colourless viscous oil (97% purity, 21%).
[0713] LC-MS (METCR1603): 97% (UV), Rt= 4.03 min, m/z (ESI+)= 363.1 [M-FH]-
[0714] 1H NMR (500 MHz, Chloroform-o) 6 0.52 ¨ 0.58 (m, 2H), 0.78 ¨ 0.85 (m,
2H),
2.67 ¨ 2.75 (m, 1H), 3.22 ¨ 3.28 (m, 1H), 3.80 ¨ 3.85 (m, 1H), 4.11 ¨4.17 (m,
2H), 4.50
(d, J= 14.6 Hz, 1H), 4.59 (d, J= 14.6 Hz, 1H), 6.94 (s, 1H), 7.24 ¨7.28 (m,
5H), 7.29 ¨
7.37 (m, 5H)
Rac-N-cyclopropy1-2-1(3R,4S)-1-[(5-methy1-1,2-oxazol-3-yl)methyl]-5-oxo-4-
phenylpyrrolidin-3-yI]-2-oxoacetamide (FP-100)
[0715] The title compound was synthesized from rac-
(cyclopropylcarbamoy1)[(3R,45)-
1-[(5-methyl-1,2-oxazol-3-yl)methyl]-5-oxo-4-phenylpyrrolidin-3-yl]methyl
acetate (I-
118) in a similar manner to general procedure 7 (general scheme 4) as an off-
white
solid (32 mg, 100% purity, 45%) after purification by FCC on normal phase
silica (10 g
SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient) and further washes
with 1M
Na2S203.

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
112
[0716] LC-MS (METCR1603): 100% (UV), Rt= 3.49 min, m/z (ES14-)= 368.1 [M+H]
[0717] 1H NMR (500 MHz, Chloroform-a) 6 0.52 - 0.63 (m, 2H), 0.78 - 0.88 (m,
2H),
2.42 (d, J= 0.7 Hz, 3H), 2.71 -2.78 (m, 1H), 3.39 (dd, J= 6.8, 10.2 Hz, 1H),
3.91 -
3.97(m, 1H), 4.09 (d, J= 7.6 Hz, 1H), 4.17 - 4.23 (m, 1H), 4.54 (d, J= 15.2
Hz, 1H),
4.60 (d, J= 15.2 Hz, 1H), 5.97 (d, J= 0.8 Hz, 1H), 6.94 (s, 1H), 7.23 - 7.29
(m, 3H),
7.31 - 7.37 (m, 2H)
Rac-2-[(3R,4S)-1-[(5-methy1-1,2-oxazol-3-yl)methyl]-5-oxo-4-phenylpyrrolidin-3-
y1]-2-
oxo-N-(propan-2-yl)acetamide (FP-101)
[0718] The title compound was synthesized from rac-R3R,4S)-1-[(5-methy1-1,2-
oxazol-3-yl)methyl]-5-oxo-4-phenylpyrrolidin-3-yl][(propan-2-
yl)carbamoyl]methyl
acetate (1-119) in a similar manner to general procedure 7 (general scheme 4)
as an
off-white solid (16 mg, 100% purity, 69%) after purification by FCC on normal
phase
silica (10 g SNAP Ultra cartridge, 0-100% Et0Ac in heptane gradient).
[0719] LC-MS (METCR1603): 100% (UV), Rt= 3.76 min, m/z (ES1+)= 370.1 [M-FH]4-
[0720] 1H NMR (500 MHz, Chloroform-o) 6 1.15 - 1.21 (m, 6H), 2.42 (d, J= 0.6
Hz,
3H), 3.39 (dd, J=6.8, 10.2 Hz, 1H), 3.91 - 3.97 (m, 1H), 3.97 - 4.04 (m, 1H),
4.10 (d,
J= 7.6 Hz, 1H), 4.17 - 4.23 (m, 1H), 4.54 (d, J= 15.2 Hz, 1H), 4.60(d, J= 15.2
Hz,
1H), 5.97 (d, J= 0.5 Hz, 1H), 6.74 (d, J= 7.8 Hz, 1H), 7.22 - 7.29 (m, 3H),
7.31 - 7.35
(m, 2H)
Rac-N-cyclopropy1-2-[(3R,45)-1-[(4-methoxyphenyl)methyl]-5-oxo-4-
phenylpyrrolidin-3-
y11-2-oxoacetamide (FP-102)
[0721] The title compound was synthesized from rac-
(cyclopropylcarbamoy1)[(3R,4S)-
1-[(4-methoxyphenyl)methyl]-5-oxo-4-phenylpyrrolidin-3-yl]methyl acetate (1-
116) in a
similar manner to general procedure 7 (general scheme 4) as a colourless
viscous oil
(23 mg, 98% purity, 72%) after purification by FCC on normal phase silica (10
g SNAP
Ultra cartridge, 0-100% Et0Ac in heptane gradient).
[0722] LC-MS (METCR1603): 98% (UV), Rt= 4.02 min, m/z (ES1+)= 393.2 [M-FH]+
[0723] 1H NMR (500 MHz, Chloroform-a) 6 0.50 - 0.57 (m, 2H), 0.78 - 0.84 (m,
2H),
2.66 - 2.75 (m, 1H), 3.20 - 3.25 (m, 1H), 3.77 - 3.82 (m, 4H), 4.07 - 4.13 (m,
2H), 4.42
(d, J= 14.5 Hz, 1H),4.51 (d, J= 14.5 Hz, 1H), 6.84 - 6.90 (m, 2H), 6.94 (s,
1H), 7.17 -
7.21 (m, 2H), 7.21 - 7.27 (m, 3H), 7.27 - 7.33 (m, 2H)
Rac-N-buty1-2-oxo-2-[(3R,45)-5-oxo-4-phenylpyrrolidin-3-yl]acetamide (FP-103)

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
113
[0724] The title compound was synthesized from rac-(butylcarbamoy1)[(3R,4S)-5-
oxo-
4-phenylpyrrolidin-3-yl]methyl acetate (1-120) in a similar manner to general
procedure
7 (general scheme 4) as an off-white solid (23 mg, 100% purity, 10%) after
purification
by FCC on normal phase silica (10 g SNAP Ultra cartridge, 0-100% Et0Ac in
heptane
gradient) followed by preparative LC (basic pH, standard elution method).
[0725] LC-MS (METCR1603): 100% (UV), Rt= 3.41 min, m/z (ES14-)= 289.2 [M+H]4-
[0726] 1H NMR (500 MHz, DMSO-d6) 50.85 (t, J= 7.4 Hz, 3H), 1.19 ¨ 1.28 (m,
2H),
1.37¨ 1.46 (m, 2H), 3.04 ¨ 3.15 (m, 2H), 3.32 ¨ 3.35 (m, 1H), 3.66 ¨ 3.73 (m,
2H), 4.07
¨4.19 (m, 1H), 7.23 ¨ 7.28 (m, 3H), 7.29 ¨ 7.36 (m, 2H), 7.95 (s, 1H), 8.65 ¨
8.77 (m,
1H)
GENERAL SCHEME 5:
R2 R2
/ / & ) R2
N
/
N Hydrolysis Ylide formation
S
_____________ 0 ________ 0- 0 ________
RO HO 0
General General
.-----
procedure 1 procedure 2 N -----
0 R3 0 R3 0 R3
R= Me, Et
IOxidation
General
procedure 3
R2 R2
N/
N/
0 Amidation 0
________________________________________ 0
R1N General
HO
H procedure 4
0 R3 0 R3
GENERAL PROCEDURE 1 (GENERAL SCHEME 5): Hydrolysis
1-Benzy1-5-oxopyrrolidine-3-carboxylic acid (1-121)
[0727] To a solution of methyl 1-benzy1-5-oxo-pyrrolidine-3-carboxylate (5.0
g, 21.43
mmol) in 1:1:1 THF:water:Me0H (120 mL) was added LiOH monohydrate (1.35 g,
32.17 mmol) and the reaction stirred at RT for 45 min. The mixture was
concentrated
in vacuo to a volume of ¨30 mL, diluted with water (30 mL) and washed with
Et20 (40
mL). The aqueous layer was acidified to ¨pH 1 with 6N HCI and extracted with
DCM (2
x 40 mL). The combined organic layers were dried over Na2SO4and concentrated
in
vacuo to afford 4.67 g of 1-benzy1-5-oxo-pyrrolidine-3-carboxylic acid as an
off-white
solid (86% purity, 85%) which was used in the next step without further
purification.
[0728] LC-MS (METCR1410): 86% (UV), Rt= 0.84 min, m/z (ES14-)= 220.2 [M+H]4-

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
114
[0729] 1H NMR (500 MHz, DMSO-d6) 6 2.47 - 2.53 (m, 1H), 2.59 (dd, J= 9.7, 16.9
Hz, 1H), 3.17 - 3.25 (m, 1H), 3.36 (dd, J= 5.5, 9.9 Hz, 1H), 3.45 (dd, J= 8.9,
9.8 Hz,
1H), 4.33 (d, J= 15.0 Hz, 1H), 4.41 (d, J= 15.0 Hz, 1H), 7.19 - 7.23 (m, 2H),
7.25 -
7.30 (m, 1H), 7.32 - 7.36 (m, 2H)
GENERAL PROCEDURE 2 (GENERAL SCHEME 5): Ylide formation
3-(1-Benzy1-5-oxopyrrolidin-3-y1)-3-oxo-2-(110-thiolan-1-
ylidene)propanenitrile (1-122)
[0730] To a solution of 1-benzy1-5-oxo-pyrrolidine-3-carboxylic acid (1-121)
(86%
purity, 1.5 g, 5.88 mmol) and DIPEA (3.94 mL, 22.62 mmol) in DCM (30 mL) was
added HATU (2.91 g, 7.65 mmol) and 1-(cyanomethyl)thiolan-1-ium bromide (90%
purity, 1.60 g, 6.92 mmol, synthesized by the procedure outlined in Note 1,
general
experimental details. The mixture was stirred at RT under nitrogen for 1 h
then
quenched with sat. NH4C1(50 mL). The aqueous layer was extracted with DCM (2 x
40
mL) and the combined organic layers were washed with brine (30 mL), dried over
Na2SO4 and concentrated in vacuo. The residue was purified by FCC on normal
phase
silica (100 g SNAP KP-SIL cartridge, 0-100% Et0Ac in heptane gradient then 0-
25%
Me0H in Et0Ac gradient) to afford 2.19 g of 3-(1-benzy1-5-oxopyrrolidin-3-y1)-
3-oxo-2-
(1A4-thiolan-1-ylidene)propanenitrile as a brown viscous oil (87% purity by 1H
NMR,
99%).
[0731] LC-MS (METCR1410): 98% (UV), Rt= 0.88 min, m/z (ES14-)= 329.0 [M+H]
[0732] 1H NMR (500 MHz, Chloroform-d) 6 2.05 - 2.13 (m, 2H), 2.53 - 2.67 (m,
3H),
2.77 (dd, J= 7.7, 17.0 Hz, 1H), 3.25 - 3.41 (m, 5H), 3.44 (t, J= 9.3 Hz, 1H),
3.56 -
3.64 (m, 1H), 4.38 - 4.44 (m, 1H), 4.45 - 4.50 (m, 1H), 7.20 - 7.24 (m, 2H),
7.24 - 7.34
(m, 3H).
GENERAL PROCEDURE 3 (GENERAL SCHEME 5): Oxidation
2-(1-Benzy1-5-oxopyrrolidin-3-y1)-2-oxoacetic acid (1-123)
[0733] To an ice-cooled solution of 3-(1-benzy1-5-oxopyrrolidin-3-y1)-3-oxo-2-
(1A4-
thiolan-1-ylidene)propanenitrile (1-122) (87% purity by 1H NMR, 2.18 g, 5.77
mmol) in
2:1 THF/water (45 mL) was added at 0 C Oxone (7.1 g, 11.55 mmol) in one
portion.
The mixture was stirred at 0 C for 45 min, quenched slowly with 1N HC1(30 mL)
and
extracted with Et0Ac (50 mL). The organic layer was washed with 1N HC1(30 mL)
and
the combined aqueous layers extracted with Et0Ac (2 x 30 mL). The combined
organic
extracts were dried over Na2SO4 and concentrated in vacuo to give 1.86 g of 2-
(1-

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
115
benzy1-5-oxo-pyrrolidin-3-y1)-2-oxo-acetic acid as a yellow oil (51% purity by
1H NMR,
66%) which was used in the next step without further purification.
[0734] LC-MS (METCR1410): 76% (UV), Rt= 0.73 min, m/z (ES14-)= 248.0 [M+H].
[0735] 1H NMR (250 MHz, Chloroform-o) 5 2.70 - 2.94 (m, 2H), 3.45 - 3.66 (m,
2H),
3.84 - 4.04 (m, 1H), 4.36 - 4.48 (m, 1H), 4.48 - 4.59 (m, 1H), 7.17 - 7.26 (m,
2H), 7.27
- 7.40 (m, 3H).
GENERAL PROCEDURE 4 (GENERAL SCHEME 5): Amidation
2-(1-Benzy1-5-oxopyrrolidin-3-y1)-N-cyclopropy1-2-oxoacetamide (FP-104)
[0736] To a cooled solution of 2-(1-benzy1-5-oxopyrrolidin-3-y1)-2-oxoacetic
acid (I-
123) (51% purity by 1H NMR, 520 mg, 1.07 mmol) in DMF (10 mL) was added
cyclopropylamine (0.15 mL, 2.16 mmol), DIPEA (0.58 mL, 3.33 mmol) and T3P (50%
in DMF, 1.9 mL, 3.22 mmol) in quick succession. The mixture was stirred at RT
under
nitrogen for 45 min, diluted with Et0Ac (30 mL) and washed with water (3 x 15
mL).
The combined aqueous layers were washed with Et0Ac (20 mL) and the combined
organic extracts were washed with brine (20 mL), dried over Na2SO4 and
concentrated
in vacuo. The residue was purified by FCC on normal phase silica (10 g SNAP KP-
SIL
cartridge, 0-65% Et0Ac in heptane gradient then 0-25% Me0H in Et0Ac gradient)
followed by preparative LC (acidic pH, standard elution method) to afford 57
mg of 2-
(1-benzy1-5-oxo-pyrrolidin-3-y1)-N-cyclopropy1-2-oxo-acetamide as a colourless
oil
(100% purity, 19%).
[0737] LC-MS (METCR1603): 100% (UV), Rt= 3.32 min, m/z (ESI)= 287.2 [M+H]4-
[0738] 1H NMR (500 MHz, Chloroform-o) 5 0.52 - 0.64 (m, 2H), 0.80 - 0.90 (m,
2H),
2.70 - 2.79 (m, 3H), 3.36 (dd, J= 5.8, 10.4 Hz, 1H), 3.61 (dd, J= 9.4, 10.3
Hz, 1H),
4.09 (qd, J= 5.8, 8.4 Hz, 1H), 4.39 -4.50 (m, 2H), 6.95 (br. s, 1H), 7.19 -
7.24 (m,
2H), 7.26 - 7.35 (m, 3H).
Table 1: Intermediates (1-1 -1-123)
Br
Br Br
OH oCH3 oCH3
0 0
0
1-1 1-2 1-3

CA 03075812 2020-03-13
WO 2019/068841 PCT/EP2018/077072
116
_
N N
Br 0 I I 0 H
F H3C
,¨...,o o H3C 0 .........õCH3
...../.\,... o./..''CH3
0
1411
0 50
1-4 1-5 1-6
N N
0 I I I 0 0 I NH3
0
1-13C0 \./C1-13 0 ...0 o'`...
CH'
H30,.....0 \ H3C
0
110
1411 0
11101 0
F
-
1-7 1-8 1-9
NH2 NHBoc
NH3 0
0
0
0
H3C....... 0 Ft3C . \,-.'cl-I3
õ,....--., oCH'
H3C 0 0 \ CH3
0
0 0
01111
OOP 0
F _
1-10 1-11 1-12
_ _
NH
0
, 0
slec>IFI (>1H
0
H3C 0 H3C.,.....,,,O.,,,....0õ. H3C o
r-
= =
0 0
4111 0 lip
AND ENANT1OMER AND ENANT1OMER AND ENANTIOMER
_
1-13 1-14 1-15
_ 01 NH NH _
0 0 0
H3Co-,s' H3Co
- . .3,...
=
=
0 0 0
AND ENANTIOMER
0
¨
1-16 1-17 1-18
NH Irc>11--1 1(01
0
0 0
HO HO
_
0, - - -
- -
= -
0 0
AND ENANTIOMER AND ENANTIOMER
F
_
1-19 1-20 1-21

DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 A 116
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des
brevets
JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 116
NOTE: For additional volumes, please contact the Canadian Patent Office
NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:

Representative Drawing